Structure-function relationships in matrix metalloproteinase-1 by Butt, Louise
Structure-Function Relationships 
in 
Matrix Metalloproteinase-1 
Louise Butt
The thesis is submitted in partial fulfillment of  the requirements for the 
award of  the degree of  Doctor of  Philosophy of  the University of  
Portsmouth
Institute of  Biomedical and Biomolecular Sciences
School of  Biological Sciences
University of  Portsmouth
August 2013
ABSTRACT
Collagenolysis, the catabolism of triple helical collagen, is essential for the physiological 
remodeling of connective tissues during growth and development.  Aberrant collagen 
degradation is a feature of both inflammatory diseases and cancer cell invasion. Matrix 
metalloproteinase-1 (MMP-1) is a known collagenase and previous studies have 
implicated its hemopexin (HPX) domain in binding and possibly destabilising collagen 
in preparation for hydrolysis by the catalytic (CAT) domain.  More recently, 
conformational freedom and domain separation of the CAT and HPX domains has 
been proposed to play a role in collagen degradation.  This study aims to explore HPX 
mediated collagen recognition and the postulated flexible state of MMP-1, in order to 
enhance our understanding of  the collagenolytic mechanism.
 Here, biophysical methods have been used to study the complex formed 
between the MMP-1 HPX domain and a synthetic triple helical peptide (THP) that 
encompasses the MMP-1 cleavage site of the collagen α1(I) chain.  A programme of 
site-directed mutagenesis was used to produce an extensive library of recombinant 
proteins.  Surface plasmon resonance (SPR) has been used to characterise a previously 
unknown collagen binding site (exosite) located in blade 1 of the HPX domain and 
small angle x-ray scattering has been used to probe the conformational freedom and 
transient domain separation in mutant forms of both zymogen and mature MMP-1 
enzymes.
 Significant reductions in THP affinity were observed on mutation of either 
Phe301, Val319 and Asp338, residues forming part of a “ball and socket” joint in the 
CAT-HPX interface.  Disruption of the CAT-HPX interface by mutagenesis, of any of 
these three residues, severely impacts collagen recognition.  Conversely, the reduced 
collagen binding activity of a "stapled" mutant (in which the CAT and HPX domains 
are constrained with a disulphide bridge) indicates that the ability of the domains to 
transiently dislocate is also important.   Thus, a balanced equilibrium between these 
compact and dislocated states is an essential feature of  MMP-1 collagenolytic activity.
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Abstract: 
Matrix metalloproteinase-1 (MMP-1) is an instigator of collagenolysis, the catabolism of 
triple helical collagen. Previous studies have implicated its hemopexin (HPX) domain in 
binding and possibly destabilizing the collagen substrate in preparation for hydrolysis of 
the polypeptide backbone by the catalytic (CAT) domain. Here, we use biophysical 
methods to study the complex formed between the MMP-1 HPX domain and a 
synthetic triple helical peptide (THP) that encompasses the MMP-1 cleavage site of the 
collagen α1(I) chain.  The two components interact with 1:1 stoichiometry and 
micromolar affinity via a binding site within blades 1 and 2 of the four-bladed HPX 
domain propeller.  Subsequent site-directed mutagenesis and assay implicates blade 1 
residues Phe301, Val319, and Asp338 in collagen binding.  Intriguingly, Phe301 is 
partially masked by the CAT domain in the crystal structure of full-length MMP-1 
implying that transient separation of the domains is important in collagen recognition. 
However, mutation of this residue in the intact enzyme disrupts the CAT-HPX interface 
resulting in a drastic decrease in binding activity.  Thus, a balanced equilibrium between 
these compact and dislocated states may be an essential feature of MMP-1 collagenase 
activity.  
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CHAPTER 1: PROTEOLYSIS OF THE 
EXTRACELLULAR MATRIX
1.1 The Extracellular Matrix
Extracellular matrices (ECMs) are complex assemblies of proteoglycans, 
glycosaminoglycans (GAGs) and protein components, such as laminin, elastin and 
collagen.  These macromolecules contribute to the unique composition and topology of 
all tissues within multicellular vertebrate organisms, promoting both tissue organisation 
and structural integrity.
	 GAGs are a significant class of unbranched polysaccharide chains characterised 
by typical repeating disaccharide units, typically a hexauronic acid linked to an N-
acetylated hexosamine, which is usually sulfated.  They are ubiquitously distributed at 
the cell-ECM interface of eukaryotic cells and are usually found covalently linked to 
proteins in the form of proteoglycans.  Proteoglycans are highly diverse in both form 
and function, from the large supramolecular structure of aggrecan bound to hyaluronic 
acid that keeps the matrix hydrated, to membrane-bound syndecan with both matrix 
adhesion and cell-signalling properties (Reviewed in Hardingham and Fosang 1992, 
Sasisekharan, Raman et al. 2006).  The ECM is further enriched by the presence of a 
number of fibrillar proteins which possess structural and adhesive functions via cell 
surface receptors (e.g. integrins) that control tissue cohesion.
 It is estimated that approximately 300 genes encode the core ECM constituents 
with additional ECM-associated proteins contributing to the complete 
‘matrisome’ (Naba, Clauser et al. 2012).  Not only do these diverse matrisome 
constituents provide structural support but act collectively to influence cellular 
behaviour. 
	 Homeostasis in resting tissue is maintained through continual synthesis and 
deposition of these ECM constituents opposed by regulated proteolysis, while essential 
developmental events and wound healing require radical remodelling of connective 
tissues.  Degradation of the ECM permits exposure and release of latent sequested 
bioactive molecules, such as growth factors and cytokines with causative downstream 
effects on cell adhesion and migration, cell surface receptor localization and instigation 
of signalling cascades (Reviewed in Lukashev and Werb 1998).  Matrix degradation 
observed in both homeostasis and remodelling, is orchestrated primarily by members of 
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the matrix metalloproteinase (MMP) family, of which 23 homologous members have 
been identified in humans (Visse and Nagase 2003). 
1.2 Collagen
 Collagens are multi-gene extracellular proteins abundant throughout vertebrate 
tissues, providing essential structural resilience within the ECM.  Currently, 28 types of 
collagen with 43 unique polypeptide α chains have been identified in vertebrates, 
alongside numerous proteins with triple helical collagenous domains (Khoshnoodi, 
Cartailler et al. 2006).  They have been classified accordingly as fibril-forming, fibril-
associated containing interrupted triple helices (FACIT), beaded filament, anchoring 
fibril, network-forming and transmembrane collagen (Reviewed in Ricard-Blum 2011).  
	 All family members possess the characteristic triple helical domain but differ in 
size, function and tissue distribution, therefore, it is beyond the scope of this thesis to 
review each group.  Instead further discussions will be limited to the quarter-staggered 
fibril-forming collagens exemplified by type I collagen.
 1.2.1 Collagen Biosynthesis
Fibril-forming collagens are ubiquitously distributed throughout connective tissue, skin 
and bone and are synthesised by stromal cells, principally fibroblasts, as soluble 
procollagens with N and C terminal non-helical extensions (Figure 1.1).  
 Initially individual pro-α peptide chains are deposited into the rough 
endoplasmic reticulum prior to removal of the signal peptide.  Here, the pro-α chains 
undergo significant post-translational modifications which include hydroxylation of 
selected prolines and lysines by the action of prolyl-4-hydroxylase (P4H) and lysyl 
hydroxylases (LH), glycosylation of lysine and hydroxylysine residues by galactosyl- and 
glucosyltransferases (GT), and sulfation of tyrosine residues (Harwood, Grant et al. 
1974, Harwood, Grant et al. 1975, Kellokumpu, Sormunen et al. 1994, Passoja, 
Rautavuoma et al. 1998, Valtavaara, Szpirer et al. 1998).  The extent of prolyl 
hydroxylation appears to be species dependent (Reviewed in Myllyharju 2003). 
	 The non-collagenous C-terminal domains (NC-C) are essential for chain 
selection and initiation of trimeric procollagen formation (Lees, Tasab et al. 1997, 
Bourhis, Mariano et al. 2012).  These globular domains are stabilised by the action of 
protein disulphide isomerase (PDI) which introduces intrachain disulphide bonds.  
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 Recognition and association of the NC-C domains from three pro-α chains 
initiates trimerization, thus triggering propagation of the triple helix from the C-N 
terminus (Doege and Fessler 1986).  Efficient folding is promoted by the action of 
peptidyl prolyl cis-trans isomerase which converts cis-peptide bonds to the trans form 
(Bachinger, Bruckner et al. 1978, Bachinger 1987, Davis, Boswell et al. 1989) and 
molecular chaperones like HSP47 and BiP (Chessler and Byers 1993, Sauk, Smith et al. 
1994, Satoh, Hirayoshi et al. 1996, Nagai, Hosokawa et al. 2000).
 The newly formed procollagen traverses the secretory pathway through the golgi 
body by cisternal maturation (Bonfanti, Mironov et al. 1998) and is extruded into the 
ECM through specialised plasma membrane structures termed ‘fibripositors’ (Canty, Lu 
et al. 2004).  Procollagen is further processed in the ECM with cleavage of both NC-C 
and NC-N terminal domains by bone morphogenetic protein-1 (BMP-1) and closely 
related members of the mammalian tolloid-like metalloproteinase family, and ADAMTS 
(a disintegrin and metalloproteinase with thrombospondin motifs) family members 
displaying aminoprocollagen peptidase activity (Leung, Fessler et al. 1979, Kadler, 
Hojima et al. 1987, Kessler, Takahara et al. 1996, Li, Sieron et al. 1996, Fernandes, 
Hirohata et al. 2001, Colige, Vandenberghe et al. 2002, Wang, Lee et al. 2003). 
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Figure 1.1: Overview of Collagen Biosynthesis. (1) Synthesis of pro α chain and hydroxylation of 
proline and lysine residues.  (2) Glycosylation of lysine and hydroxylysine residues by galactosyl- and 
glucosyltransferases.  (3) Nucleation at the C-terminal domains mediated by protein disulphide isomerase, 
and subsequent self-assembly of 3 pro α chains.  (4) Folding promoted by peptidyl-prolyl cis-trans isomerase 
and HSP47.  (5) Secretion of collagen monomers into the extracellular space.  (6) Cleavage of N-terminal 
domains by N-proteinases,  typically ADAMTs. (7) C-terminal processing by BMP-1.  (8) Fibril self-assembly 
stabilised by lysine-derived crosslinks.
Removal of the N and C propeptides generates tropocollagen with diminished solubility 
that undergoes spontaneous fibril self-assembly (Kadler, Hojima et al. 1987). 
 1.2.2 Collagen Structure
The triple helical conformation of the type I tropocollagen structural unit results from 
an unusual abundance of glycine (G), and imino acids proline (P) and hydroxyproline 
(O).  Together they form the characteristic G-X-Y triplet (Figure 1.2).  
	 The role of glycine cannot be underestimated. Tight packing of the polypeptide 
chains into a super-coiled helical assembly, with 103 screw symmetry (3.3 residues per 
turn), necessitates the presence of the smallest amino acid, glycine, at every third 
position (Ramachandran and Kartha 1955, Rich and Crick 1955).  Substitution 
mutations that replace invariant glycine with larger residues are known to significantly 
distort normal propagation, stability and function of the triple helix as seen in many 
types of osteogenesis imperfecta (Beck, Chan et al. 2000), a connective tissue disorder 
characterised by bone fragility. 
	 Triple helical stability is greatly improved with increasing imino acid content as 
observed in studies of triple helical model peptides (Bella, Eaton et al. 1994, Persikov, 
Ramshaw et al. 2005).  The restricted rotation placed on the iminopeptide bond ensures 
optimal chain geometry for formation of a right-handed helix with a ladder of 
interchain hydrogen bonds between the amide hydrogen atom of glycine and the 
carbonyl oxygen atom of the residue in position X in the adjacent chains 
(Ramachandran and Kartha 1955, Rich and Crick 1955).  Stability is further enhanced 
by hydroxyproline in position Y, which mediates hydrogen bonding with water and 
induces formation of a structured hydation shell around the collagen helix (Bella, 
Brodsky et al. 1995).  
 GPO is the most commonly occurring sequence accounting for 10.5% of all 
triplets found in collagen.  However, more than 60% of triplets distributed throughout 
collagen have variant amino acid residues at the Y position (Ramshaw, Shah et al. 1998). 
Clusters of such triplets constitute regions that are considered “imino poor”. These 
localised conformationally labile regions may be necessary for physiological functions. 
Crystallographic data shows collagen recognition by both Discoidin Domain receptor 2 
and Integrin α2β1 at imino poor sequences (Emsley, Knight et al. 2000, Carafoli, Bihan 
et al. 2009).  Furthermore, the collagenase cleavage sites of collagen types I-III are 
located within an imino acid poor region (Xiao, Addabbo et al. 2010).
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Figure 1.2:  Collagen structure. (A) Structures of glycine, proline and 4-hydroxyproline. 
These amino residues form the characteristic G-X-Y tripeptide repeat. Structures were rendered 
using MarvinSketch (version 5.10.3.),  ChemAxon. (B) Cross-sectional schematic showing the G-X-
Y sequence for each α-helix. The presence of glycine at every third position ensures occupation 
throughout the centre of the triple helix. (C) Longitudinal view of a triple helical collagen 
monomer with sequence [(Pro-Pro-Gly)10]3; space-filling model of chain in black, cartoon model of 
chain in blue and stick model of chain in green (1K6F.pdb).  Rendered using the Pymol Molecular 
Graphics System (version 1.5.0.4.), Schrödinger, LLC.  General domain structure is shown in 
schematic form, (N-NC and C-NC: N-terminal and C-terminal domains respectively).  
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 Periodic overlapping by collagen monomers produces a 67 nm axial quarter-
staggered pentameric microfibril, which is visibly striated when stained (Petruska and 
Hodge 1964, Baselt, Revel et al. 1993, Gutsmann, Fantner et al. 2004).  These 
polymerized homo- and heterotrimeric collagen microfibrils are stabilised by the 
formation of covalent intermolecular cross links, which ultimately result from the 
hydroxylation pattern of lysine residues.  Specific lysyl and hydroxylysyl residues in the 
telopeptides undergo oxidative deamination of ε-amino groups mediated by copper-
dependent lysyl oxidase forming allysine and hydroxyallysine (Pinnell and Martin 1968, 
Siegel 1974).  Immature ketoimine cross links are formed by condensation of these 
reactive aldehydes with lysine and hydroxylysine in helical regions of adjacent 
tropocollagen molecules primarily at the overlap zone of the quarter-staggered fibrils 
(Eyre, Weis et al. 2008).  Further lateral packing of interdigitated microfibrils generates 
bundles of  collagen fibres (Perumal, Antipova et al. 2008).  
	 Fibrillar collagens are noted for their unique strength and resilience. The 
combination of structural features including a highly invariant glycine content, 
abundance of imino acids and extensive post-translational modifications are essential 
for providing protection from proteolysis, particularly by serine and sulfhydryl proteases 
at physiological pH (Drake, Davison et al. 1966, Bruckner and Prockop 1981, Birkedal-
Hansen, Taylor et al. 1985).
1.3 Collagenolysis
Controlled collagen degradation and necessary remodelling within the ECM is required 
to ensure normal connective tissue homeostasis.  Collagenolytic activity has been 
implicated in the physiological processes of epithelial cell migration and 
reepithelialisation during wound repair, formation of the embryonic circulatory system 
by angiogenesis, postpartum uterine involution and weakening of the preovulatory 
follicle wall during ovulation (Butler, Zhu et al. 1991, Alexander, Hansell et al. 1996, 
Seandel, Noack-Kunnmann et al. 2001).
	 Collagenolytic processing of interstitial collagens requires the action of 
collagenases; either cathepsin K, a lysosomal cysteine protease that operates in acidic 
environments (Garnero, Borel et al. 1998, Kafienah, Bromme et al. 1998); or certain 
members of the MMP family, in which an ATP-independent hydrolytic reaction occurs 
at neutral pH.  In humans these members have been identified as MMP-1, -2, -8, -13, 
-14 and -16 (Gross and Lapiere 1962, Hibbs, Hasty et al. 1985, Hasty, Jeffrey et al. 1987, 
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Aimes and Quigley 1995, Knauper, Lopez-Otin et al. 1996, Pei and Weiss 1996, 
Ohuchi, Imai et al. 1997, Shimada, Nakamura et al. 1999).  However, they display 
distinctly variable cleavage specificities.  Collagen specificities have been well-described 
for MMP-1 (type III collagen), -8 (type I collagen) and -13 (type II collagen) (Welgus, 
Jeffrey et al. 1981, Hasty, Jeffrey et al. 1987, Knauper, Lopez-Otin et al. 1996, Mitchell, 
Magna et al. 1996).
 Hydrolysis of type I-III collagen by MMPs (Figure 1.3) occurs between the 
Gly775-Ile776 or  Gly775-Leu776 scissile bond generating characteristic ¼ and ¾ 
length fragments which retain triple helical structure but are unstable and undergo 
further enzymatic processing by gelatinases (Gross and Nagai 1965, Evanson, Jeffrey et 
al. 1968, Seltzer, Adams et al. 1981, Allan, Docherty et al. 1995).
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Figure 1.3:  Collagenolysis by collagenases produces characteristic ¼ and ¾ length 
fragments.  The heterotrimeric type I collagen cleavage site is located within the sequence 769-783 
of the α1 and α2 chains (UniProt accession number P02452  and P08123 respectively) and is 
indicated by a tilde symbol.   Amino acid sequences were obtained from the UniProtKB database 
(Apweiler, Bairoch et al. 2004).
	 Collagen turnover is exceptionally slow.  Age-related accumulation of D-aspartic 
acid through racemization indicates articular cartilage and skin collagen has a half-life of 
117 years and 14.8 years respectively (Verzijl, DeGroot et al. 2000).  It has been 
suggested that slow collagen turnover may result from initial accessibility to binding 
sites in supramolecular collagen assemblies (Welgus, Jeffrey et al. 1980), this is supported 
by recent computational and molecular modelling of collagen fibrils in rat tail tendon 
which identified restrictions when accessing the MMP collagenase cleavage site due to 
quasihexagonal packing and the presence of obstructive C-telopeptides (Orgel, Irving et 
al. 2006, Perumal, Antipova et al. 2008).  However, accelerated collagen destruction is 
associated with up-regulation of MMP expression as observed in a number of 
pathologies, as displayed in degenerative arthritic disease characterised by articular 
cartilage destruction, the progressive matrix lysis observed in periodontal disease, and 
proteolysis of ECM constituents and basement membranes facilitating tumour cell 
metastasis (Mehraban, Kuo et al. 1994, Shah, Kumar et al. 1994, Sapna, Gokul et al. 
2013).
1.4 The Matrix Metalloproteinase Family
The MMP family is comprised of zinc- and calcium-dependent multidomain secreted 
endopeptidases known to degrade multiple ECM components in vitro, these including 
laminin, proteoglycans, fibronectin, entactin, as well as fibrillar collagens (Galloway, 
Murphy et al. 1983, Muir and Manthorpe 1992, Sires, Griffin et al. 1993).  MMP 
activity is, however, not restricted to ECM substrates.  Studies have shown a number of 
cytokines, cell-surface adhesion receptors and growth factors undergo MMP-mediated 
cleavage.  Activity towards interleukin-8, N-cadherin, syndecan-1 and hyaluronan 
receptor CD44 indicate that MMPs may have significant involvement in a number of 
key physiological processes, such as neutrophil activation, cell migration, proliferation 
and invasion  (Van den Steen, Proost et al. 2000, Kajita, Itoh et al. 2001, Endo, Takino 
et al. 2003, Nakamura, Suenaga et al. 2004, Su, Blaine et al. 2008, Williams, Johnson et 
al. 2010).
	 Fibroblast interstitial collagenase MMP-1 (EC number 3.4.24.7) was the first 
MMP to be described following observations of dissolution of the bullfrog tadpole tail 
and collagenolysis during amphibian metamorphosis (Gross and Lapiere 1962, Gross 
and Nagai 1965) and is now considered the archetypal member of  the family.  
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	 Classified as a subfamily of the metzincin superfamily of proteases, all MMP 
members have a conserved structural topology, sharing similar primary, secondary and 
tertiary structure.  Typically, MMPs contain an N-terminal signal sequence rich in 
hydrophobic residues that targets the enzyme to the endoplasmic reticulum prior to 
secretion, a propeptide (PRO) domain to maintain latency, a Zn2+ containing catalytic 
(CAT) domain and a variant length proline-rich flexible linker region connecting the C-
terminal hemopexin (HPX) domain (Li, Brick et al. 1995, Jozic, Bourenkov et al. 2005, 
Iyer, Visse et al. 2006, Nagase, Visse et al. 2006).  Subtle structural variations on this 
central modular design (Figure 1.4), typified by MMP-1, contributes to some of the 
observed diverse substrate specificities. 
	 Although many MMPs are multifunctional and frequently share substrate 
specificities, they are further subcategorised into six groups based on sequence similarity 
and domain organisation.  These are collagenases, gelatinases, stromelysins, matrilysins, 
MT-MMPs and a miscellaneous group of family members that have yet to be fully 
characterised.  General sub-family features and characteristics are covered briefly below. 
Readers are directed to a number of reviews (Massova, Kotra et al. 1998, Bode and 
Maskos 2003, Nagase, Visse et al. 2006, Page-McCaw, Ewald et al. 2007) and references 
therein for further information.
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Figure 1.4:  Matrix metalloproteinase domain structure.  Structure and substrate specificity 
determine the sub-family classification.  The five main groups are collagenases, gelatinases, 
stromelysins, matrilysins, membrane-bound MMPs.  Other MMP members can not be classified due to 
non-typical features.  The basic domain structure is characterised by the presence of a signal peptide, 
an inhibitory propeptide (PRO), a zinc-binding catalytic domain (CAT) and a hemopexin-like C-
terminal domain (HPX) attached by a variable length linker.  Addition of accessory domains to the 
basic topology enhance both structural and functional diversity (Adapted from Bourboulia and Stetler-
Stevenson 2010).
 1.4.1 Collagenases
MMP-1, -8 and -13 are interstitial collagenases secreted by multiple cell types in 
response to the stimulatory effects of growth factors and pro-inflammatory cytokines, 
primarily TNFα and IL-Iβ, upregulating gene expression (Borden, Solymar et al. 1996). 
These MMPs are principally responsible for degradation of fibrillar collagen (types I-
III), which is imparted by cooperative action of the CAT and HPX domains (Murphy, 
Allan et al. 1992, Hirose, Patterson et al. 1993, Knauper, Cowell et al. 1997, Chung, 
Yoshida et al. 2004).  Conserved residues Tyr210, Asp231 and Gly233 have also been 
described as a collagenase specificity determinant and are a unique feature of all 
collagenases from humans, rabbits and pigs (Sanchez-Lopez, Alexander et al. 1993, 
Freije, Diez-Itza et al. 1994).
	 Ubiquitously expressed, MMP-1 was the first vertebrate collagenase purified to 
homogeneity (from human skin fibroblasts) and cloned as cDNA (Goldberg, Wilhelm et 
al. 1986).  MMP-1 is secreted in two zymogenic forms; a minor 57 kDa protein with N-
linked glycosylation of Asn120 (Wilhelm, Eisen et al. 1986, Saarinen, Welgus et al. 1999) 
and a predominant unglycosylated protein of 52 kDa.  The physiological role of 
MMP-1 glycosylation modification has yet to be elucidated.  Cleavage of the PRO 
domain produces a mature enzyme composed of a CAT domain tethered to a HPX 
domain, a structure typical of  both collagenases and stromelysins.
	 MMP-1 is generally undetectable in normal resting tissue, but is associated with 
a number of disease states.  Constitutive expression accompanied by collagenolysis has 
been observed in aggressive and invasive human carcinomas (Templeton, Brown et al. 
1990, Benbow, Schoenermark et al. 1999, Huntington, Shields et al. 2004, Eck, Cote et 
al. 2009) as well as the articular cartilage destruction connected with rheumatoid 
arthritis (Konttinen, Ainola et al. 1999, Yoshihara, Nakamura et al. 2000, Tetlow, Adlam 
et al. 2001).
	 MMP-8 is primarily synthesised and stored in specific granules of the 
polymorphonuclear leukocytes of maturing bone marrow, and was cloned from mRNA 
extracted from a patient with granulocytic leukaemia (Hasty, Pourmotabbed et al. 1990), 
hence the common name neutrophil collagenase.  MMP-8 is released upon stimulation 
by chemical signals that trigger degranulation (Schettler, Thorn et al. 1991).  Its 
presence in chondrogenic tissues has been reported (Cole, Chubinskaya et al. 1996) and 
work in a murine model showed that MMP-8 is expressed during embryogenesis 
(Giambernardi, Sakaguchi et al. 2001).  MMP-8 exists as a highly-glycosylated 75 kDa 
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enzyme with an estimated carbohydrate content of 35% (Knauper, Kramer et al. 1990). 
It has 57% amino acid sequence homology to MMP-1 (Hasty, Pourmotabbed et al. 
1990), and has a 15-fold preference for type I collagen over type III (Horwitz, Hance et 
al. 1977).
 The third member of the collagenase sub-family, MMP-13, was identified in 
1994 during a search for putative MMPs involved in breast carcinoma (Freije, Diez-Itza 
et al. 1994).  Due to it’s broad substrate specificity (Knauper, Cowell et al. 1997) and 
marked increase in expression in various invasive metastatic carcinomas (Johansson, 
Airola et al. 1997, Airola, Karonen et al. 1999), MMP-13 was considered a potent 
pathological collagenase.  However, it has a substantial role in skeletal development; not 
only is MMP-13 expression restricted to mineralizing skeletal tissue during 
embryogenesis (Stahle-Backdahl, Sandstedt et al. 1997), but also Mmp-13-/- mice show 
significant defects in cartilage formation concomitant with collagen accumulation and 
delayed ossification (Inada, Wang et al. 2004).
 Despite shared global structural homology between collagenase members there 
are significant differences in collagen processing capability (Table 1.1).  Extensive 
differences in the depth and composition of collagenase specificity pockets within the 
active site are known to impact inhibitor selectivity (Lovejoy, Welch et al. 1999), 
therefore, it is not unreasonable to assume that subtle structural variations within the 
catalytic domain may also affect collagenolysis.  In addition, significant differences in 
catalytic efficiency has also been observed as a result of substrate variation.  For 
example, comparison of MMP-1 action on human and guinea pig type III collagen 
showed a 30-fold difference in kcat/Km (Welgus, Jeffrey et al. 1981).  Equally there is 
disparity within the α2(I) collagenase cleavage site sequence between these two species. 
Such variation likely contributes to the observed species-dependent substrate catalytic 
efficiency of  human collagenases.
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Table 1.1: Kinetic parameters of  human collagenasesab
Enzyme Substrate Km (μM) kcat
(s-1 . 103)
kcat/Km (M-1 
s-1 x 10-3)
Ref.
MMP-1 Type I collagen 0.8 15 18
Welgus, Jeffrey, 
et al. 1981
Type II collagen 2.1 0.28 0.13
Type III collagen 1.4 160 69
MMP-8 Type I collagen 0.7 1.8 2.5
Hasty, Jeffrey et 
al. 1987
Type II collagen 1.1 0.65 0.59
Type III collagen 1.8 0.23 0.13
MMP-13 Type I collagen ND ND ND
Mitchell et al. 
1996
Type II collagen 2 6.3 3.9
Type III collagen ND ND ND
a Data obtained at 25 oC, pH 7.5
b ND: Not Determined
Adapted from Cancer Drug Discovery and Development: Matrix Metalloproteinase Inhibitors in 
Cancer Therapy
Edited by: Neil J. Clendeninn and Krzysztof  Appelt © 2011 Humana Press Inc., Totowa, NJ 
 1.4.2 Gelatinases
Gelatinases (MMP-2 and -9) have the typical secreted MMP structure with the addition 
of a fourth domain distinguished by tandem triple fibronectin type II (F2) domains 
inserted within the CAT domain (Morgunova, Tuuttila et al. 1999).  These enzymes 
readily digest gelatin, elastin, as well as type IV collagen, a major constituent of the 
basal lamina (Murphy, Cockett et al. 1991) and are grouped together by structural 
homology and enzymatic activity.
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 The MMP-2 gene was initially characterised and reported as a potential house-
keeping gene due to an apparent lack of regulatory elements in the promoter region 
(Huhtala, Chow et al. 1990).  This was supported by constitutive expression of the 72 
kDa MMP-2 enzyme in a number of cell types and cancer cell lines (Qin, Moellinger et 
al. 1998, Roomi, Monterrey et al. 2009) as well as unaltered mRNA expression after 
treatment with MMP inducers IL-1 and TNα (Mackay, Ballin et al. 1992).  However, 
mRNA production has been stimulated in specific tissues as seen with TGF-β treatment 
(Overall, Wrana et al. 1991, Marti, Lee et al. 1994) and it now appears that regulation of 
MMP-2 may be much more complex than previously anticipated.  
	 Removal of the PRO domain proved to be another area of complexity for this 
particular gelatinase when it became apparent that activation was the result of cell-
surface localization mediated by both membrane-bound MMP-14 and Tissue inhibitor 
of metalloproteinase-2 (TIMP-2), an endogenous MMP inhibitor (Itoh, Binner et al. 
1995, Fernandez-catalan, Bode et al. 1998, Overall, Tam et al. 2000).  In addition, a 
published crystal structure of the zymogen showed an interaction between a 
phenylalanine residue of the PRO domain and the third F2 domain (Morgunova, 
Tuuttila et al. 1999).  Clearly this interaction must be disrupted, uncovering substrate-
binding sites, thereby allowing full gelatin degrading properties to emerge (Banyai, 
Tordai et al. 1994, Murphy, Nguyen et al. 1994, Xu, Wang et al. 2004).
 Despite recognition as a gelatinase, full-length MMP-2 has been reported as 
having the capacity to degrade fibrillar collagens (Konttinen, Ceponis et al. 1998) with a 
reported type I collagen affinity of 8.5 μM (Aimes and Quigley 1995).  This is not a 
general feature of the gelatinase family, as MMP-9 lacks collagenolytic activity against 
collagen types I and II (Aimes and Quigley 1995, Konttinen, Ceponis et al. 1998) 
despite sharing F2 domain homology.  The F2 domains of MMP-2 appear to direct 
gelatin-binding properties (Banyai, Tordai et al. 1994, Murphy, Nguyen et al. 1994, Xu, 
Wang et al. 2004), as well as type I collagen-binding activity (Tam, Moore et al. 2004), 
unlike the collagenases which utilise the C-terminal HPX domain.  However, the HPX 
domain of MMP-2 also remains important because without it collagenolytic behaviour 
is lost (Steffensen, Wallon et al. 1995, Wallon and Overall 1997, Patterson, Atkinson et 
al. 2001, Tam, Moore et al. 2004).  Therefore, MMP-2 requires both the presence of the 
HPX domain and F2 domains for collagenolysis, and operates a fundamentally different 
mode of  action compared to the collagenases.  
 MMP-9 is distinctive: when found secreted in human lung fibroblasts the 92 kDa 
enzyme was found to have an additional flexible fifth domain with sequence homology 
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to a segment of the α2(V) collagen chain (Wilhelm, Collier et al. 1989).  This domain is 
approximately 60 residues in length, is particularly rich in proline, serine and threonine 
and is heavily glycosylated.  In fact, around 85% of the total sugar content is O-linked 
glycans attributed to this flexible linker domain (Mattu, Royle et al. 2000).
	 A combined small angle x-ray scattering (SAXS) and atomic force microscopy 
(AFM) study of full-length and C-terminally truncated MMP-9 investigated the inherent 
flexibility of the linker domain.  Significant global conformational changes were 
reported highlighting the potential role of dynamic domain mobility for full-length 
enzyme-substrate interactions (Rosenblum, Cohen et al. 2007). 
	 Homodimerisation, a feature not seen in other secreted MMPs, has also been 
reported for MMP-9.  The asymmetric dimer is formed via non-covalent interactions 
between HPX domains (Olson, Bernardo et al. 2000, Cha, Kopetzki et al. 2002). 
Dimerization has been observed effecting both the autolytic activation mechanism 
(Olson, Bernardo et al. 2000) and MMP-9 mediated COS-1 cell migration (Dufour, 
Zucker et al. 2010), however regulation and function of dimerization has yet to be 
elucidated fully. 
 1.4.3 Stromelysins
MMPs -3, -10 and -11 constitute the stromelysin subfamily.  They are secreted enzymes 
containing the simple structural arrangement seen in collagenases but lacking the ability 
to hydrolyse the fibrillar collagens (type I-III).  
	 Comparison of MMP-3 and MMP-1 amino acid sequences demonstrate the 
close homology (~54%) between the members (Whitham, Murphy et al. 1986, Saus, 
Quinones et al. 1988).  This, combined with the location of stromelysin and collagenase 
genes clustered on chromosome 11 (Formstone, Byrd et al. 1993), suggests a common 
evolutionary origin.  However, despite the above homology, and presence of a collagen-
binding hemopexin domain (Allan, Hembry et al. 1991), MMP-3 is unable to cleave 
type I collagen (Wilhelm, Collier et al. 1987).
 MMP-3 was originally purified from human rheumatoid synovial cells (Okada, 
Nagase et al. 1986) displaying proteolytic activity against a broad range of ECM 
substrates, including fibronectin, laminin and type IV collagen (Galloway, Murphy et al. 
1983, Chin, Murphy et al. 1985, Wilhelm, Collier et al. 1987, Okada, Konomi et al. 
1989), as well as autoproteolytic activity that removes it’s own HPX domain (Okada, 
Harris et al. 1988).  Another feature, first described by observing MMP-3 proteolysis, 
15
was it’s ability to activate a number of MMPs in vitro by cleaving within the N-terminal 
PRO domain.  It has activity against proMMP-9 (Ogata, Enghild et al. 1992) and -8 
(Knauper, Wilhelm et al. 1993) as well as being an activator of proMMP-1 cleaving 
specifically at the Gln80-Phe81 scissile bond generating a mature MMP-1 enzyme with 
enhanced proteolytic activity (Murphy, Cockett et al. 1987, Suzuki, Enghild et al. 1990). 
	 MMP-10 by contrast is much less well-characterised but is anticipated to have 
similar properties to MMP-3 due to significant homology between both the catalytic and 
HPX domains, 86% and 74% respectively (Bertini, Calderone et al. 2004).  As an MMP 
activator, this is certainly true of MMP-10 with activity observed against proMMPs -1, 
-8 and -9 (Windsor, Grenett et al. 1993, Knauper, Murphy et al. 1996, Nakamura, Fujii 
et al. 1998).  Therefore, both MMP-3 and -10 can indirectly affect collagen degradation 
by participating in an activation cascade of  latent collagenases.
	 Although originally described as the third member of the stromelysin subfamily, 
due to overexpression in the stromal cells surrounding invasive breast neoplastic cells 
(Basset, Bellocq et al. 1990) and structural similarities, MMP-11 is arguably more suited 
to reclassification as it has a number of additional features.  These include a furin 
activation sequence that is processed by a transmembrane serine protease in the trans-
golgi network (Pei and Weiss 1995); an inability to be activated by 4-
aminophenylmercuric acetate (APMA) (Santavicca, Noel et al. 1996), an 
organomercurial that typically induces activation in other secreted MMPs; and an 
unusual alanine substitution in place of a highly conserved proline residue within the 
CAT domain (Noel, Santavicca et al. 1995).  This structural alteration has been 
suggested to affect enzyme activity and hence the restricted substrate profile associated 
with MMP-11.  This profile does not include the classic ECM constituents normally 
associated with MMPs (Murphy, Segain et al. 1993, Pei, Majmudar et al. 1994).  A 
recent study has demonstrated MMP-11 activity against cellular substrate galectin-1 
(Kleifeld, Doucet et al. 2010), which has been associated with increased tumour growth 
and spontaneous metastasis (Banh, Zhang et al. 2011).
 1.4.4 Matrilysins
MMP-7 and -26 are known as matrilysins, MMPs containing the minimal domain 
requirements necessary for secretion, latency and activity.  As such they are functionally 
distinctive lacking the characteristic HPX domain that is often implicated in substrate 
selection and unsurprisingly are unable to cleave fibrillar collagens (Miyazaki, Hattori et 
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al. 1990, Uria and Lopez-Otin 2000).  They also possess a threonine residue adjacent to 
the zinc-binding site which appears to be a specific feature of all known matrilysins from 
human, rat, mouse and cat (Uria and Lopez-Otin 2000), the function of which, is 
unknown.
	 The cDNA encoding MMP-7 displays amino acid sequence homology of ~40 % 
with MMP-3 and MMP-1 (Muller, Quantin et al. 1988).  The secreted protein was 
isolated from a rectal carcinoma line (Miyazaki, Hattori et al. 1990) and shows activity 
against a broad range of ECM glycoproteins including fibronectin, aggrecan and 
entactin expression (Woessner and Taplin 1988, Fosang, Neame et al. 1992, Sires, 
Griffin et al. 1993). 
	 MMP-26 has the same structural topology as MMP-7 but in contrast is more 
closely related to the metalloelastase MMP-12 (de Coignac, Elson et al. 2000).  The 
enzyme appears to have restricted expression in both uterine and placental tissues with 
the original cDNA cloned from human placental and endometrial tumour lines (Park, Ni 
et al. 2000, Uria and Lopez-Otin 2000) and therefore most likely has a distinctive role in 
the menstrual cycle and other reproductive processes.
 1.4.5 MT-MMPs
Six membrane-bound MMPs have been reported and are defined by possession of a C-
terminal extension that is involved in cell membrane insertion.  They are subdivided 
into two groups; MMP-14, -15, -16 and -24 are classed as Type I transmembrane (TM) 
proteins and utilise a single pass cytoplasmic intracellular domain; the second group, 
comprised of MMP-17 and -25, have a glycosylphosphatidylinositol (GPI) anchor (Itoh, 
Kajita et al. 1999, Kojima, Itoh et al. 2000).  Phosphorylation (Nyalendo, Michaud et al. 
2007) and binding of regulatory proteins like gC1qR (Rozanov, Ghebrehiwet et al. 
2002) via the cytoplasmic tail has been reported, validating suggestions of roles in 
intracellular signalling, localisation and trafficking which may subsequently impact cell 
migration (Gingras, Bousquet-Gagnon et al. 2001).
	 The basic tetrapeptide RRKR/RRRR sequence within the PRO domain 
(Takino, Sato et al. 1995, Puente, Pendas et al. 1996) is common to all membrane-bound 
MMPs as well as the secreted MMPs -11, -21, -23, -28.   Recognition of this motif by 
furin was considered sufficient to ensure these proteins were secreted from the golgi in 
an activated state (Pei and Weiss 1995, Sato, Kinoshita et al. 1996, Yana and Weiss 
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2000).  However, a recent study demonstrated enzyme maturation required multi-
proteolytic steps (Golubkov, Cieplak et al. 2010). 
	 Similar to the stromelysins, certain members of this subfamily have been 
identified as major MMP activators.  MMP-14 was initially recognised as a key player in 
proMMP-2 activation (Will, Atkinson et al. 1996, Itoh, Takamura et al. 2001) and has 
since been proposed to be an activator of proMMP-13 (Knauper, Will et al. 1996, 
Knauper, Bailey et al. 2002), although the mechanism has yet to be fully elucidated. 
MMP-15, -16, -24 and -25 have also been reported to process proMMP-2 (Pei 1999, 
Morrison, Butler et al. 2001, Nie and Pei 2003, Zhao, Bernardo et al. 2004, Morrison, 
Butler et al. 2009).  This action will most certainly amplify the proteolytic cascade 
directly at the cell surface, i.e. in the pericellular environment.
	 In addition to degrading ECM constituents such as type I collagen (d'Ortho, Will 
et al. 1997, Ohuchi, Imai et al. 1997) these enzymes can target a number of cell-surface 
proteins, such as transglutaminase, CD44 and syndecan-1 (Belkin, Akimov et al. 2001, 
Kajita, Itoh et al. 2001, Endo, Takino et al. 2003).  Presumably contributing to complex 
cell-signalling pathways.
 1.4.6 Others
A further seven MMPs exist that have not been classified in the other categories.  These 
include MMP-12, MMP-20 and MMP-23, among others which demonstrate the great 
structural and functional diversity displayed by this family of  metalloproteases. 
	 MMP-12 is a metalloelastase originally found expressed in the alveolar 
macrophages of cigarette smokers (Shapiro, Kobayashi et al. 1993).  It is particularly 
effective against elastin and is therefore important in mediating elastin turnover. 
MMP-12 is an abundant elastase found in lung and arterial wall, consequently it has 
been associated with both emphysema and athersclerosis (Liang, Liu et al. 2006, 
Yamada, Wang et al. 2008, Churg, Zhou et al. 2012).  Like many MMPs, the gene is not 
transcribed in normal resting tissues. Gene expression has been identified in both the 
macrophage and stromal cells of the placenta.  Analysis of the amino acid sequence 
indicates homology with collagenase MMP-1 and stromelysin MMP-3 (Belaaouaj, 
Shipley et al. 1995). 
	 MMP-19, first isolated from a patient with rheumatoid arthritis (Kolb, Mauch et 
al. 1997), possesses the typical domain organisation observed in secreted MMPs. 
However, it also exhibits two distinctive features, a threonine-rich sequence at the C-
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terminus and an oligoglutamate stretch in the linker region (Sedlacek, Mauch et al. 
1998).  Expression has been identified in a wide distribution of tissues including 
placenta, lung, pancreas, ovary, spleen and intestine (Pendas, Knauper et al. 1997), 
suggesting a possible role in normal tissue homeostasis. 
	 MMP-20, also known as enamelysin, was originally identified from a porcine 
enamel organ-specific cDNA library (Bartlett, Simmer et al. 1996).  MMP-20 is tooth- 
specific and digests amelogenin (Ryu, Fincham et al. 1999), the major protein 
constituent in the enamel matrix of teeth. Defects in enamel bio-mineralization are the 
principal characteristic of amelogenin imperfecta and mutations of MMP-20 have been 
implicated in this disorder (Caterina, Skobe et al. 2002, Kim, Simmer et al. 2005).
 MMP-21 is the human orthologue of XMMP, a matrix metalloproteinase 
transiently expressed at the initiation of gastrulation of Xenopus laevis (Yang, Murray et 
al. 1997).  MMP-21 was isolated from a human placenta cDNA library (Ahokas, Lohi et 
al. 2002) and has been seen expressed during human embryogenesis as shown by it’s 
presence in fetal kidney, brain and liver tissues (Marchenko, Marchenko et al. 2003). 
Structurally similar to most MMPs, MMP-21 has a furin activation sequence, an 
unconserved proline-rich insertion between the PRO and CAT domain that is seen in 
both X. laevis and Cynops pyrrhogaster (Japanese Fire-bellied newt) orthologues (Suzuki, 
Tadano et al. 2001), while lacking a linker region connecting the HPX and CAT 
domains (Marchenko, Marchenko et al. 2003).
 A particularly unusual member is MMP-23.  Originally isolated during 
characterisation of the terminal end of chromosome 1, MMP-23 is encoded by two 
genes located within two identical tandemly-linked genomic regions (Gururajan, Grenet 
et al. 1998, Gururajan, Lahti et al. 1998).  MMP-23 was subsequently cloned from an 
ovarian cDNA library and appears to be expressed predominantly in reproductive 
tissues of the ovary, testis and prostate (Velasco, Pendas et al. 1999).  MMP-23 has some 
unique features that include an N-terminal transmembrane signal sequence (Pei, Kang 
et al. 2000), a shortened PRO domain lacking the typical ‘cysteine switch‘ motif and a 
truncated C-terminal domain with no homology to the HPX domain.  This has been 
“replaced” with a novel cysteine array motif (Cys-X(6)-Cys-X(8)-Cys-X(10)-Cys-X(3)-Cys-
X(2)-Cys), and an Ig-like domain (Pei 1999).  These features aside, MMP-23 has been 
classified as a matrix metalloproteinase due to the homology of it’s CAT domain and 
possession of  a furin recognition motif  (Pei, Kang et al. 2000).
 MMP-27 is potentially the last uncharacterised human MMP.  Initially it was 
cloned from the sclera of Tupaia belangeri (Common tree shrew) and with sequence data 
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deposited in the GenBank sequence database (accession number AF281673) by 
Guggenheim and Frost in 2000 (unpublished).  The human orthologue was identified 
during a large-scale bioinformatic search of novel human secreted and transmembrane 
proteins (Clark, Gurney et al. 2003).  It’s substrate specificity and physiological relevance 
have yet to be determined. 
 MMP-28 (epilysin) is expressed in a wide range of healthy tissues with 
constitutive expression observed in the testis, lung epithelium, invertebral disc, heart, 
colon and intestine (Lohi, Wilson et al. 2001, Marchenko and Strongin 2001, Gruber, 
Ingram et al. 2009, Manicone, Birkland et al. 2009).  Interestingly, mRNA levels for 
MMP-28 appear to be unaffected by a number of pro-inflammatory cytokines 
(Saarialho-Kere, Pentland et al. 1994, Klawitter, Quero et al. 2011).  This is in contrast 
to a number of other MMPs which are upregulated in the presence of TNF-α, IL-1α 
and IL-1β (Hanemaaijer, Koolwijk et al. 1993, Makela, Salo et al. 1998, Solomon, Li et 
al. 2000). Therefore, it appears that MMP-28 functions in normal tissue homeostasis. 
 Phylogenetic analysis indicates it  is closely related to MMP-19 (~40%) but in 
contrast it possesses the furin activation motif and an atypical promoter, noted for 
absence of the regulatory TATA box (Illman, Keski-Oja et al. 2001, Marchenko and 
Strongin 2001).
1.5 Matrix Metalloproteinase Domain Structure
 1.5.1 Inhibitory Domain
Enzyme maturation and catalytic activity acquisition occur as a direct result of 
propeptide cleavage.  Our understanding regarding CAT and PRO domain interactions 
and the mechanism of auto-inhibition has been enhanced by published structures of full 
length proMMPs -1 (Jozic, Bourenkov et al. 2005) and -2 (Morgunova, Tuuttila et al. 
1999), and C-terminally truncated proMMPs -3 (Becker, Marcy et al. 1995) and -9 
(Elkins, Ho et al. 2002), which are virtually superimposable over the main-chain atoms 
(Figure 1.5).
 Essentially, the propeptide is a small globular domain of ~ 80 residues that form 
three α helices and connecting loops.  This is stabilised by hydrogen bonds between the 
helices and formation of a hydrophobic core, in proMMP-1 this is supported by the 
side-chain interaction between Asp61 and Gln49.  Latency is maintained through steric 
blockage of the active site, excluding water as a potential fourth ligand for the zinc-ion, 
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Figure 1.5: Structure of the inhibitory propeptide.  (A) Superimposition of the propeptide of MMP-1 
(1SU3.pdb), MMP-2 (1CK7.pdb), MMP-3 (1SLM.pdb) and MMP-9 (1L6J.pdb). Structures were aligned 
against proMMP-1 to minimize the RMSD interatomic distance difference on main-chain atoms 
(0.47-0.78 Å) using Pymol Molecular Graphics System (version 1.5.0.4.), Schrödinger, LLC. The zinc ion is 
represented as a yellow sphere.   Protease sensitive loop 1 is indicated by the filled triangle. (B) Amino acid 
sequence alignment and individual views of relevant MMP propeptides. Alignment is coloured with 
increasing percentage identity (75-100%).  ‘Bait region’ motif of proMMP-1 is underlined.  Invariant cysteine 
residue of the ‘cysteine switch‘ motif is shown in black stick form coordinating the catalytic zinc ion. (C) 
Schematic representation of interactions between an MMP and propeptide. The sulfhydryl group of the 
unpaired cysteine residue forms an intramolecular tetrahedral complex with the zinc-ion binding histidine 
triad of the catalytic domain. Propeptide is in red and catalytic domain is in green. Image rendered using 
MarvinSketch (version 5.10.3.), ChemAxon. 
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and occluding substrate entry.  This interaction is achieved by the presence of an 
invariant cysteine residue found at position 73 within the highly conserved inactivation 
motif P71-R-C-G-X-P-D77 known as the ‘cysteine switch’ (Springman, Angleton et al. 
1990, Van Wart and Birkedal-Hansen 1990).  All known MMPs share this signature 
feature, with the exception of MMP-23.  Mutations in the cysteine switch consensus 
sequence have been shown to significantly reduce latency.  For example, replacement of 
the critical cysteine residue with other potential zinc-binding residues leads to complete 
loss of  inhibitory activity (Park, Matrisian et al. 1991).
	 Other residues contribute to PRO domain stabilisation.  Tyr18 and Leu19 in 
helix 1 are conserved in a number of MMPs and MMP-3 mutagenesis experiments 
involving these residues demonstrates their role as N-terminal stabilisation motifs, as 
alanine substitution resulted in increased autolytic activity (Freimark, Feeser et al. 1994). 
Furthermore, a number of hydrogen bonds link the PRO and CAT domains (Figure 
1.6).  Solved structures of MMPs equipped with accessory domains also display non-
covalent interactions between the domains.  proMMP-1 has residues located within 
blade I of the HPX domain that appear to support the propeptide thus promoting a 
compact zymogenic state (Jozic, Bourenkov et al. 2005).  In the case of the gelatinases, a 
phenylalanine is buried in a hydrophobic pocket on the surface of the third F2 repeat 
(Morgunova, Tuuttila et al. 1999, Elkins, Ho et al. 2002).  In MMP-2 this is held in place 
by a salt bridge between Asp40 and Arg368 and hydrogen bonding between Ile35 and 
Gly367.  
 Loop regions are frequently missing in the electron density as observed in the 
proMMPs -1, -3 and -9 crystal structures.  Protease-sensitive “bait regions” like that of 
proMMP-1 are known to reside within solvent exposed loop 1 (Nagase, Enghild et al. 
1990) and cleavage within this region is thought to destabilise helix-helix interactions 
and the overall propeptide fold allowing further proteolysis.  MMP-2, in contrast, has a 
unique disulphide bond between Cys60-Cys65 (Morgunova, Tuuttila et al. 1999) 
presumably conferring rigidity to loop 1, and which may feature in the specific MT-
MMP/TIMP-2 activation mechanism.  
	
 1.5.2 Catalytic Domain
The MMP CAT domain is well documented with over 200 structures solved and 
available in the Protein Data Bank (Table 1.2).  Roughly spherical in shape and ~40 Å 
in diameter (Tallant, Marrero et al. 2010), the CAT domain is composed of ~165 
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residues.  The tertiary structure of this particular domain consists of 3 α-helices and 5 
twisted β-strands (Figure 1.6) with a minimum of two calcium-binding sites and an 
additional two zinc-binding sites, one of which is critical for catalysis.  The domain is 
asymmetrically bisected by the shallow substrate-binding cleft forming an N-terminal 
upper subdomain, which terminates at Gly225, followed by a much smaller lower C-
terminal subdomain (Bode, Fernandez-Catalan et al. 1999).  This configuration is 
almost identical in all currently known MMP structures. 
 Removal of the PRO domain is required for enzyme maturation.  The method 
of activation is known to significantly impact the proteolytic activity status of the MMP 
CAT domain.  Catalytic efficiency is highly dependent on the specific N-terminal 
residue generated during the activation process.  MMP-1 activity is known to be 
enhanced by the action of MMP-3 (Murphy, Cockett et al. 1987), this is compared to 
other activation methods which lead to only ~14-25% of maximal activity.  This 
observed superactivation occurs as a result of Phe81 occupying the N-terminal position 
(Nagase, Suzuki et al. 1992).  In the case of MMP-8, a stromelysin-specific cleavage after 
Gly78 is necessary to generate the most effective enzyme (Knauper, Wilhelm et al. 1993, 
Knauper, Murphy et al. 1996).  This results in a salt bridge between the ammonium 
group of the N-terminal Phe79 and the side chain carboxylate group of Asp232 
(Reinemer, Grams et al. 1994, Iyer, Visse et al. 2006), which is thought to stabilise the 
‘Met-turn’ positioned at the base of  the active site.   
 Hydrolytic activity of mature collagenases occurs within the 5Å wide active site 
cleft, which extends horizontally (Figure 1.6C) with generation of a β-turn containing a 
strictly conserved methionine eight residues after the consensus sequence 
HExxHxxGxxH (Van Wart and Birkedal-Hansen 1990).  This characteristic ‘Met-turn’ 
then forms a hydrophobic base beneath the catalytic zinc ion (Bode, Gomis-Ruth et al. 
1993).  The zinc ion is coordinated by the imidazole Nε atoms of the three invariant 
histidine residues (Figure 1.6) and H2O as a fourth ligand (Li, Brick et al. 1995, Iyer, 
Visse et al. 2006).  Mutagenesis of any of the above glutamate and histidine residues has 
been demonstrated to ablate catalytic activity (Sanchez-Lopez, Nicholson et al. 1988, 
Windsor, Bodden et al. 1994, Roeb, Behrmann et al. 2000, Steele, El-Kabbani et al. 
2000, Ozdemir, Hart et al. 2005).
	 Substrate binding involves the peptide bond carbonyl group coordinating with 
the active site Zn2+ ion.  Positioning of the carboxylate group of the essential catalytic 
glutamate residue deprotonates zinc-bound H2O permitting a water-based nucleophilic 
attack on the substrate scissile bond (Pelmenschikov and Siegbahn 2002).
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Table 1.2: Experimentally derived Protein Data Bank accession codes for 
all MMP structures containing at least the catalytic domain 
(www.pdb.org; closing date: October 16, 2012).
Subfamily MMP PDB Codes
Collagenase MMP-1 966C 1AYK 1CGE 1CGF 1CGL 1FBL 1HFC 1MNC 
2AYK 2TCL 3AYK 4AYK 1SU3 2J0T 2CLT 3SHI 
4AUO 
MMP-8 1JH1 1JJ9 1KBC 1MMB 1MNC 1ZVX 2OY4 1ZS0 
1JAN 1A85 1A86 1BZS 1I73 1I76 1JAO 1JAP 1JAQ 
1ZP5 2OY2 1JH1 3DPE 3DPF 3DNG 1ZS0
MMP-13 456C 830C 1CXV 1EUB 1FLS 1FM1 2PJT 2OZR 
2OW9 2E2D 2D1N 1ZTQ 1YOU 1XUR 1XUD 
1XUC 3ELM 2YIG 317G 3I7I 3KEC 3KEJ 3KEK 
3KRY 3LJZ 3O2X 3TVC 3ZXH 4A7B
Gelatinase MMP-2 1CK7 1HOV 1QIB 1GXD 1EAK 3AYU
MMP-9 1GKC 1GKD 1l6J 2OW0 2OW1 2OW2 2OVZ 2OVX
Stromelysin MMP-3 1B3D 1B8Y 1BIW 1BM6 1BQO 1C3I 1CAQ 1CIZ 
1CQR 1D7X 1D8F 1G49 1G4K 1OO9 1QIA 1QIC 
1SLM 1SLN 1UEA 1UMS 1UMT 1USN 2D1O 2JNP 
2JT5 2JT6 2USN 3OHL 3OHO 3USN 1C8T 1D8M 
1D5J 1G05 1HY7 1HFS 2USN 1B8Y
MMP-10 1Q3A 3V96
MMP-11 1HV5
MMP-12 1JIZ 1JK3 2Z2D 2K2G 3BA0 2OXU 2OXZ 2OXW 
2HU6 1Z3J 1YCM 1Y93 1RMZ 1OS9 1OS2 2POJ 
1UTZ 1UTT 1ROS 2W0D 3EHX 3EHY 1ZRG 2JPV 
3F15 3F16 3F17 3F18 3F19 3FLA 2K9C 2JXY 2KRJ 
2OXU 2OXW 2OXZ 2POJ 2W0D 2WO8 2WO9 
2WOA 2Z2D 3BA0 3EHX 3EHY 3F15 3F16 3F17 
SF18 3F19 3F1A 3LIK 3LIL 3LIR 3LJG 3LK8 3N2U 
3N2V 3NX7 3RTS 3RTT 3TS4 3TSK 4EFS 4GUY 
3LKA 3TT4 
Matrilysin MMP-7 1MMP 1MMQ 1MMR 2DDY 2Y6C 2Y6D
Membrane-
bound
MMP-14 1BQQ 1BUV 3MA2
MMP-16 1RM8
Other MMP-20 2JSD
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	 Substrate catalysis results from a number of interactions located within the zinc-
binding region directly responsible for cleavage of the peptide scissile bond.  These 
contributions include substrate main chain binding within the active site cleft and 
specificity sub-site pockets that accommodate substrate side chain residues and mediate 
substrate preference.  Additional contributions stem from potential exosites in the 
accessory domains that may act as secondary binding sites and/or manipulate the 
substrate prior to hydrolysis.
  1.5.2.1 Specificity Sub-site Pockets
Several recognition pockets are distributed along the active site cleft, from S3-
S3’ (Babine and Bender 1997),  mediating interactions with equivalent substrate peptide 
substituents (Figure 1.7).  The S1’ sub-site specificity pocket is the prime influencer of 
substrate specificity and compatibility within the CAT domain.  The MMP-1 S1’ pocket 
invaginates to the right of the active site zinc ion and is shaped by His218, Leu235 of 
the ‘Met-turn’ and the Pro238-Tyr240 wall forming segment (Bode, Fernandez-Catalan 
et al. 1999, Iyer, Visse et al. 2006).  However, the presence of Arg214 tends to exclude 
entry of large side chains into the solvent filled pocket, thereby determining substrate 
preference (Bode, Fernandez-Catalan et al. 1999).  This pocket diverges in shape and 
depth among MMPs as a result of leucine, arginine and tyrosine residues present at 
positions analogous to Arg214.  
 MMPs can be grouped dependent on S1’ pocket depth (Figure 1.7).  Shallow 
and intermediate pockets define MMP-1 and -7, and MMP-2 and -8 respectively.  In 
contrast, MMP-3, -14 and -20 are distinguished by deep tube-like cavities (Yamamoto, 
Tsujishita et al. 1998, Lovejoy, Welch et al. 1999, Moy, Chanda et al. 1999, Pavlovsky, 
Williams et al. 1999, Park, Jin et al. 2003, Turk, Lee et al. 2006).  These deep pocket 
MMPs can accommodate residues with much larger side chains (Mucha, Cuniasse et al. 
1998).  However, the CAT domain is far from rigid.  Increased flexibility around the 
active site cleft has been reported for synthetic inhibitor-bound MMP-1, suggestive of 
either an induced-fit mechanism (Moy, Chanda et al. 1999) or conformational selection. 
This is supported by further observations using RS-104966-bound MMP, which 
displayed enhanced mobility in the  backbone around Arg214 to accommodate the 
diphenylether backbone.  Despite these structural observations, in the case of synthetic 
oligopeptides, mutations at the P1’ position are rarely tolerated by MMP-1 (Netzel-
Arnett, Fields et al. 1991), which prefers Ile/Leu at this position.  
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 1.5.3 Hemopexin Domain
The HPX domain is tethered to the CAT domain via a variable length linker.  The 
linker region in MMP-1 is 16 residues long (Jozic, Bourenkov et al. 2005) and therefore 
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Figure 1.7: The S1’ specificity pocket.  (A) Schematic of a general peptide substrate bound 
within the active site of a protease.  Pn and Pn’ (n = 1, 2, 3) refer to substrate residues and unprimed 
Sn and primed Sn’ refer to the cognate protease binding site. The MMP S1’ (coloured green) site is the 
most variable binding pocket.  (B) Surface view of MMP-1 (1HFC.pdb) in standard orientation.  The 
zinc ion is depicted as a yellow sphere. The S1’ pocket is located to the left side of the catalytic zinc 
residue and is defined by Arg214, His218, Leu235 and the wall forming segment Pro238-Ser239-
Tyr240 (Bode, Fernandez-Catalan et al. 1999). (C) Variable S1‘ specificity pockets. MMP-1 (left) is 
occluded by Arg214 (green sticks) while MMP-3 (right) has a leucine at the equivalent position leading 
to an open channel. 
(A) (B)
(C)
the HPX domain is within close proximity of the C-terminal helix of the CAT domain. 
In contrast, MMP-9 and -15 have much longer linkers, exceeding 60 residues in length 
(Wilhelm, Collier et al. 1989, Will and Hinzmann 1995). 
 For MMPs that possess the HPX domain, the topology is generally equivalent for 
sharing homology with rabbit serum hemopexin, a haem-transporting plasma 
glycoprotein (Faber, Groom et al. 1995).   Comparison of resolved structures (MMP-1, 
-2, -9, -12, -13, -14) show a C-terminal domain of ~200 residues, forming a four blade 
β-propeller arrangement displaying pseudo four-fold symmetry that is stabilised by an 
intradomain disulphide bond between cysteine residues in blades I and IV (Gohlke, 
Gomis-Ruth et al. 1996, Gomis-Ruth, Gohlke et al. 1996, Morgunova, Tuuttila et al. 
1999, Cha, Kopetzki et al. 2002, Jozic, Bourenkov et al. 2005, Iyer, Visse et al. 2006, 
Bertini, Calderone et al. 2008, Tochowicz, Goettig et al. 2011).  Disruption of this bond 
by mutagenesis was reported to abolish collagenase activity by MMP-1 (Windsor, 
Birkedal-Hansen et al. 1991) and significantly impact collagenolysis by MMP-8 with 
alanine substitutions reducing activity against type I collagen by 62% (Hirose, Patterson 
et al. 1993).
 A solvent-accessible funnel-shaped tunnel is positioned at the centre of the HPX 
domain and is shaped by the first strand of each β sheet.  In MMP-1, the carbonyl 
oxygen atoms of Asp266, Asp359, Asp408 and Glu310 coordinate a central structural 
calcium ion (Iyer, Visse et al. 2006).  MMP-2 possesses a similar acidic patch at the 
tunnel entrance, which is formed by four aspartate residues (Gohlke, Gomis-Ruth et al. 
1996).  Although calcium is typically found within the channel, sodium and chloride ions 
have also been observed (Gohlke, Gomis-Ruth et al. 1996, Gomis-Ruth, Gohlke et al. 
1996, Tochowicz, Goettig et al. 2011).  Whether these extraneous ions are an artifact of 
the crystallisation process, or have some physiological relevance, has yet to be 
established. 
 A single turn of α-helix and a four-stranded anti-parallel β sheet connected by 
long loops, constitute each blade (Figure 1.8).  The majority of the surface contours are 
formed by these loop regions.  Loop diversity, particularly associated with the outermost 
β-strand of each blade, is proposed to directly impart MMP-specific recognition 
properties. For example, collagen breakdown by MMP-1, cell-surface activation of 
proMMP-2 mediated by TIMP-2, and dimerisation of both MMP-9 and -14 is known 
to occur via the C-terminal HPX domain.  MMP-9 forms asymmetric homodimers 
through reduction-sensitive bonding between loops in blade IV (Cha, Kopetzki et al. 
2002) while membrane-bound MMP-14 forms symmetrical homodimers mediated 
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primarily by short loops in blade III (Tochowicz, Goettig et al. 2011). MMP-2 is 
localised at the cell-surface by blade III/IV interactions with intermediary TIMP-2 
(Morgunova, Tuuttila et al. 2002). Conversely, MMP-1 is apparently reliant on 
determinants within blade I for collagen-substrate recognition (Lauer-Fields, Chalmers 
et al. 2009).  
	
Although lacking inherent catalytic activity, the HPX domain of MMP-1 is an absolute 
requirement for collagen breakdown.  Production of chimeric proteins combining 
features of MMP-1 and -3 as well as HPX domain deletion mutants showed complete 
abolishment of collagenolytic activity without any demonstrable effect on general 
hydrolytic activity towards gelatin, casein and other simple synthetic peptides (Murphy, 
Allan et al. 1992, Hirose, Patterson et al. 1993, Sanchez-Lopez, Alexander et al. 1993). 
Potentially complex substrate specificity determinants are controlled, in part, by the 
hemopexin domain.  Certainly this is true for fibrillar collagen recognition, which 
requires complete full-length domain structure to ensure correct interplay between both 
the HPX and CAT domain.
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900
Figure 1.8: MMP-1 hemopexin domain. Structure of the C-terminal domain (~45 Å at the 
longest axis) showing semitransparent surface and ribbon representations in the same orientation. 
Blades I-IV are labelled clockwise. The calcium ion, depicted as a black sphere, is positioned at the base 
of the propeller channel. The ball and stick representation of the disulphide bond between blade I and 
IV is coloured yellow.
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1.6 Matrix Metalloproteinase Regulation
MMPs possess the ability to catabolise various matrix constituents necessary to alter cell 
fates and control developmental pathways.  To prevent aberrant activity and subsequent 
overwhelming destruction within the ECM, exquisite regulatory mechanisms are in 
place (Figure 1.9).  	
 
30
1. Transcription
2. Translation
3. Secretion
4. Localisation
5. Activation
6. Inhibition
TIMPs α2-macroglobulin
ECM bound
Membrane associated
TM or GPI 
Serine proteases
Furin cleavage
Other MMPs
Figure 1.9: Overview of MMP regulation. Regulation occurs initially at both the (1) RNA 
transcription and (2) protein synthesis level.  MMP activity is further controlled during (3) secretion through 
the trans-golgi network to the ECM, (4) localisation as seen with MMP-8 and membrane-bound MMPs, (5) 
zymogen activation and (6) inhibition by reversible endogenous inhibitors like TIMPs, or α2-macroglobulin 
which binds MMPs and leads to their clearance by endocytosis (Adapted from Page-McCaw, Ewald et al. 
2007).
 1.6.1 Transcriptional Regulation
Eight known human MMP genes are clustered on chromosome 11 at 11q21-23 with 
others distributed on chromosomes 1, 8, 12, 14, 16, 18, 20, 22.  Extensive gene 
duplications in early vertebrate evolution particularly in the tetrapod lineage is 
responsible for the great protein structural divergence of MMPs (Huxley-Jones, Clarke 
et al. 2007).  However, a number of MMP promoters share common features and as a 
result, genes are often transcribed simultaneously, in response to various inductive 
stimuli. Several cis-elements (e.g. activator protein (AP-1), polyoma enhancer A3 (PEA3), 
SP-1, beta-catenin/Tcf-4 and nuclear factor-kB (NF-kB) sites), and their corresponding 
trans-activators (Figure 1.10), have been implicated in regulating expression of MMP 
genes (Reviewed in Yan and Boyd 2006).    
	 MMP promoters are grouped into three categories based on promoter 
composition.  The first group of inducible promoters (MMP-1, -3, -7, -9, -10, -12, -13, 
-19 and -26) contain a TATA box and often a PEA3-binding site adjacent to an AP-1 
binding site approximately ~70 bp upstream of the transcriptional start site.  The 
second group (MMP-8, -11 and -21), lack the AP-1 site while the third group (MMP-2, 
-14 and -28) also lack the TATA box with constitutive expression mainly determined 
through binding of the GC box by the ubiquitous SP-1 family of transcription factors 
(Reviewed in Yan and Boyd 2006).
	 Basal MMP gene expression in normal resting tissue is usually low or even 
undetectable.  Transient increases in transcription occur during normal matrix 
remodelling in response to signal transduction events that target and induce specific 
elements within the promoter region.  For example, presence of a Tcf-4 site within the 
MMP-2, 7, -9 and -26 promoters mediates MMP expression in response to Wnt 
signalling (Crawford, Fingleton et al. 1999, Marchenko, Marchenko et al. 2004, Wu, 
Crampton et al. 2007), while possession of a NF-KB site within the MMP-9 promoter 
directs expression via an inflammatory cytokine-activated pathway (Bond, Fabunmi et 
al. 1998).  The addition of MAPK, SMAD and STAT signalling as well as differential 
promoter response adds further levels of complexity and thereby directs combinatorial 
control of  MMP promoters to generate diverse tissue-specific ECM environments.  
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 1.6.2 Localisation
Direct tethering to the cell-surface via transmembrane and GPI-anchors is an obvious 
method of localisation achieved by the MT-MMP family, whereby membrane 
integration and tethering can ensure the focused proteolysis necessary for cellular 
motility and invasion of neighbouring tissues.  For example, MMP-14 has been shown to 
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Figure 1.10: Signal transduction pathways known to induce MMPs. Ligand-receptor 
interactions occuring at the stromal-epithelial interface activate several signal transduction pathways. 
Spatial and temporal regulation can be achieved through integration of trans-activating factors with 
different combinations of cis-binding elements within the promoter region, in this case MMP-1. 
Relative positions of cis-elements are not drawn to scale. Abbreviations: RTK, receptor tyrosine kinase; 
TGF-β, transforming growth factor beta; GPCR, G-protein coupled receptor;  JAK, Janus kinases; 
STAT, signal transducer and activator of transcription; MAPK, mitogen-activated protein kinase; 
ERK, extracellular signal-related kinase; JNK, c-Jun N-terminal activated kinases; NF-κB, nuclear-
factor-κB; Ets,  erythroblastosis twenty six; PEA3, polyomavirus enhancer-A binding protein site;  AP-1, 
Activator protein-1 site; Tcf, T-cell factor site; SBE, STAT-binding element.  (Adapted from Overall 
and Lopez-Otin 2002, Rowan and Young 2007).
accumulate at the invadopodia of breast carcinoma cell line MDA-MB-231 (Artym, 
Zhang et al. 2006) as a result of membrane integration, which is evident by 
transmembrane and cytoplasmic domain truncations of MMP-14 that prevented 
invadopodial localisation (Nakahara, Howard et al. 1997, Lehti, Valtanen et al. 2000). 
MMP-14 has also been reported in lamellopodia of migrating osteoclasts and 
endothelial cells (Sato, del Carmen Ovejero et al. 1997, Galvez, Matias-Roman et al. 
2001), this cellular migration appears to be mediated by adhesion protein CD44 (Mori, 
Tomari et al. 2002).  Furthermore, CD44 receptor clustering is reported to facilitate cell-
surface docking of MMP-7 and -9 (Bourguignon, Gunja-Smith et al. 1998, Yu and 
Stamenkovic 1999, Yu, Woessner et al. 2002, Desai, Rogers et al. 2007).
 Other cell adhesion molecules heavily implicated in MMP localisation are the 
heterodimeric transmembrane integrins. Immunofluorescence and immunoprecipitation 
studies show co-localisation of MMP-14 with integrins αvβ3 and β1 (Ellerbroek, 
Fishman et al. 1999, Hofmann, Westphal et al. 2000, Deryugina, Ratnikov et al. 2001). 
It has been suggested that these integrins may have distinctly different roles, with β1 
integrins acting as a reservoir for MMP-14 at endothelial cell junctions prior to 
redistribution to the αvβ3 integrins at the migrating cell front (Galvez, Matias-Roman et 
al. 2002).  Similarly MMP-2 is known to bind the αvβ3 integrin (Brooks, Stromblad et 
al. 1996).  This is mediated by the C-terminal HPX domain and is linked to vascular 
invasion during angiogenesis (Brooks, Stromblad et al. 1996, Brooks, Silletti et al. 1998, 
Silletti, Kessler et al. 2001).  However other roles of this interaction may exist and 
include impairment of integrin signalling (Menon, Singh et al. 2006), presumably by 
occluding access of extracellular cognate signalling molecules; and potentially as an 
additional cell-surface activation mechanism (Hofmann, Westphal et al. 2000).  MMP-1 
also utilises its HPX domain as a contact point for specific α2β1 integrin-binding 
(Dumin, Dickeson et al. 2001, Stricker, Dumin et al. 2001).  These particular integrins 
show enhanced pericellular expression at the leading edge of migrating human 
keratinocytes (Decline and Rousselle 2001), thereby spatially restricting MMP-1 
proteolysis. Migration across type I collagen in the dermal matrix is dependent on the 
action of MMP-1 as demonstrated by a series of experiments which inhibited cellular 
motility by directly preventing collagenolytic activity, this included using α2 antibodies to 
block the integrin-MMP complex (Pilcher, Dumin et al. 1997).   
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 1.6.3 Zymogen Activation
All secreted MMPs are thought to be released into the ECM in an inhibited zymogen 
form with enzyme latency maintained by the small globular PRO domain that occludes 
the active site cleft thus preventing substrate hydrolysis.  Thiol modification, allosteric 
perturbation or stepwise processing of protease susceptible loop regions of the PRO 
domain are postulated to destabilise the domain.  This is believed to disrupt the cysteine 
coordination of the zinc ion, thus triggering the ‘cysteine switch’ (Springman, Angleton 
et al. 1990, Van Wart and Birkedal-Hansen 1990) and exposing the autolytic cleavage 
site (Figure 1.11).  
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Figure 1.11: Protease cleavage of the PRO domain. Schematic illustration of enzymatic activity 
suppression by the PRO maturation by proteolytic propeptide removal, indicated by purple stars, which 
disrupt Zn2+ chelation by the thiol moiety in the ‘cysteine switch’  PRCGVPD consensus sequence. 
Primary amino acid sequence of the MMP-1 PRO domain. Structural helix elements are shown in red. 
The bait region in loop one is indicated by the blue dashed box. The cysteine switch region is indicated 
by the green dashed box. The position of protease cleavage sites are indicated by arrows (1) trypsin site, 
(2) trypsin and plasma kallikrein (PKK) site, (3) MMP-1 autocatalytic site following treatment with PKK 
and plasmin, (4) MMP-1 autocatalytic site following treatment with APMA, (5) MMP-3 site, (6) MMP-1 
autocatalytic site, (7) MMP-1 autocatalytic site following treatment with APMA. (Adapted from Birkedal-
Hansen, Moore et al. 1993).
Zymogen Intermediate Mature enzyme
	 However, the complex physiological and biochemical activation mechanisms 
during enzyme maturation continue to remain largely elusive.  Nevertheless, they are 
theorized to occur either at the cell surface via complexation with MT-MMPs mediated 
by endogenous MMP inhibitors, members of the TIMP family (Itoh, Binner et al. 1995, 
Overall, King et al. 1999, Overall, Tam et al. 2000, Morgunova, Tuuttila et al. 2002), or 
via an activation cascade initiated by serine proteases (Nagase, Enghild et al. 1990, 
Suzuki, Enghild et al. 1990).  
	 Activation mechanisms are not limited to proteases.  In vitro organomercurial 
compounds like 4-aminophenyl mercuric acetate (APMA), chaotropic ions, disulfide 
compounds, sulfhydryl alkylating agents and oxidants have all been shown to activate 
MMPs most likely through exposure, permanent modification or liberation of the 
inhibitory zinc-binding cysteine residue (Stricklin, Jeffrey et al. 1983, Nagase, Enghild et 
al. 1990, Rajagopalan, Meng et al. 1996, Gu, Kaul et al. 2002).
  1.6.3.1 Matrix Metalloproteinases
In vitro, many MMPs have been shown to participate in processing other proMMPs 
(Figure 1.12), by triggering the stepwise activation mechanism leading to autolysis and 
PRO domain removal.
 Maturation of proMMP-2 has been well-studied and is achieved by TIMP- 
dependent activation.  TIMP-2 binds membrane bound MT1-MMP using it’s inhibitory 
N-terminal domain (Fernandez-catalan, Bode et al. 1998).  Now immobilized, the 
TIMP-2 C-terminal domain binds the hemopexin domain of proMMP-2 through 
blades III and IV (Itoh, Binner et al. 1995, Overall, King et al. 1999, Overall, Tam et al. 
2000).  MT1-MMP homodimerization occurs (Itoh, Takamura et al. 2001) forming a 
tetrameric complex thereby allowing cleavage of the proMMP-2 scissile peptide bond 
between Asn37 and Leu38 (Will, Atkinson et al. 1996).  A mature MMP-2 molecule 
with full gelatinase activity is produced following subsequent transactivation by MMP-2 
(Atkinson, Crabbe et al. 1995).  MT1-MMP has also been shown to activate 
proMMP-13 (Knauper, Bailey et al. 2002), although independently of  TIMP-2.
 MMP-3 has also been shown to be a potent activator of several MMPs including 
MMP-9 (Ogata, Enghild et al. 1992).  For the collagenases, MMP-1 and MMP-8, N-
terminal processing by MMP-3 results in enzyme ‘superactivation’ with a 4-12 fold 
increase in activity when compared to activation initiated by mercurials and other 
proteases (Murphy, Cockett et al. 1987, He, Wilhelm et al. 1989, Suzuki, Enghild et al. 
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1990, Knauper, Wilhelm et al. 1993).  Thus, MMP-3 may play a key role in ECM 
degradation by initiating a cascade of MMP activity with subsequent degradation of the 
basement membrane and interstitial matrix via the collagenases MMP-1, -8 and -13, 
and MMP-9.  However, the relevance of these superactivated enzyme forms and the 
physiological activation mechanism of most proMMPs remains unclear, particularly as a 
study using MMP-3 deficient mice revealed no impaired proMMP-9 activation (Lijnen, 
Silence et al. 1998).
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Figure 1.12: MMP activation network. Zymogen forms are labeled in black and active MMPs are 
labeled in red.  The interactions depicted are not exhaustive. Data was compiled from (Ito and Nagase 
1988, Nicholson, Murphy et al.  1989, Quantin, Murphy et al. 1989, Suzuki, Enghild et al.  1990, Nagase, 
Suzuki et al. 1992, Ogata, Enghild et al. 1992, Knauper, Wilhelm et al.  1993,  Crabbe, O'Connell et al. 
1994, Fridman, Toth et al. 1995, Sang, Birkedal-Hansen et al. 1995, Takino, Sato et al.  1995, Knauper, 
Murphy et al. 1996, Nakamura, Fujii  et al. 1998, Ramos-DeSimone, Hahn-Dantona et al. 1999,  Uria and 
Lopez-Otin 2000, Morrison, Butler et al. 2001).
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 1.6.3.2 Serine Proteases
To date, 178 human serine protease members have currently been identified (Quesada, 
Ordonez et al. 2009) and the vast majority of these enzymes can be grouped within four 
classic serine protease families S1, S8, S10, S14; typified by chymotrypsin, subtilisin, 
carboxypeptidase Y and Clp protease respectively (Reviewed in Hedstrom 2002). 
Known MMP activators urokinase-type-plasminogen activator (uPA), tissue-type-
plasminogen activator (tPA), plasmin, plasma kallikrein and furin are all denoted as S1 
serine proteases, i.e each possesses the characteristic Asp-His-Ser triad with preference 
for cleavage of substrates, dependent on arginine or lysine at position P1 (Rawlings and 
Barrett 1999).  As previously mentioned, the general mechanism of MMP activation 
involving stepwise proteolytic processing begins within protease susceptible loop regions 
of the PRO domain.  Hydrolysis occurs within basic amino acid motifs located within 
the ‘bait’ region of the solvent exposed loop between helix 1 and 2 (Nagase, Suzuki et al. 
1991).More detail of the molecular basis of proteolytic activation has been revealed 
during a stopped-flow, freeze-quench, x-ray spectroscopic study of proMMP-9 activation 
catalysed by the serine protease tissue kallikrein.  The temporal sequence of events 
leading to catalysis is apparently triggered during protein-protein complexation with 
activation occurring via a pentacoordination intermediate (contributions from Cys73, 
His218, His222, His228 and Glu219) transient Zn2+ ion charge changes and proton 
transfer from the active site glutamate residue (Rosenblum, Meroueh et al. 2007). 
Intriguingly, this study concluded that cysteine dissociation occurs prior to significant 
proteolysis.  MMP activity in the absence of PRO domain removal has previously been 
reported (Bannikov, Karelina et al. 2002), but whether this is a general feature of 
physiological relevance remains to be determined.  However, what is clear, is that for 
many MMPs proteolytic processing forms unstable intermediates that are rapidly 
processed to the mature, active enzyme (Stricklin, Jeffrey et al. 1983, Okada, Harris et 
al. 1988, Murphy, Ward et al. 1989, Nagase, Enghild et al. 1990, Suzuki, Enghild et al. 
1990, Suzuki, Lees et al. 1995, Knauper, Lopez-Otin et al. 1996, Knauper, Will et al. 
1996, Monea, Lehti et al. 2002, Golubkov, Chekanov et al. 2007).      
   1.6.3.2.1 uPA-plasmin System
The urokinase-type Plasminogen Activator (uPA)-plasmin system plays a pivotal role in 
matrix degradation by regulating the extracellular proteolytic cascade resulting in 
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plasmin formation.  Proteolytic processing of ubiquitous zymogen plasminogen (Plg) by 
uPA or tPA results in activated plasmin, which has a distinct role in thrombolysis as well 
as being implicated as a potential physiological activator of proMMPs (Nagase, Enghild 
et al. 1990, Ramos-DeSimone, Hahn-Dantona et al. 1999, Monea, Lehti et al. 2002). 
Blood and vasculature restricted expression of tPA suggests that the uPA-plasmin system 
is more relevant for pericellular MMP activation, particularly as urokinase-type 
plasminogen activator receptor (uPAR) possesses a GPI-anchor ensuring the Plg 
activation cascade is localised to the cell surface.
  The central binding cavity of uPAR is formed by a concave arrangement of 
three domains (Llinas, Le Du et al. 2005), which mediate high affinity binding (0.1-1 
nM) with 1:1 stoichiometry to both zymogen (pro-uPA) and mature uPA (Cubellis, Nolli 
et al. 1986, Roldan, Cubellis et al. 1990, Moller, Pollanen et al. 1993).  Specific binding 
to uPAR increases the cell surface concentration of active uPA, which in turn promotes 
uPAR clustering in the lipid-enriched microdomains of the plasma membrane 
(Cunningham, Andolfo et al. 2003).  Plg, in contrast, is restricted to the cell surface by a 
large group of heterogeneous receptors, which in combination contribute to the high 
cellular Plg binding capacity estimated at 104-107 binding sites per cell (Hajjar, Harpel et 
al. 1986, Ganz, Dupuis et al. 1991).  Reported candidate Plg-receptors include actin, 
cytokeratin (Hembrough, Li et al. 1996), α-enolase (Redlitz, Fowler et al. 1995) and 
integrin αVβ3, which typically bind in a lysine-dependent manner (Ellis, Whawell et al. 
1999).  
 As well as providing protection from circulating inhibitors (Plow, Freaney et al. 
1986, Redlitz, Fowler et al. 1995) α2-antiplasmin and the serpins, plasminogen activator 
inhibitor 1 (PAI-1) and PA-2, binding to cell-surface receptors appears to promote a 
conformationally altered activation-susceptible Plg form (Christensen and Molgaard 
1991, Andronicos and Ranson 2001).  Presumably close spatial proximity between the 
uPA-uPAR complex and receptor-bound Plg then stimulates cleavage of the Arg561-
Val562 Plg peptide bond (Robbins, Summaria et al. 1967) resulting in enzymatic 
maturation and subsequent conversion of surface-bound plasminogen to plasmin.  Plg 
activation is accelerated in the presence of receptor-bound uPA, while another study 
observed colocalisation between integral membrane receptor Plg-RKT and uPAR 
(Andronicos, Chen et al. 2010).
	 Cell surface-associated plasmin is known to process in vitro a number of latent 
MMPs including MMP-1, -2, -3, -9, -13 and -14 (Grant, Eisen et al. 1987, He, Wilhelm 
et al. 1989, DeClerck, Yean et al. 1991, Knauper, Will et al. 1996, Mazzieri, Masiero et 
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al. 1997, Okumura, Sato et al. 1997, Ramos-DeSimone, Hahn-Dantona et al. 1999, 
Santala, Saarinen et al. 1999, Monea, Lehti et al. 2002, Liu, Li et al. 2005).  In all cases 
the PRO domain is targeted and processed by plasmin leading to decreases in molecular 
mass.  Murine knockout experiments studying the effects of Plg-deficiency on wound-
healing identified phenotypic overlap or synergy between the two enzyme systems 
(Lund, Romer et al. 1999, Lund, Green et al. 2006, Juncker-Jensen and Lund 2011) with 
decreased keratinocyte migration during reepithelialisation (Romer, Bugge et al. 1996, 
Green, Almholt et al. 2008).  A similar study showed defective placental vascularization, 
intrauterine growth retardation and increased embryonic lethality in Plg-/- mice treated 
with broad spectrum MMP inhibitor galardin (Solberg, Rinkenberger et al. 2003).  In a 
mouse model of inflammatory skin disease Bullous pemphigold, MMP-9 activation was 
found to be plasmin-dependent during the early stages of sub-epidermal blistering (Liu, 
Li et al. 2005).  However, further support for the role of plasmin as a physiological 
activator in the MMP activation pathway has been lacking.
   1.6.3.2.2 Furin
Furin is a ubiquitously expressed member of the proprotein convertase (PC) family, a 
group of mammalian calcium-dependent subtilisin/kexin-like serine proteases primarily 
distributed in the trans-golgi network (Bosshart, Humphrey et al. 1994, Molloy, Anderson 
et al. 1999) that cleave proteins traversing constitutive secretory routes.  The furin-like 
PCs; PC1, PC2, PACE4, PC4, furin, PC5A, PC5B and PC7 (Reviewed in Thomas 
2002), are structurally related to yeast Saccharomyces cerevisiae endoproteinase Kex2 
(Nakayama 1997) and recognise dibasic consensus sequences RXRR/RRKR/RRRR in 
protein precursors (Molloy, Bresnahan et al. 1992, Walker, Molloy et al. 1994, Rawlings 
and Barrett 1999).  The stringent requirements of furin for arginine at P1 and P4 
positions and the preference for polybasic substrate segments is the result of surface 
loops extending into the active site and negative electrostatic potential of subsite surfaces 
(Henrich, Cameron et al. 2003).
 A number of MMPs, including MT-MMPs, are activated upon cleavage of the 
furin consensus sequence, which is located at the C-terminal end of the PRO domain. 
Furin-deficient cell lines, LoVo and RPE.40, have been repeatedly used to show the 
predominant role of furin as an activator of certain MMPs, of these MMP-14 is 
certainly the best characterised.  Two potential proprotein convertase tetrabasic cleavage 
motifs reside within the MMP-14 PRO domain, R89-R-P-R↓C93 and R108-R-K-
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R↓Y112 (Yana and Weiss 2000), however the first site exists as part of the cysteine 
switch motif (Remacle, Rozanov et al. 2006) and therefore enzyme maturation is the 
result of cleavage generating the Y112 N-terminus (Strongin, Collier et al. 1995, Lehti, 
Lohi et al. 1998, Osenkowski, Toth et al. 2004).   Furthermore, Golubkov and colleagues 
have shown that maturation cleavage is facilitated by intradomain proteolytic processing 
at the P47-G-D↓L50 site (Golubkov, Chekanov et al. 2007).  Intriguingly, in the absence 
of this processing, the MMP-14 PRO domain excised by furin retained potent inhibitory 
activity with a ki of 160-200 nM (Golubkov, Cieplak et al. 2010).  Retention of a 
metalloproteinase inhibitory domain has been observed previously.  Following furin 
processing in the trans-Golgi network the PRO domain of ADAM12 remained non-
covalently associated with the mature enzyme (Wewer, Morgelin et al. 2006).  Therefore, 
it is unlikely that furin alone plays a significant role in PRO domain destabilisation and 
MMP maturation.
  1.6.3.3 Other Mechanisms
Organomercurial compounds are routinely employed to activate latent MMPs in vitro, 
and are thought to initiate the stepwise autolytic excision of the PRO domain.  It has 
been proposed that compounds like APMA directly react with the Zn2+-chelating 
cysteine residue leading to displacement of the sulfhydryl group.  However, CD data 
suggests that APMA stimulates enzyme maturation through PRO domain perturbation 
rather than direct cysteine modification, at least for MMP-3 (Chen, Noelken et al. 1993). 
As yet, the mode of  action by non-physiological agents, like APMA, remains unknown.  
	 In contrast, oxidative mechanisms are the likely instigator of MMP activation in 
vivo, along with serine proteases.  Increases in MMP expression and activation in hepatic 
stellate cells, human monocytes and human coronary smooth muscle cells has been 
observed during periods of oxidative stress (Galli, Svegliati-Baroni et al. 2005, Lu and 
Wahl 2005, Valentin, Bueb et al. 2005).  Furthermore, the physiological nitrous oxide 
(NO) donor S-nitrosocysteine has been shown to activate proMMP-9 by S-nitrosylation 
of  the cysteine during cerebral ischemia (Gu, Kaul et al. 2002).
	 Reactive oxygen and nitrogen species are known to readily react with thiol 
moieties.  Fu and colleagues previously demonstrated proMMP-7 activation after 
subsequent treatment with the cytotoxic oxidant hypochlorous acid (HOCl), a derivative 
of hydrogen peroxide (H2O2).  In this study, liquid chromatography electrospray 
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ionization mass spectrometry (LC/MS) was used to show thiol residue conversion to 
sulfinic acid, which preceeded increased proteolytic activity (Fu, Kassim et al. 2001). 
HOCl is produced following the release of myeloperoxidase (MPO) from the 
cytoplasmic granules of neutrophils and monocytes during phagocytosis (Bergt, 
Marsche et al. 2001).  Consequently, agents known to inhibit the MPO-H2O2 system or 
scavenge the resulting chlorinated oxidants have been shown to significantly reduce 
MMP activity (Peppin and Weiss 1986, Meli, Christen et al. 2003) and are therefore of 
interest when considering MMPs and their role in inflammatory response.
 1.6.4 Endogenous Inhibitors
A variety of molecules have been implicated in MMP inhibition.  The abundant non-
specific endopeptidase inhibitor, plasma α2 macroglobulin (α2M), is known to bind 
irreversibly to all active MMPs. Upon cleavage of ‘bait domains’ within α2M, a 
structural change results in covalent endopeptidase capture along with exposure of 
receptor domains, which facilitate rapid scavenger receptor-mediated endocytosis and 
clearance (Enghild, Salvesen et al. 1989, Sottrup-Jensen and Birkedal-Hansen 1989, 
Sottrup-Jensen and Birkedal-Hansen 1992, Moestrup, Holtet et al. 1993). 
Thrombospondin-1 binds progelatinases preventing enzymatic activation and RECK, a 
GPI-anchored glycoprotein, has been shown to downregulate levels of MMP-9 
(Takahashi, Sheng et al. 1998, Oh, Takahashi et al. 2001). However, the best 
characterised and principal endogenous inhibitors are members of the broad spectrum 
TIMP family.  
  1.6.4.1 TIMPs
Four TIMPS have been identified in vertebrates, and together they can preferentially 
suppress the MMP degenerative potential in connective tissue through tight reversible 
binding with MMPs in a 1:1 stoichiometry (Cawston, Murphy et al. 1983, Welgus, 
Jeffrey et al. 1985, Overall 1994).    
 TIMP-1, -2, -3 and -4 have six disulphide bonds forming the inhibitory N-
terminal and C-terminal domains (Williamson, Marston et al. 1990).  The complex 
crystal structures of N-TIMP-1 with the catalytic domains of MMP-1 and MMP-3 
(Figure 1.13) show the coordination of the catalytic zinc via the α-amino nitrogen and 
the peptide carbonyl group of the strictly conserved TIMP cysteine residue at position 1. 
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Inhibition is maintained through interaction with the glutamate residue leading to 
expulsion of the catalytic water molecule.  Further interactions, with the active site cleft 
and the S1’ specificity pocket, bind and block the active site (Gomis-Ruth, Maskos et al. 
1997, Iyer, Wei et al. 2007).
Understanding the structural basis of TIMP and MMP interactions is essential 
for future development of therapeutic inhibitors for diseases with unbalanced 
degradation of ECM components as a consequence of MMP activity.  Currently nearly 
all synthetic inhibitors incorporate hydroxamic acid, carboxylate or thiol group to 
chelate the catalytic zinc ion.
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Figure 1.13 : Structure of TIMP-1 and its interaction with MMP-3. (A) Ribbon representation of 
the crystal structure of TIMP-1, showing locations of disulphide bonds (yellow sticks). (B) TIMP-1 (purple) 
bound to the MMP-3 catalytic domain (green), zinc ions are depicted as yellow spheres and calcium ions are 
coloured black (PDB accession code - 1UEA). (C) The primary TIMP-1 interaction site, subsites within the 
MMP active site cleft are indicated (grey). (Adapted from Brew and Nagase 2010).
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1.7 The Paradox of Collagenolysis
How collagenases recognise and hydrolyse collagen is not clearly understood.  Despite 
the presence of 31 potential cleavage sites in the triple helical regions of type I, II, III 
and IV collagens (Fields 1991), interstitial collagenases process the collagen triple helix 
with precision at a single locus generating characteristic ¼ and ¾ length fragments. 
Analysis suggests this specificity is conferred by imino-rich sequences preceeding the 
scissile bond followed by a loose helical region within the subsequent four triplets, as well 
as the presence of an arginine residue at position P’5 or P’8 (Fields 1991).  However, 
proteolytic cleavage of collagen by collagenases is inhibited by localisation of this unique 
cleavage site within a narrow cleft, created both by microfibril formation and the 
presence of the C-telopeptide (Perumal, Antipova et al. 2008).  Of the total number of 
procollagen monomers present in a collagen fibril (50 nm diameter), only 10-12 % are 
surface exposed and accessibility is further restricted due to the polymerization of these 
fibrils, which may account for the modest cleavage rate of 22 collagen molecules 
degraded per collagenase per hour (Welgus, Jeffrey et al. 1980).  
 Further still is the conflicting size dimension of enzyme and substrate, which 
typically prevents peptide bond hydrolysis. Tropocollagen (15 Å diameter) is 
substantially larger than the active site presented by MMP-1 (5 Å), which is able to 
accommodate individual polypeptide chains only (Chung, Yoshida et al. 2004).  Studies 
using type III collagen-like peptides also reveal that collagen scissile bonds are not 
solvent exposed and are positioned at least 7 Å from the catalytic Zn2+ ion, and therefore 
remain inaccessible to collagenases (Stultz 2002, Chung, Yoshida et al. 2004).
	 It has been postulated that either the active site undergoes large structural 
rearrangements to accommodate the triple helical substrate, or collagen needs to be 
unwound for a single polypeptide chain to be delivered to the active site.  Unwinding 
may occur spontaneously or be induced by collagenases.  
	 Arguably, unfolded vulnerable collagen states exist.  NMR studies and molecular 
dynamics (MD) simulations suggest an absence of the triple helical fold near the 
collagenase cleavage site (Fiori, Sacca et al. 2002, Nerenberg and Stultz 2008). 
However, these vulnerable regions are generally resistant to degradation when treated 
with isolated collagenase CAT domains (Schnierer, Kleine et al. 1993, Chung, Yoshida 
et al. 2004, Han, Makareeva et al. 2010).  A recent study explored type I collagen 
degradation by MMP-1 and -8 CAT domains, demonstrating the redundancy of the 
HPX domain (Salsas-Escat, Nerenberg et al. 2010).  While degradation was observed, it 
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was significantly less than that observed for full-length MMP-1, requiring high enzyme 
concentrations and long incubation times.  Therefore, the HPX domain, which has been 
proposed to either unwind or stabilise conformationally-labile substrate states, is 
essential for efficient collagenolysis.  
	
1.8 Collagen-binding by the HPX domain
It has long been suspected that non-catalytic domains are involved in collagenolysis 
through either the conformational selection mechanism or via substrate processing and 
preparation prior to cleavage.  Both the HPX domain of collagenases and the FN2 
domains of gelatinases have been implicated in this process and are thought to possess 
exosites with essential roles in collagen binding.    
	  The presence of the HPX domain has been shown as an absolute requirement 
for catalysis and has been proposed to facilitate bond presentation through substrate 
positioning via these exosites (Lauer-Fields, Juska et al. 2002).  
Topology of the HPX domain is generally equivalent for the vast majority of 
MMPs with the final C-terminal ~200 residues constructing the typical four blade β-
propeller arrangement (Li, Brick et al. 1995, Gomis-Ruth, Gohlke et al. 1996, Jozic, 
Bourenkov et al. 2005, Iyer, Visse et al. 2006, Bertini, Calderone et al. 2008, Tochowicz, 
Goettig et al. 2010).  In MMP-1 the domain is stabilised by the presence of an 
intradomain disulphide bond between blades 1 (Cys259) and 4 (Cys447) (Jozic, 
Bourenkov et al. 2005, Iyer, Visse et al. 2006).  Substitution of these cysteine residues 
disrupts the HPX domain of MMP-1 sufficiently, resulting in complete loss of type I 
collagenolysis (Windsor, Birkedal-Hansen et al. 1991).  Total HPX domain deletion 
mutants have equivalent reduction in collagenolytic ability but with no effect on general 
catalytic competence with hydrolytic activity toward gelatin, casein and simple synthetic 
peptides maintained (Clark and Cawston 1989, Murphy, Allan et al. 1992). 
Circular dichroism spectroscopical analysis of triple helical collagen in the 
presence of the HPX domain suggests non-catalytic domain (NCD) induced 
perturbation of collagen substrate (Tam, Moore et al. 2004, Gioia, Monaco et al. 2007) 
and triple helicase activity mediated by the HPX domain of MMP-1 has been 
demonstrated with local unwinding of the collagen chains through preferential binding 
of α2(I) chain of Type I collagen (Chung, Yoshida et al. 2004).  This appears to be 
necessary for scissile bond exposure and sequential polypeptide chain cleavage.  The 
molecular basis of this interaction remains to be elucidated, however exosite regions 
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Table 1.3: HPX interactions with PRO domain residues
MMP-1 
residues
PRO domain residues 
Shift in Cα 
position (Å)van der Waals 
interactions
Hydrogen bonds
Phe308 Lys74, Asp80, Glu82 - 15.52
Tyr309 Gly72, Leu73, Glu82 Tyr309 OH- Glu82 OE1 
(2.6 Å)
11.88
Pro310 Gly72, Leu73, Lys74 - 8.87
(Adapted from Iyer, Visse et al. 2006)
Figure 1.14: Conformational differences in the HPX domain of proMMP-1 and MMP-1. 
PRO-1, CAT-1 and HPX-1 domains are shown in red, green and blue respectively. Zymogen and mature 
MMP-1 have been superimposed using their catalytic domains (RMSD 0.815). The curved arrows 
indicates the relative movement upon activation. The CD-loop is denoted by an asterisk (*). Coordinates 
taken from PDB depositions (1SU3 and 2CLT). Image rendered in Pymol Molecular Graphics System 
(version 1.5.0.4.), Schrödinger, LLC.
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involved in collagen recognition and binding have been identified by hydrogen/
deuterium exchange mass spectrometry (HD/MS) experiments.  Subsequent 
mutagenesis of residues Ile290 and Arg291, result in decreased affinity for collagen 
(Lauer-Fields, Chalmers et al. 2009).  However, HPX domain deletion studies of 
interstitial collagenase MMP-13 have shown that catabolic activity towards collagens IV, 
IX, X and XIV, fibronectin and tenascin is maintained indicative of exosite absence in 
some MMPs.
	 Domain replacement studies are revealing.  Collagenolytic activity is abolished in 
catalytically-competent chimeric proteins comprised of either the MMP-1 or -8 CAT 
domain fused with the HPX domain from members of the stromelysin family (Murphy, 
Allan et al. 1992, Hirose, Patterson et al. 1993, Sanchez-Lopez, Alexander et al. 1993). 
Despite type I collagen binding activity by the MMP-3 HPX domain (Murphy, Allan et 
al. 1992), fusion of this domain is insufficient to restore collagenase activity.  Therefore, 
collaboration between correctly paired collagenase domains is necessary for 
collagenolysis.  This is supported in a study by Chung and colleagues, which found high 
concentrations of isolated MMP-1 CAT and HPX domains was required for collagen 
breakdown, but connection of the two domain components by the linker was necessary 
for a more effective enzyme (Chung, Yoshida et al. 2004).
1.9 MMP Domain Rearrangements
Non-catalytic domains clearly play a major role in fibrillar collagen binding however 
little is known about the collaborative mechanism between domains which facilitates 
collagen catabolism. Significant conformational changes subsequent to propeptide 
cleavage, allowing enzyme maturation, have been observed. Superimposition of the 
human proMMP-1 structure (PDB accession code: 1SU3) with MMP-1 (PDB accession 
code: 2CLT) reveals significant changes in conformation. Removal of the PRO domain 
appears to disrupt a number of hydrophobic interactions unmasking residues Phe308-
Pro310 located within the loop region between β-strand C and D on blade I of the 
hemopexin domain.  The CD-loop undergoes a notable rearrangement of position 
(Figure 1.14) with the largest shift observed in the Phe308 Cα position (Table 1.3).  It has 
been suggested that HPX displacement is mediated by Arg300, which acts as a pivot 
(Jozic, Bourenkov et al. 2005). However, changes in domain orientation may also result 
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from conformational freedom of the variable-length linker region, which ranges from 14 
to the 68 amino acid residues observed for MMP-9.  
	 Collagenase linkers are known to play a role in collagen degradation.  De Souza 
et al. (1996) suggested a role for the flexible linker region as a potential intercalating 
agent driving the unwinding process of collagen through insertion between the 
polypeptide chains supported by interactions with the HPX domain.  However, a 
chimeric protein composed of the N-terminal MMP-3 domain combined with the C-
terminal region of MMP-1, including the linker, was not endowed with collagenolytic 
activity (Murphy, Allan et al. 1992).  Instead, extensive mutagenesis and assay of 
MMP-1 linker residues identified the importance of a glycine residue at position 272 
(P270-I-G-P-Q-T275).  Substitution with asparagine at this position was found to reduce 
type I collagen breakdown to 13% without affecting substrate specificity and binding, 
and consequently it was proposed that the linker is more likely to govern spatial domain 
arrangements through a hinge-bending motion (Tsukada and Pourmotabbed 2002). 
Furthermore, such conformational freedom may be a general feature of MMPs. 
Solution studies of MMP-9 and -12 support the existence of multiple enzyme 
conformations, which transiently assume more elongated conformations (Rosenblum, 
Cohen et al. 2007, Bertini, Calderone et al. 2008).  More recently, interdomain flexibility 
has been observed for MMP-1, although less pronounced than that of MMP-9 and -12 
(Bertini, Fragai et al. 2009).  It remains unclear if collagenase flexibility is a requirement 
for triple helical substrate recognition, manipulation and breakdown.
1.10 Aims and Objectives
The success of collagenolysis relies on determinants in both the triple helical collagen 
substrate and the collagenase enzyme.  MMP-1 induces collagenolysis and previous 
studies have implicated it’s HPX domain in binding and destabilising the collagen 
substrate in preparation for hydrolysis by the CAT domain.  Furthermore, studies of 
full-length MMPs support a hypothesis in which a structurally dynamic enzyme is able 
to utilise a collaborative domain mechanism to recognise and degrade collagen. 
Therefore, the primary purpose of this study is to both explore HPX domain mediated 
collagen recognition and the postulated flexible state of MMP-1, with an aim to 
facilitate understanding of the collagenolytic mechanism.  Initially this involved the 
expression of recombinant human MMP proteins from clones provided by Dr Rob Visse 
and Prof. Hideaki Nagase (Imperial College, London) in E. coli, and the optimised 
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purification of refolded proteins to produce yields sufficient for structural and functional 
characterisation.  This work is described in detail in Chapter 2, along with structural 
assessment of isolated domains by nuclear magnetic resonance (NMR) and limited 
proteolysis, and initial characterisation of hydrolytic activity using substrate cleavage 
assays.  
	 The precise location of HPX exosite(s) has, until recently, remained largely 
elusive.   However, work conducted in the laboratory of Dr Andrew Pickford (University 
of Portsmouth) has identified a putative collagen-binding site within the HPX domain of 
MMP-1.  An extensive alanine-scanning site-directed mutagenesis strategy is combined 
with Surface Plasmon Resonance (SPR) to characterise this site.  This work is described 
in Chapter 3.
	 Conformational freedom and transient separation of the CAT and HPX domain 
of MMPs has been observed during NMR and SAXS studies, consequently interdomain 
flexibility has been proposed to play a role in the collagenolytic mechanism.  Therefore, 
the role of the dislocated and compact state of MMP-1 will be elucidated using SAXS 
undertaken at the Diamond Light Source (Harwell Science and Innovation Campus, 
Didcot) and SPR, the results of  which are described in Chapters 4 and 5.
	 Comparison of the zymogen and mature MMP-1 crystal structures highlights 
the potential role of PRO-HPX contacts, which may restrain domain mobility and/or 
prohibit substrate recognition and proteolysis by maintaining enzyme latency.  In 
Chapter 6 mutagenesis is used to disrupt the PRO-HPX interface, SAXS is used to 
investigate the global zymogen form and SPR is used to assess collagen recognition by 
these mutants. 
	 During the latter stages of this project, two studies were published that provide 
significant insight into collagen catabolism by collagenases.  The first study describes a 
mechanism of collagenolysis that is derived from NMR experimental data of MMPs 
and MMP-peptide complexes, and docking experiments using protein-protein docking 
programme HADDOCK (Bertini, Fragai et al. 2012).  The second study used 
biochemical experiments and the first crystallographic structure of MMP-1 in complex 
with a triple helical peptide to show that collagenolysis relies on multiple exosite 
interactions (Manka, Carafoli et al. 2012).  These studies are discussed in detail within 
Chapter 7, and the results contained within this thesis are considered in the context of 
these latest findings.
49
CHAPTER 2: MMP PRODUCTION
2.1 Introduction
Protein expression strategies exploit prokaryotic or eukaryotic cellular machinery to 
synthesise heterologous functional proteins for proteomic study.  The expression systems 
available are highly variable (Table 2.1) and selection is typically dependent on the 
physical properties and function of the target protein.  However, laboratory resources, 
production cost and downstream experimental applications may often impact host 
system selection.  
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Table 2.1: Comparison of  Expression Systems
Desired 
characteristics
Bacteria Yeast Insect Mammalian cell 
culture
Cell growth Rapid Rapid Slow Slow
Complexity of  
growth medium
Minimum Minimum Complex Complex
Cost of  growth 
medium
Low Low High High
Expression level High Low-High Low-High Low-Moderate
Extracellular 
expression
Secretion to 
periplasm
Secretion to 
medium
Secretion to 
medium
Secretion to 
medium
Protein folding Refolding 
usually required
Refolding may 
be required
Proper folding Proper folding
N-linked 
glycosylation
None High mannose Simple, no sialic 
acid
Complex 
O-linked 
glycosylation
No Yes Yes Yes
Phosphorylation No Yes Yes Yes
Acetylation No Yes Yes Yes
Acylation No Yes Yes Yes
ɣ-Carboxylation No No No Yes
Reproduced from Gene Expression Systems: Using Nature for the Art of  Expression. 
Edited by: Joseph M. Fernandez and James P. Hoeffler © 1999 Academic Press., San Diego, CA 
	 Recombinant MMP proteins have been successfully expressed in chinese hamster 
ovary cells (Housley, Baumann et al. 1993), in the methylotrophic yeast Pichia pastoris 
(Rosenfeld, Ross et al. 1996) and in the Sf9 insect cell line using the baculovirus 
expression system (del Mar Barbacid, Fernandez-Resa et al. 1998).  However, Escherichia 
coli remains the most widely used prokaryotic expression host for many recombinant 
proteins and MMP production is no exception (Young, Rowan et al. 2010).  E. coli is 
often the preferred system for large-scale heterologous protein production. In fact, 80% 
of all solved protein structures submitted to the PDB in 2003, and nine of the thirty one 
approved therapeutic proteins in the subsequent three years, were prepared in E.coli 
(Sorensen and Mortensen 2005, Walsh 2006). Rapid, high-density cultivation on 
inexpensive substrates, high heterologous protein yields, well-established isotopic 
labelling protocols and versatile expression vector systems ensure its continued 
popularity. 
 The pET System (Novagen) includes over 42 commercially available plasmid 
expression vector types and 15 accompanying bacterial host strains developed for 
efficient target protein production (MerckMillipore n.d.).  Derived from cloning vector 
pBR322, the pET plasmids (Studier and Moffatt 1986) are almost exclusively for use in 
E. coli λDE3 lysogen strains, that contain a phage construct encoding T7 RNA 
polymerase (T7RNAP) under the control of the lacUV5 promoter (Figure 2.1).  Target 
genes are transcriptionally silent until T7RNAP expression is induced by the lactose 
analogue, isopropyl-1-thio-β-D-galactopyranoside (IPTG).  T7RNAP is highly efficient 
and promoter-specific (Chamberlin and Ring 1973, Cheetham, Jeruzalmi et al. 1999). 
Consequently, the translational machinery of E. coli is rapidly saturated by the 
transcribed mRNA, generating target protein levels exceeding 50% of total cellular 
protein content within hours (Studier and Moffatt 1986).  However, heterologous protein 
expression may be severely diminished as a result of codon bias, where synonymous 
codons are used with varying species-dependent frequencies (Grantham, Gautier et al. 
1980, Sharp, Cowe et al. 1988).  Rare E. coli codons include AGG, AGA and CGA 
encoding arginine, and CTA, ATA and CCC encoding leucine, isoleucine and proline 
respectively (Data obtained through the website http://www.kazusa.or.jp/codon/
Nakamura, Gojobori et al. 2000).  Deficiencies in cognate tRNAs, which are more 
commonly found in eukaryotic genomes, may lead to enhanced mRNA degradation, 
amino acid misincorporation, frame shifts and stalled translation (Reviewed in Kane 
1995).  Bacterial codon bias-adjusted BL21 derivatives have been devised to maximise 
expression.  Commercially available host strains include Rosetta (DE3) cells and Agilent 
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Technologies’ BL21-CodonPlus (DE3) series which contain extra copies of the E. coli 
argU, ileY, and leuW tRNA genes to overcome codon bias of the heterologous target 
gene. 
	
	 Further complications ensue as protein expression progresses.  E. coli has a 
limited capacity for complex posttranslational modifications, and inefficiently forms 
disulphide bonds.  Therefore, enhanced heterologous protein yields often result in 
insoluble inclusion bodies (Bowden, Paredes et al. 1991) formed almost exclusively from 
aggregated target protein (Rinas and Bailey 1992).  Nevertheless, recovery of bioactive 
proteins is possible and inclusion body (IB) deposition provides protection from host 
proteases, and a convenient method for purification of over-expressed proteins.  A high 
specific density of ~1.3 g/ml-1 (Margreiter, Messner et al. 2008) means IBs can be 
isolated from the cell homogenate by centrifugation using moderate rotor speeds, while 
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Host Cell - BL21(DE3)
lac I gene
LacR
T7 gene 1placUV5 placUV5 T7 gene 1 Target gene
pET 
pT7
E.coli genome
-IPTG +IPTG
1. 2a. 2b.
Figure 2.1: Vector and host elements of the prokaryotic pET expression system.   An E. 
coli strain containing a chromosomal copy of the T7 RNA polymerase (T7 gene 1) is transformed with a 
recombinant plasmid containing the gene of interest.   (1) T7 gene 1 transcription is repressed by the lac 
repressor (LacR) bound to its cognate operator within the lacUV5 promoter.  (2a) Transcription of T7 
gene 1 and subsequent expression of T7 RNA polymerase (T7RNAP) is stimulated using IPTG, an 
analogue of allolactose, which displaces LacR from the operator allowing binding by E. coli RNA 
polymerase (pink).  (2b) Induced production of T7RNAP (blue) transcribes the target gene (green) by 
binding specifically to the T7 viral promoter (pT7). (Adapted from Csun.edu n.d.) 
development of efficient solubilisation procedures using denaturants such as urea and 
guanidine hydrochloride, can produce IB preparations of high purity.  Acquisition of 
protein functionality relies on suitable refolding methods, which reduce the propensity 
for aggregation via hydrophobic intermolecular interactions while promoting formation 
of the native state.  Common strategies include dilution or dialysis to remove detergents 
and denaturants.    
 2.1.1 Nuclear Magnetic Resonance
Production of high-quality heterologous proteins amenable for further structural and 
biochemical studies is essential.  Determining sample quality is often achieved using 
protein Nuclear Magnetic Resonance (NMR) spectroscopy to assess the structural nature 
of the target protein.  While a detailed description of NMR spectroscopy is beyond the 
scope of  this thesis, a brief  description of  the NMR phenomenon is provided.  
 Atomic nuclei possess the intrinsic quantum property of angular momentum, 
termed ‘spin’, and a magnetic moment.  Nuclei with an odd mass number (e.g. 1H, 13C, 
15N, 19F) have fractional spins. Nuclei with a ½  integer spin quantum value (I), enables 
the existence of two energy spin states when an external magnetic field is applied; a low 
energy α ground state (I = +½) and a high energy β state (I = -½).  An unequal 
population of the two possible quantum energy states in thermal equilibrium results in 
bulk sample magnetization in the direction (z-axis) of the applied field.  The spins 
precess at a resonance frequency determined by the individual nuclear gyromagnetic 
ratio (Table 2.2) multiplied by the strength of the applied magnetic field.  Application of 
radio-frequency electromagnetic radiation at this frequency stimulates transitions 
between the energy states rotating the magnetization vector onto the transverse plane. 
Magnetization in this plane decays exponentially as the spin system returns to thermal 
equilibrium and is detected as a Free Induction Decay (FID).  A fourier transformation 
is then applied to the FID to obtain the NMR spectrum. 
 The precise resonant frequency of the energy transition is directly proportional 
to the strength of the applied magnetic field.  However, variations in local magnetic 
‘shielding’ by valence electrons, due to the surrounding chemical environment, affect the 
precessional frequency of nuclei and, thus, the radiation required to stimulate the 
energy transition.  Differences in this resonance frequency is termed ‘chemical shift’ (δ) 
and can be measured relative to a standard compound.
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	 Local deviations in shielding resulting from the proximity of adjacent atoms in 
folded proteins can easily be determined from the dispersed NMR spectra of two 
dimensional heteronuclear chemical shift correlation spectra.  The 1H, 15N 
Heteronuclear Single Quantum Correlation (HSQC) experiment used in this study, 
exploits the strong scalar spin-spin coupling (1JHN = ~92 Hz) between directly bonded 
amide proton and nitrogen nuclei of 15N isotopically-enriched proteins, to assess the 
native structure of  MMP-1 domains.
 2.1.2 Site-Directed Mutagenesis
Alanine-scanning mutagenesis is a powerful technique for determining the catalytic or 
functional role of individual residues in a protein.  Alanine is the most popular residue 
for substitution since it does not alter the main-chain conformation, unlike glycine and 
proline, and possesses a non-reactive aliphatic sidechain, a single methyl group. 
Therefore, substitution with alanine allows sidechain deletion effects of protein-ligand 
complex affinity to be measured while attempting to preserve native tertiary structure.  
 Using in vitro site-directed mutagenesis (SDM), oligonucleotide primers 
containing the desired mutation, in this case the alanine codon, can be incorporated into 
the amplicon thereby changing the original nucleotide sequence and consequently the 
translated amino acid sequence.  The QuikChange® XL Site-Directed Mutagenesis Kit 
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Table 2.2: Properties of  selected spin -½ nuclei
Isotope Natural 
abundancea
(%)
Magnetic 
moment
(μ/μN)
Gyromagnetic 
ratio
(ɣ/107 rad s-1 
T-1)
1H 99.9885 4.837353570 26.7522128
13C 1.07 1.216613 6.728284
15N 0.368 -0.49049746 -2.71261804
19F 100 4.553333 25.18148
31P 100 1.95999 10.8394
a representative isotopic compositions
(Taken from Harris, Becker et al. 2001) 
(Agilent Technologies) provides a rapid and efficient means of manipulating and 
modifying E. coli plasmid DNA containing the gene of  interest (Figure 2.2).  
 In brief, this method uses a thermostable high fidelity DNA polymerase, PfuUltra 
HF, for mutagenic oligonucleotide primer-directed plasmid replication.  PfuUltra HF 
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Figure 2.2: In vitro site-directed mutagenesis using the QuikChange® XL Site-Directed 
Mutagenesis Kit (Agilent Technologies).  Thermal cycling is utilised to denature the DNA 
template,  anneal mutagenic primers and extend the primers using PfuUltra HF DNA polymerase 
during Mutant Strand Synthesis (1).  The original template is digested with Dpn I, which targets GATC 
methylated and hemimethylated sites, shown as dark blue circles (2).  The remaining mutated plasmid is 
transformed into competent cells for nick repair (3). (Adapted from Agilent Technologies n.d.)
lacks terminal transferase activity but possesses 3’-5’ exonuclease activity, as a 
consequence this enzyme synthesises DNA with significantly higher fidelity than Taq 
DNA polymerase.  Mutant strand synthesis is achieved by annealing complementary 
primers incorporating the desired mutation during temperature cycling in the presence 
of PfuUltra HF, which generates a mutated plasmid with staggered nicks.  Treatment 
with Dpn I, an endonuclease specific for a methylated restriction site 5´-GATC-3´, which 
is a target in dam+ strains of E. coli, is used to selectively digest the parental DNA 
template.  The isolated in vitro synthesised ‘mutant’ plasmid is then transformed into 
competent cells for nick repair.  
 Mutagenic efficiency is determined using pWhitescript (4.5 kb) as a control 
plasmid, which contains a premature stop codon (TAA) in place of glutamine codon 
(CAA) within the β-galactosidase gene of pBluescript II SK(-) phagemid.  This disrupts 
β-galactosidase hydrolysis of 5’bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), 
an analogue of lactose, producing white colonies.  Mutagenic oligonucleotide control 
primers incorporate a point mutation that reverts the C residue in the glutamine codon, 
restoring  β-galactosidase activity.  Subsequent cleavage of X-gal yields 5’bromo-4-
chloro-3-hydroxyindole and galactose, the former product dimerises and is oxidized into 
the blue product 5,5’-dibromo-4,4’-dichloro-indigo.  Transformed XL10-Gold 
Ultracompetent cells can then be screened for β-galactosidase activity as demonstrated 
by a blue colony phenotype.  However, non-control reactions require DNA sequencing 
to ensure the desired mutation has been successfully incorporated.
 This chapter describes the expression and purification of the recombinant 
human proteins proMMP-3ΔHPX (hereafter referred to as proCAT-3), proMMP-1 (and 
mutants thereof), HPX-1 (and mutants thereof) and proMMP-1ΔHPX (hereafter 
referred to as proCAT-1*) using the pET vector system, and the subsequent analysis of 
protein quality using both NMR and substrate cleavage assays. 
56
2.2 Materials
 2.2.1 Chemical and Biochemical Reagents
Except where stated otherwise, all chemical and biochemical reagents were supplied by 
Fisher Scientific. 15N ammonium sulphate for isotopic labeling was supplied by 
Cambridge Isotope Laboratories, Inc.  Protogel 37.5:1 Acrylamide:Bisacrylamide 
stabilised solution (30% total monomer) for SDS-PAGE was supplied by National 
Diagnostics.  SeeBlue Plus2 Pre-Stained Standard for protein molecular weight 
visualisation was supplied by Life Technologies. COmplete, EDTA-free Protease 
Inhibitor Cocktail Tablets for general protease inhibition was supplied by Roche 
Applied Science. IEX Sepharose™ Fast Flow chromatography media and columns were 
supplied by GE Healthcare Life Sciences.  Urea (99.9%), cystamine dihydrochloride 
(97%) and deoxycholic acid (98.5%) were supplied by Acros Organics. Centrifugal filter 
units for protein concentration were supplied by Millipore. Standard Regenerated 
Cellulose Spectra/Por dialysis membrane was supplied by Spectrum Laboratories, Inc. 
StrataClean resins were supplied by Agilent Technologies. MMP substrates Ac-Pro-Leu-
Gly-[2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OC2H5 and Mca-Arg-Pro-Lys-Pro-Val-
Glu-Nva-Trp-Arg-Lys-(Dnp)-NH2 were purchased from Enzo Life Sciences and 
Bachem, respectively. Mca (7-methoxycoumarin-4-acetic acid) and Dnp (2,4-
dinitroaniline) are a common donor/quencher pair incorporated into FRET-based 
fluorescent probes.
 
 2.2.2  Nucleic Acids
The original pET-3a plasmid constructs containing the sequences for 
proMMP-3ΔHPX, proMMP-1*, HPX-1 and proMMP-1*ΔHPX cloned between NdeI 
and BamHI were generously donated by Dr Rob Visse and Prof. Hideaki Nagase, 
Imperial College London (See Appendix).  The proMMP-1ΔHPX and 
proMMP-3ΔHPX inserts were subcloned into the equivalent sites of pET-28b by Dr 
Andy Pickford (University of Portsmouth), thus endowing the proteins with an N-
terminal His6 fusion tag.
 2.2.3  Cell Strains
The E. coli DH5α strain [E. coli F- endA1 glnV44 thi-1 recA1 gyrA96 deoR nupG 
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Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(RK- mK-), λ-] was used for plasmid 
preparation. 
 XL10-Gold ultracompetent cells [E.coli TetrΔ (mcrA)183 Δ(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F’ proAB lacIqZΔM15 Tn10 (Tetr) 
Amy Camr] were provided as part of the Quikchange II XL Site-Directed Mutagenesis 
Kit supplied by Agilent Technologies, for use in nick repair following mutagenesis and 
blue-white colour screening.
The E. coli strain BL21 (DE3) [E. coli B F– dcm ompT hsdS(rB– mB–) gal λ(DE3)] was 
a general protein expression strain used that lacks both the lon protease and the ompT 
outer membrane protease, which can degrade proteins during purification.  
The E. coli strain BL21-CodonPlus® (DE3)-RIPL [E. coli B F– ompT hsdS(rB– mB–) 
dcm+ Tetr gal λ(DE3) endA Hte [argU proL Camr] [argU ileY leuW Strep/Specr] was 
routinely used for protein expression of  proMMP-1, HPX-1 and proMMP-3ΔHPX.
 2.2.4  Buffer and Media Recipes
All buffers and growth media were made with 18.2 MΩ deionised water (Purite) and 
autoclaved at 120°C for 20 minutes at 15 psi, except for those containing heat-sensitive 
components, which were filter-sterilised using 0.22 μm filters (Millipore).
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2.3  Methods
Due to the number of recombinant proteins expressed and purified during the course of 
this investigation (Table 2.3), the methods described herein remain non-specific.  
Table 2.3: Recombinant proteins produced for study
Protein Name Description
proMMP-3ΔHPX proCAT-3 C-terminally truncated MMP-3 zymogen form
MMP-3ΔHPX CAT-3 C-terminally truncated catalytically active MMP-3
HPX-1
HPX-1 Isolated C-terminal hemopexin domain of  wild-type MMP-1
HPX-1 R300A Arginine → Alanine mutation at position 
300 in the hemopexin domain
HPX-1 F301A Phenylalanine → Alanine mutation at 
position 301 in the hemopexin domain
HPX-1 P307A Proline → Alanine mutation at position 
307 in the hemopexin domain
HPX-1 Y309A Tyrosine → Alanine mutation at position 
309 in the hemopexin domain
HPX-1 F316A Phenylalanine → Alanine mutation at 
position 316 in the hemopexin domain
HPX-1 S318A Serine → Alanine mutation at position 
318 in the hemopexin domain
HPX-1 V319A Valine → Alanine mutation at position 
319 in the hemopexin domain
HPX-1 P325A Proline → Alanine mutation at position 
325 in the hemopexin domain
HPX-1 R337A Arginine → Alanine mutation at position 
337 in the hemopexin domain
HPX-1 D338A Aspartate →  Alanine mutation at 
position 338 in the hemopexin domain
HPX-1 Q354A Glutamine → Alanine mutation at 
position 354 in the hemopexin domain
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Table 2.3: Recombinant proteins produced for study
HPX-1 H358A Histidine → Alanine mutation at position 
358 in the hemopexin domain
HPX-1 P361A Proline → Alanine mutation at position 
361 in the hemopexin domain
proMMP-1
proMMP-1 wild-type full-length zymogen
proMMP-1 R300A
wild-type full-length zymogen with 
Arginine → Alanine mutation at position 
300 in the hemopexin domain
proMMP-1 F301A
wild-type full-length zymogen with 
Phenylalanine → Alanine mutation at 
position 301 in the hemopexin domain
proMMP-1 F316A
wild-type full-length zymogen with 
Phenylalanine → Alanine mutation at 
position 316 in the hemopexin domain
proMMP-1 S243C, 
S318C
wild-type full-length zymogen with Serine 
→ Cysteine mutations at position 243 in 
the catalytic domain and 318 in the 
hemopexin domain 
MMP-1
(active enzyme)
MMP-1 wild-type full-length mature enzyme
MMP-1 R300A
wild-type full-length mature enzyme with 
Arginine → Alanine mutation at position 
300 in the hemopexin domain
MMP-1 F301A
wild-type full-length mature enzyme with 
Phenylalanine → Alanine mutation at 
position 301 in the hemopexin domain
MMP-1 F316A
wild-type full-length mature enzyme with 
Phenylalanine → Alanine mutation at 
position 316 in the hemopexin domain
MMP-1 S243C, 
S318C
wild-type full-length mature enzyme with 
Serine → Cysteine mutations at position 
243 in the catalytic domain and 318 in 
the hemopexin domain 
proMMP-1ΔHPX
(hydrolytically 
impaired)
proCAT-1*
Inactive C-terminally truncated MMP-1 
zymogen form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain
MMP-1ΔHPX
(active enzyme) CAT-1
C-terminally truncated MMP-1 active 
enzyme form
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Table 2.3: Recombinant proteins produced for study
proMMP-1*
(hydrolytically 
impaired)
proMMP-1*
Inactive full-length zymogen form with 
Glutamine → Alanine mutation at 
position 200 in the active site of  the 
catalytic domain
proMMP-1* R300A
Inactive full-length zymogen form with 
Glutamine → Alanine mutation at 
position 200 in the active site of  the 
catalytic domain and Arginine → Alanine 
mutation at position 300 in the 
hemopexin domain
proMMP-1* F301A
Inactive full-length zymogen form with 
Glutamine → Alanine mutation at 
position 200 in the active site of  the 
catalytic domain and Phenylalanine → 
Alanine mutation at position 301 in the 
hemopexin domain
proMMP-1* P307A
Inactive full-length zymogen form with 
Glutamine → Alanine mutation at 
position 200 in the active site of  the 
catalytic domain and Proline → Alanine 
mutation at position 307 in the 
hemopexin domain
proMMP-1* F308A
Inactive full-length zymogen form with 
Glutamine → Alanine mutation at 
position 200 in the active site of  the 
catalytic domain and Phenylalanine → 
Alanine mutation at position 308 in the 
hemopexin domain
proMMP-1* Y309A
Inactive full-length zymogen form with 
Glutamine → Alanine mutation at 
position 200 in the active site of  the 
catalytic domain and Tyrosine → Alanine 
mutation at position 309 in the 
hemopexin domain
proMMP-1* P310A
Inactive full-length zymogen form with 
Glutamine → Alanine mutation at 
position 200 in the active site of  the 
catalytic domain and Proline → Alanine 
mutation at position 310 in the 
hemopexin domain
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Table 2.3: Recombinant proteins produced for study
proMMP-1* F316A
Inactive full-length zymogen form with 
Glutamine → Alanine mutation at 
position 200 in the active site of  the 
catalytic domain and Phenylalanine → 
Alanine mutation at position 316 in the 
hemopexin domain
proMMP-1* 
S243C, S318C
Inactive full-length zymogen form with 
Glutamine → Alanine mutation at 
position 200 in the active site of  the 
catalytic domain and Serine → Cysteine 
mutations at position 243 (catalytic 
domain) and 318 in the hemopexin 
domain
MMP-1*
(hydrolytically 
impaired)
MMP-1*
Inactive mature form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain
MMP-1* R300A
Inactive mature form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain and 
Arginine → Alanine mutation at position 
300 in the hemopexin domain
MMP-1* F301A
Inactive mature form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain and 
Phenylalanine → Alanine mutation at 
position 301 in the hemopexin domain
MMP-1* P307A
Inactive mature form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain and 
Proline → Alanine mutation at position 
307 in the hemopexin domain
MMP-1* F308A
Inactive mature form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain and 
Phenylalanine → Alanine mutation at 
position 308 in the hemopexin domain
MMP-1* Y309A
Inactive mature form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain and 
Tyrosine → Alanine mutation at position 
309 in the hemopexin domain
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Table 2.3: Recombinant proteins produced for study
MMP-1* P310A
Inactive mature form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain and 
Proline → Alanine mutation at position 
310 in the hemopexin domain
MMP-1* F316A
Inactive mature form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain and 
Phenylalanine → Alanine mutation at 
position 316 in the hemopexin domain
proMMP-1* 
S243C, S318C
Inactive mature form with Glutamine → 
Alanine mutation at position 200 in the 
active site of  the catalytic domain and 
Serine → Cysteine mutations at position 
243 (catalytic domain) and 318 in the 
hemopexin domain
Construct-specific methods are described in Tables 2.5-2.8 and contain details of both 
the purification pathway required and conditions necessary for optimal production of 
the recombinant protein of  interest.
 2.3.1  Preparation of E. coli strains for chemical transformation
E.coli bacterial strains frozen and stored at -80°C were streaked out on Lysogeny Broth 
(LB) agar plates and incubated at 37°C for 12-16 hours.  Single, well-isolated colonies 
were selected and used to inoculate 10 mL of pre-mixed LB Miller liquid media 
(components per L: 10 g Tryptone, 5 g Yeast extract, 10 g NaCl, pH 7.0 at 25 °C) and 
incubated overnight at 37°C with shaking at 250 rpm using an Innova 4400 shaking 
incubator.  
A baffled flask containing 250 mL of LB liquid media was inoculated with 250 
μL of the overnight culture and cells were grown at 37°C with shaking at 250 rpm until 
an OD600 of 0.6 was reached.  Growth rate was monitored at 600 nm using a Bioware 
CO8000 Cell Density Meter.  The culture was decanted into a pre-chilled 500 mL flat-
bottomed centrifuge bottle and cells were harvested by centrifugation at 5000 rpm for 
10 minutes at 4°C in a Beckman Coulter Allegra 25R refrigerated centrifuge (rotor 
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AT-14-10).  The supernatant was discarded and the remaining pellet was gently 
resuspended in 80 mL of ice-cold CCMB80 buffer (10 mM KOAc, 80 mM 
CaCl2.2H2O, 20 mM MnCl2.4H2O, 10 mM MgCl2.6H2O, 10% (v/v) glycerol, adjusted 
to pH 6.4 with 1 mM HCl, filter-sterilised and stored at 4°C) and incubated on ice for 
20 minutes.  Cells were re-centrifuged and supernatant discarded as previously 
described, prior to resuspension in 10 mL of ice-cold CCMB80 buffer.  250 μL of 
resuspended cells were mixed with 1 mL of liquid LB media and cell density was 
assessed as previously described.  Chilled CCMB80 was added to harvested cells to yield 
a final OD600 of 1-1.5.  These chemically competent cells were routinely stored in 250 
μL aliquots at -80°C for 6-12 months without notable effects on transformation 
efficiency. 
 2.3.2 Transformation of chemically competent E. coli strains
An aliquot of chemically competent cells was thawed on ice and 50 μL of this cell 
suspension was decanted into a pre-chilled 15 mL polypropylene tube. 1 μL of the 
appropriate plasmid DNA at a concentration of 10 ng/μL was added to the cell 
suspension and incubated for 30 minutes on ice.  The transformation reaction was heat-
pulsed for 45 seconds in a 42°C water bath and immediately cooled on ice for an 
additional 2 minutes.  900 μL of liquid LB media was added to the transformation 
reaction prior to incubation at 37°C  with shaking at 225 rpm for 1 hour to allow cell 
recovery and expression of antibiotic resistance.  200 μL of the reaction suspension was 
spread onto an LB agar plate supplemented with appropriate antibiotics for selection 
purposes (100 μg/mL ampicillin for pET-3a selection, 25 μg/mL kanamycin for 
pET-28b selection and 34 μg/mL chloramphenicol to maintain the pACYC plasmid in 
the BL21-CodonPlus® (DE3)-RIPL cell strain).  Plates were inverted and incubated at 
37°C for 12-16 hours.  Typically this transformation method generated efficiencies of 
>1x106 cfu/μg of  plasmid DNA. 
 2.3.3  Plasmid DNA purification and maintenance
DNA plasmid templates were extracted from E. coli DH5α cells using the QIAprep Spin 
Miniprep Kits for plasmid DNA purification supplied by QIAGEN, which uses the 
modified alkaline lysis method of  Birnboim and Doly (1979).
 A single transformed DH5α colony was used to inoculate 10 mL of LB liquid 
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media supplemented with appropriate antibiotic(s) (100 μg/mL ampicillin, 50 μg/mL 
kanamycin, 34 μg/mL chloramphenicol) and was incubated at 37°C for 12-16 hours 
with shaking (250rpm).  Bacterial cells were harvested by centrifugation in 15 mL 
polypropylene tubes at 4000 rpm for 10 minutes at 4°C using a Beckman Coulter 
Allegra 25R refrigerated centrifuge (rotor TS-5.1-500) and the QIAprep miniprep 
procedure was followed (Qiagen 2006).  In brief, cleared bacterial cell lysate was applied 
and reversibly bound to the QIAprep silica membrane in the presence of chaotrophic 
salts.  After extensive washing, purified plasmid DNA was eluted in nuclease-free ddH2O 
(Purite)
 Plasmid DNA concentration was determined from its A260 using a Thermo 
Scientific NanoDrop 2000c and the concentration was adjusted to 50 ng/μL prior to 
storage at -20°C.  
 2.3.4 Oligonucleotide Design and Preparation
Mutagenic oligonucleotide primers were individually designed SDM as described within 
the guidelines of the QuikChange XL Site-Directed Mutagenesis Kit Instruction 
Manual (Agilent Technologies n.d.).  
 Oligonucleotide primers were synthesized by Invitrogen™ and were diluted to 
50 ng/μL with the addition of nuclease-free H2O, prior to storage at -20°C.  The 
primer sequences used for SDM are listed in the Appendix. 
 2.3.5 Site-Directed Mutagenesis
All mutagenesis reactions were completed using the protocol supplied with the 
Quikchange® II XL Site-Directed Mutagenesis Kit by Agilent Technologies.  In brief, 
single amino acid substitutions were introduced into the parental double-stranded DNA 
vector using PfuUltra HF DNA polymerase for strand synthesis, this was followed by Dpn 
I endonuclease restriction digestion (target sequence: 5’-Gm6ATC-3’) of the parental 
template.  The undigested vector containing the desired mutation was then transformed 
into the provided XL10-Gold ultracompetent cell strain for nick repair. 
 All kit components, plasmids and oligonucleotide primers were thawed on ice. 
PCR reactions were prepared as recommended by Agilent Technologies and placed in 
Fisherbrand 0.5 mL thin-walled PCR tubes.  Amplification cycling parameters (Table 
2.4) were followed as suggested (Agilent Technologies n.d.) using a Techne TC-512 PCR 
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thermal cycler.  Dpn I digestion immediately followed strand synthesis, with incubation 
of reactions at 37°C in a water bath for 1 hour, prior to transformation into XL10-Gold 
ultracompetent cells.
	
The pWhitescript mutagenesis control and the pUC18 transformation control were used 
at all times.  Mutagenic efficiency was determined from the number of colonies 
displaying a blue phenotype indicative of  acquisition of  β-galactosidase production. 
 2.3.6  Plasmid DNA sequencing
Sequencing of all recombinant plasmid DNA constructs was completed using Applied 
Biosystems BigDye Terminator chemistry on an ABI PRISM 3730xl DNA Analyzer, as 
part of the QuickLane Express Sequencing service provided by Beckman Coulter 
Genomics. DNA sequence analysis was visualized and performed using FinchTV 
sequencing chromatogram trace viewer V1.4, provided by Geospiza.
 2.3.7 IPTG-induced heterologous protein expression test in E. 
coli expression strains
E. coli strains BL21 (DE3) and BL21-CodonPlus (DE3)-RIPL were used for protein 
expression.  Seven colonies were selected from the transformation plate and added to 30 
mL Sterilin tubes containing 10 mL of liquid LB media supplemented with appropriate 
antibiotic prior to incubation with shaking (250 rpm) at 37°C for 12-16 hours.  From 
these starter cultures (10 μL) were used to inoculate (1:1000) 30 mL Sterilin tubes 
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Table 2.4: Cycling parameters for the Quikchange® II XL method
Segment Cycles Temperature 
(oC)
Time
1 1 95 1 minute
2 18 95 50 seconds
60 50 seconds
68 1 minute/kb of  
plasmid length
3 1 minute 68 7 minutes
containing 10 mL of liquid LB media supplemented with appropriate antibiotic.  These 
cultures were then grown for approximately 3 hours with shaking (250 rpm) at 37°C 
until an OD600 of 0.4-0.6 was reached, at which point 1 mL from each was taken as a 
pre-induction sample and the OD600 recorded.  These samples were then centrifuged in 
separate 1.5 mL eppendorf tubes for 5 minutes at 3000 rpm and the pellets retained 
and stored at -20°C for subsequent sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis.  Remaining samples were induced with a final 
concentration of 0.4 mM IPTG and incubated for an additional 3 hours at 37°C with 
shaking (250 rpm) prior to recording the OD600 for comparison.  1 mL was taken as a 
post-induction samples and centrifuged at 3000 rpm for 5 minutes.  Pellets were retained 
and stored at -20°C.  
Thawed pellets were resuspended in 20 μL of SDS-PAGE loading buffer and 
heated at 95°C for 10 minutes. Protein expression levels were determined by SDS-PAGE 
analysis (Section 2.3.19) of pre- and post-induced samples, based on comparable cell 
density. 
Densitometric analysis of the SDS-PAGE gels was used to identify high 
heterologous protein expressing colonies suitable for creating glycerol stocks.  1 mL of 
the relevant starter culture was added to a 1.5 mL Eppendorf tube and centrifuged at 
3000 rpm for 5 minutes to harvest cells.  The pellet was then resuspended in 1 mL of 
30% (v/v) glycerol prior to storage at -80°C.
 2.3.8 IPTG-induced protein expression in E. coli expression 
strains using nutrient-rich media
10 mL of liquid LB media supplemented with appropriate antibiotic was added to a 30 
mL Sterilin tube.  This was inoculated from stored E. coli protein expression glycerol 
stocks prior to overnight incubation with shaking (250 rpm) at 37°C. 
0.5 mL of the overnight starter culture was added to 500 mL of LB antibiotic 
supplemented liquid media. Cells were grown at 37°C with shaking at 250 rpm until an 
OD600 of 0.6 was reached.  Protein expression was induced with 0.4 mM IPTG and 
cultures were incubated as described in the protein-specific method.  1 mL was taken 
from pre- and post-induction samples and protein expression was analysed as previously 
described (Section 2.3.7).
Cells were harvested in 1 L polypropylene bottles by centrifugation at 7000 rpm 
for 20 minutes at 4°C in a Beckman Coulter Avanti J-20XP centrifuge equipped with a 
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JLA 8.1000 rotor.  Pellets were collected and routinely stored at -20°C for up to 12 
months.
 
 2.3.9 IPTG-induced heterologous protein expression in E.coli 
expression strains using isotopically enriched minimal media
M9 salts minimal media was made (components per 975 mL: 6 g Na2HPO4, 3 g 
KH2PO4, 0.5 g NaCl) and autoclaved at 120°C for 20 minutes at 15 psi.  E. coli trace 
elements were made (components per L: 5 g Na2EDTA dissolved in 800 mL ddH2O, 
with addition of 5 M HCl adjusting to pH 7 after adding each of the following: 0.5 g 
FeCl3, 0.05 g ZnCl2, 0.01 g  CuCl2.2H2O, 0.01 g CoCl2.6H2O, 0.01 g H3BO3), filter-
sterilised (0.22 μm) and stored at room temperature.  
Heat-sensitive components were filter-sterilised (0.22 μm) and added to the 
autoclaved M9 salts minimal media (5 mL 20% (w/v) 15(NH4)2 SO4, 10 mL 20% (w/v) 
D-Glucose, 1 mL 1 MgSO4, 1 mL 0.1M CaCl2, 1 mL 1M thiamine, 10 mL E. coli trace 
elements and appropriate antibiotics).  Then 10 mL of the isotopically enriched 
complete minimal media was decanted into a 30 mL Sterilin tube and inoculated from 
stored E. coli protein expression glycerol stocks.  This starter culture was grown overnight 
with shaking (250 rpm) at 37°C.
The 10 mL starter culture was reintroduced to the remaining minimal media 
and incubated at 37°C with shaking at 250 rpm until an OD600 of 0.6 was reached. 
Protein expression was induced with 0.4 mM IPTG and cultures were incubated for a 
further 4 hours at 37°C with shaking at 250 rpm. 1 mL was taken from pre- and post-
induction samples and protein expression was analysed as previously described (Section 
2.3.7).
Cells were harvested in 1 L polypropylene bottles by centrifugation at 7000 rpm 
for 20 minutes at 4°C in a Beckman Coulter AvantiTM J-20XP centrifuge equipped with 
a JLA 8.1000 rotor.  Pellets were collected and routinely stored at -20°C for up to 12 
months.
 2.3.10  Physical disruption of E. coli cells by sonication
Cell pellets, previously obtained from 1 L of culture, were thawed on ice, and 
resuspended in 40-50 mL of appropriate buffer with the addition of one cOmplete, 
EDTA-free Protease Inhibitor Cocktail tablet (Roche).  Bacterial cells were disrupted by 
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sonication using a Sonics Vibra-cell (pulse on: 3.3 s; pulse off: 9.9 s; total pulse on time: 
10 minutes; probe temperature: 20°C; amplitude: 30%).  The cell suspension was kept 
on ice at all times.
 2.3.11  Isolation of soluble proteins
Post-sonicated cell suspension containing expressed soluble protein, was centrifuged at 
18000 rpm for 30 minutes at 4 °C in a Beckman Coulter Avanti J-20XP centrifuge 
(JA-25.50 rotor) to remove cellular debris.  Supernatant was retained for further 
purification by chromatography.
 2.3.12  Purification and solubilisation of E. coli inclusion bodies
Inclusion bodies were purified and solubilised as described in the protein-specific 
methods.  The presence or absence of the target protein was monitored at all stages by 
SDS-PAGE analysis (Section 2.3.19).
 2.3.13  Refolding of heterologous proteins by serial dialysis
Concentrations of partially purified protein-containing solutions were assessed at OD280 
using a Thermo Scientific NanoDrop 2000c.  Samples were diluted to protein 
concentrations of 0.2 mg/mL with appropriate buffers (see protein-specific methods). 
Using Spectrum Standard Regenerated Cellulose Spectra/Por dialysis membrane 
MWCO 3.5 kDa (Spectrum Laboratories, Inc.), the protein solution was subjected to 
repeated overnight dialysis against a series of buffers as described in the protein-specific 
methods. 
 2.3.14  Purification of heterologous proteins by Immobilised 
Metal Affinity Chromatography
Samples were filtered (0.22 μm) and applied at 1 mL/min to a pre-equilibrated 5 mL 
HisTrap FF column prepacked with Ni Sepharose 6 Fast Flow resin using the 
ÄKTAprime system.  Samples exposed to potential protease degradation were purified 
using the ÄKTApurifier system at 4°C.  Unbound proteins were collected in 4 mL 
fractions.  Bound proteins were eluted with a 0-100% gradient of appropriate buffer 
supplemented with 500 mM imidazole and collected in 1 mL fractions for further SDS-
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PAGE analysis (Section 2.3.19).
 2.3.15  Purification of heterologous proteins by Cation 
Exchange Chromatography
Refolded protein solutions were filtered (0.22 μm) and thoroughly degassed prior to 
application at 10 mL/min to a 30 mL SP-Sepharose FF XK26 column using the 
ÄKTAprime system (GE Healthcare Life Sciences) that had been pre-equilibrated with 
an appropriate low salt buffer (see protein-specific methods).  Bound protein of interest 
was eluted with a 0-100% gradient of appropriate high salt buffer and 1 mL fractions 
were collected for SDS-PAGE analysis (Section 2.3.19).
 2.3.16 N-terminal His6-tag removal
Samples were filtered (0.22 μm) and applied at 1 mL/min to a HisTrap FF column 
prepacked with Ni Sepharose 6 Fast Flow resin and pre-equilibrated with an appropriate 
buffer using the ÄKTAprime system.  Unbound proteins were washed from the column 
with 5 column volumes prior to column detachment.  Thrombin (25 U) was diluted in 5 
mL appropriate buffer and manually injected onto the column.  The column was sealed 
and incubated overnight in a 37 oC oven.  A 5.4 mL p-amidobenzamidine column was 
attached for thrombin removal and cleaved proteins were eluted with 5 column volumes 
of appropriate buffer at 2.5 mL/min and collected in 2 mL fractions.  Bound proteins 
were then eluted with a 0-100% gradient of an appropriate buffer supplemented with 
500 mM imidazole and collected in 2 mL fractions for further SDS-PAGE analysis 
(Section 2.3.19).
 2.3.17 Purification of heterologous proteins by Anion Exchange 
Chromatography
Protein solutions were filtered (0.22 μm) and thoroughly degassed prior to application at 
5 mL/min to a 30 mL Q-Sepharose FF XK26 column using the ÄKTAprime system 
that had been pre-equilibrated with an appropriate low salt buffer (see protein-specific 
methods).  Bound protein of interest was eluted with a 0-100% gradient of appropriate 
high salt buffer and 1 mL fractions were collected for SDS-PAGE analysis (Section 
2.3.19).
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2.3.18 Preparation of Tris-Tricine SDS-PAGE gels and reagents
Using Novex 1.0 mm plastic gel cassettes (Life Technologies), 16.5% Tris-Tricine SDS-
PAGE gels were cast. A 30 mL volume, suitable for 4 cassettes was made accordingly - 
16.5 mL Protogel (30% w/v) 37.5:1 Acrylamide:Bisacrylamide stabilised solution, 10 
mL 3X Tris-Tricine gel buffer, 3.1 mL glycerol, 0.4 mL distilled H2O, 100 μL 10% (w/v) 
ammonium persulphate (APS), 40 μL N, N, N′, N′-Tetramethylethylenediamine 
(TEMED).  For 12% Tris-Tricine SDS-PAGE gels the volumes of Protogel (37.5:1) 
solution and H2O was substituted with 12 mL and 4.9 mL, respectively.  The separating 
gel was overlayed with distilled H2O, and allowed to polymerise for 1 hour before 
removal of the H2O and addition of a 6% stacking gel (volume suitable for 4 cassettes – 
1.5 mL Protogel 37.5:1, 2.5 mL 3X Tris-Tricine gel buffer, 6 mL distilled H2O, 50 μL 
10% (w/v) APS, 20 μL TEMED) and appropriate sized comb.  Cast SDS-PAGE gels 
were inverted in distilled H2O and stored at 4°C.  
3X Tris-Tricine gel buffer (3 M Tris-HCl pH 8.45, 0.3% (w/v) SDS) was stored 
at room temperature along with Anode buffer (100 mM Tris-HCl pH 8.9) and Cathode 
buffer (100 mM Tris-HCl pH 8.25, 100 mM Tricine, 0.1% (w/v) SDS).
A Coomassie Blue stain solution (50% Methanol, 10% Acetic acid, 0.25% (w/v) 
Coomassie Brilliant Blue R-250 dye) was used for all SDS-PAGE protein staining.
	
 2.3.19 Analysis of protein samples by Tris-Tricine SDS-PAGE
Appropriate sample volumes were added to 2X SDS-PAGE reducing loading buffer (126 
mM Tris-HCl pH 6.8, 20% (w/v) glycerol, 4% (w/v) SDS, 0.005% (w/v) bromophenol 
blue, 5% (v/v) β-mercaptoethanol) and heated at 95°C for 10 minutes.    Samples were 
loaded onto 16.5% Tris Tricine SDS-PAGE gels (Section 2.3.18) alongside 5 μL of 
SeeBlue Plus2, a pre-stained molecular weight standard, and were run for 20 minute at 
80 V followed by 45-55 minutes at 180 V unless otherwise stated.
 2.3.20 Screening proMMP-1* activation by limited proteolysis
  2.3.20.1 Trypsin
Trypsin (Sigma Aldrich) was freshly dissolved in TNC pH 7.4 (50 mM Tris-HCl pH 7.4, 
150 mM NaCl, 5 mM CaCl2 and 0.02% (w/v) NaN3) and serially diluted prior to 
incubation with 10 μM of proMMP-1*.  Samples were then incubated at 37 oC for 5 
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minutes.  Reactions were stopped with 1 mM phenylmethylsulfonyl fluoride (PMSF) and 
heated at 95 oC for 5 minutes prior to analysis by SDS-PAGE ( Section 2.3.19).
  	

An equimolar concentration of recombinantly produced CAT-3 was added to 10 μM 
proMMP-1* in TNC pH 7.4.  Samples were then incubated at 37 oC for 0-24 hours. 
Reactions were stopped with 2X SDS-PAGE reducing loading buffer supplemented with 
20 mM EDTA and heated at 95 oC for 5 minutes prior to analysis by SDS-PAGE 
( Section 2.3.19).
 2.3.21  APMA-induced activation of proMMPs 
Purified proteins were incubated with 0.5 mM APMA for an appropriate time (see 
protein-specific methods) in a 37°C waterbath.  APMA was removed using a 35 mL 
HiPrep desalting column prepacked with Sephadex G-25 Fine resin pre-equilibrated 
with an appropriate buffer using the ÄKTAprime system.  Samples were manually 
injected directly onto the column using a glass luer-lock syringe (Fisher Scientific) and 
eluted using a flow rate of 3 mL/min.  APMA was then disposed of according to local 
regulations.
 
 2.3.22 Purification of heterologous proteins by Gel Filtration 
Chromatography
Protein-containing samples were concentrated, using centrifugal filter units with an 
appropriate MWCO (Millipore), to a volume of ~ 0.5-2 mL using a Beckman Coulter 
Allegra 25R refrigerated centrifuge (rotor AT-14-10) pre-chilled to 4 oC.  Samples were 
resuspended after each spin (3000 rpm for 1-10 minutes) and applied at 1 mL/min to a 
HiLoad Superdex 75 26/60 prep grade column pre-equilibrated with an appropriate 
buffer (see protein-specific methods).  5 mL fractions were collected and analysed by 
SDS-PAGE (Section 2.3.19).
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 2.3.23 Storage of heterologous proteins
Both zymogen and mature proteins were routinely stored at -80oC diluted 50:50 in 2x 
Storage Buffer (50 mM Tris-HCl, pH 7.5, 450 mM NaCl, 40 μM ZnCl2, 1% (w/v Brij 
35, 60% glycerol) for up to 6 months.
 2.3.24  Continuous fluorogenic assay of CAT-3
Lyophilised quenched fluorogenic MMP-3 substrate (Mca-Arg-Pro-Lys-Pro-Val-Glu-
Nva-Trp-Arg-Lys-(Dnp)-NH2 (Nagase, Fields et al. 1994) was purchased from Bachem 
and prepared as 100 μM stock solutions in DMSO.  The substrate is labelled with a 
fluorescent donor (7-methoxycoumarin-4-yl)acetyl (Mca) and quenching moiety 2,4-
dinitrophenyl (Dnp), which flank the MMP-3 susceptible bond (Glu-Nva).  Cleavage of 
this bond results in separation of the fluorophore and quencher concomitant with 
increased fluorescence emission.  Fluorescent assays were performed at λex 325 nm and 
λem 393 nm using a Perkin Elmer LS 50B fluorescence spectrometer.  Typically, 
hydrolysis assays were conducted at ambient temperature by incubating 10 nM of 
CAT-3 with 100 nM of  substrate in TNC pH 7.4 to assess CAT-3 catalytic activity.    
 2.3.25 Continuous spectrophotometric assay of MMP-1 and 
CAT-1
Lyophilised chromogenic MMP substrate (Ac-Pro-Leu-Gly-[2-mercapto-4-methyl-
pentanoyl]-Leu-Gly-OC2H5) was purchased, and prepared as 5 mM stock solutions in 
DMSO and stored at -20 oC in 1.5 mL black polypropylene LiteSafe microcentrifuge 
tubes (Sigma Aldrich).  Hydrolysis of the thioester substrate bond by MMP-1 produces a 
free sulfhydryl group, which reacts with 5,5-dithio-bis(2-nitrobenzoic acid) (DTNB; 
Ellmans’ reagent) to form 5-mercapto-2-nitrobenzoic acid (TNB).  Activity is detected 
indirectly by measuring TNB formation, which absorbs at 412 nm. Assays were 
conducted at 37 oC by incubating 0-10 nM of enzyme with 25 μM of substrate in assay 
buffer (50 mM HEPES pH 7, 10 mM CaCl2, 0.05% Brij-35 and 1 mM DTNB) and 
monitored continuously at λ412 for 10 minutes using a Thermo Scientific NanoDrop 
2000c.  The absorbance data, taken for 3 minutes after the initial 30 seconds, were fitted 
by linear regression using Grafit Version 5 (Erithacus Software Ltd).
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 2.3.26 Type I collagen preparation
Lyophilised bovine type I collagen (Sigma Aldrich) was reconstituted with 0.5 M acetic 
acid to yield a 1 mg/mL solution, which was then solubilised overnight with gentle 
stirring at 4 oC.  Using 10 kDa MWCO Spectrum Standard Regenerated Cellulose 
Spectra/Por dialysis membrane (Spectrum Laboratories, Inc.), the collagen solution was 
subjected to overnight dialysis at 4 oC against 1000 volumes of  TNC pH 7.4. 
 2.3.27 Collagenase cleavage of Type I collagen
Previously prepared collagen solutions were diluted to 0.1 mg/mL with TNC pH 7.4 
and incubated with a 30 fold molar excess of MMP-1 generated by APMA initiated 
autolysis (Section 2.3.21).  Reactions were then incubated at 37 oC for 20 hours prior to 
the addition of SDS-PAGE loading buffer supplemented with 20 mM EDTA to stop 
further MMP-1 cleavage activity.  Products were analysed by SDS-PAGE (Section 
2.3.19) and examined for production of  ¾ and ¼ collagen fragments. 
 2.3.28  Nuclear Magnetic Resonance (NMR) sample preparation
Purified isotopically 15N-labelled  protein was dialysed exhaustively against a suitable 
buffer and concentrated to 0.2-0.5 mM in a final volume of 300 μL using a centrifugal 
filter unit with appropriate MWCO (Millipore) as detailed (Section 2.3.22).  HPX-1 
protein samples were dialysed against 20 mM NaOAc pH 4.8, 5 mM CaCl2, 50 μM 
ZnCl2 and 0.02% (w/v) NaN3 and proCAT-1* protein samples were dialysed against 10 
mM Tris-HCl pH 7.2, 5 mM CaCl2, 150 mM NaCl and 0.02% (w/v) NaN3.   10% D2O 
was added to all samples in preparation for deuterium signal locking of the NMR 
spectrometer and transferred to D2O-matched 5 mm symmetrical NMR Shigemi 
microtubes (Sigma Aldrich).  Samples were stored at 4 oC prior to NMR data collection. 
 2.3.29  NMR spectral acquisition, processing and analysis
Experiments were routinely performed on an Agilent Inova 600 MHz 
spectrophotometer, operating at 14.1 Tesla and equipped with a triple resonance 
cryoprobe, at the University of Portsmouth.  1D 1H NMR and 2D 1H-15N 
heteronuclear single quantum coherence (HSQC) spectra of the target protein was 
acquired as 4096 and 256 complex points using spectral widths of 9900.99 and 2431.06 
Hz for F1 and F2 dimensions, respectively.  This gave a resolution of 19 Hz in the 
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nitrogen direction and 4.83 Hz in the hydrogen direction. The spectral data was 
acquired and processed by Dr Chris Read, University of Portsmouth, using NMRPipe 
(Delaglio, Grzesiek et al. 1995) and visualised using CcpNmr Analysis v2.2.2 (Vranken, 
Boucher et al. 2005).  NMR spectral quality was examined and assessed primarily on 
spectral dispersion, line widths and number of  resolved peaks.  
Construct-specific methods are described in the subsequent tables (Tables 2.5-2.8) and 
contain details of both the purification pathway required and conditions necessary for 
optimal production of  the recombinant protein of  interest.
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2.4 Results
 2.4.1 HPX-1 protein
The pET-3a/HPX-1 construct, containing the sequence coding for the human 
proMMP-1 HPX domain (residues Q253-N450) with an additional methionine residue 
located at the N-terminus, was used for transformations in both E. coli DH5α and BL21-
CodonPlus (DE3)-RIPL strains.  
	 Viability of transformed colonies was assessed using small-scale protein 
expression of randomly selected BL21-CodonPlus (DE3)-RIPL colonies (Section 2.3.7). 
SDS-PAGE analysis consistently identified significant over-expression of a protein (~ 24 
kDa) corresponding to HPX-1 within three hours of treatment with 0.4 mM IPTG 
(Figure 2.3A).  Densitometric analysis of post-induction HPX-1 expression (data not 
shown) was used to determine which of the transformed strains was most suitable for 
subsequent large-scale protein production.  Appropriate growth conditions had 
previously been optimised by Dr Laurence Arnold (NIMR, Mill Hill).
	
	
As anticipated from a disulphide-containing protein, all HPX-1 protein was found 
deposited in bacterial inclusion bodies.  Centrifugation and washing of this insoluble 
material produced white crystalline pellets, which after solubilisation (Section 2.3.12) 
was found to contain almost exclusively (estimated >90% of total protein content) 
85
Figure 2.3: SDS-PAGE analysis of  HPX-1 expression and Inclusion Body preparation.  
(A) Expression of a protein of ~ 24 kDa (HPX-1) was induced upon treatment with 0.4 mM IPTG and 
visualised on a 12% (w/v) Tris-Tricine reducing gel, indicated by the dashed blue box. (B) Insoluble material 
was harvested by centrifugation (IF) and washed (W1 and W2). Pelleted inclusion bodies were then 
solubilised overnight  (SIB). All samples were ran alongside SeeBlue Plus2 prestained molecular weight 
marker (M).
M M+-+ + + -- -
IPTG
IF W1 W2 SIB
16
34
45
55
78
7
210
A B
MW (kDa)
HPX-1 (Figure 2.3B).  An adapted refolding regime (Bertini, Fragai et al. 2009) was then 
utilised that allowed successful disulphide bond formation between blades 1 and 4.  Final 
purification of the folded HPX-1 domain was carried out using cation exchange 
chromatography to remove the remaining contaminants (Figure 2.4).  This purification 
strategy yielded ~ 16 mg of >99% homogeneous HPX-1 per 500 mL of LB media 
(Table 2.9).
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Figure 2.4: Final purification of  HPX-1 using cation exchange chromatography. 
(A) Refolded protein solutions were applied to a pre-equilibrated 30 mL SP-Sepharose FF XK26 
column at a flow rate of 10 mL/min. Bound protein was eluted with a 0-1 M NaCl gradient. (B) 
Pooled fractions spanning the peak (*) were visualised on a 12% (w/v) Tris-Tricine SDS-PAGE gel. 
Molecular weight was estimated using SeeBlue® Plus2 prestained molecular weight marker (M). 
M* 210*
A B
34
45
55
78
16
7
4
MW (kDa)
%
 sa
lt
The conformation of the refolded HPX-1 domain was assessed by acquisition of a 2D 
1H-15N HSQC spectrum (Section 2.3.29).  The 1H-15N HSQC spectrum shown in 
Figure 2.5 indicates extensive chemical shift dispersion characteristic of a folded protein, 
and therefore the current refolding strategy is suitable for HPX-1 production.
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Table 2.9: Purification of  MMP proteinsab
Protein Fraction Total 
Volume 
(mL)
Protein 
Concentration 
(mg/mL)
Total 
Protein 
(mg)
Recovered 
Protein 
(%)
HPX-1
Solubilised 
Inclusion Bodies
20 6.39 127.8 100
Post-CEX 30 0.53 15.90 12.44
proMMP-1*
Solubilised 
Inclusion Bodies 20 7.87 157.4 100
Post-CEX 30 0.44 13.2 8.38
Post-GF 25 0.24 5.99 3.81
proCAT-3
Solubilised 
Inclusion Bodies 20 14.02 280.40 31.53
§
Soluble protein 40 15.22 608.8 68.47§
Post-IMAC† 17.5 1.47 25.73 4.22
Post-GF† 3 0.67 2.02 0.33
proCAT-1*
Soluble protein 40 11.3 452 100
Post-IMAC 32 1.48 47.36 10.47
Post-AEX 20 0.32 6.4 1.42
Post-GF 3.7 1.39 5.14 1.13
a from 500 mL of  culture 
b protein concentration was determined spectrophotometrically (A280) using the molar extinction  
coefficient values obtained from ProtParam analysis (Gasteiger, Gattiker et al. 2003).  Assumes pure 
protein.
§ percentage of  total expressed protein
† data taken from soluble fraction and is therefore expressed as a percentage of  total soluble protein
 2.4.2 proCAT-3 protein
The pET-28b/proCAT-3 plasmid was used to express C-terminally truncated human 
proCAT-3 as an N-terminal hexahistidine (H6) tagged fusion protein, thereby allowing 
purification of the target protein by immobilised metal affinity chromatography (IMAC). 
Small-scale protein expression was trialled in the E. coli BL21-CodonPlus (DE3)-RIPL 
strain (Section 2.3.7) and analysis of pre- and post-induction expression indicated the 
presence of a protein (~ 33 kDa) corresponding to H6-proCAT-3.  Further analysis 
indicated that H6-proCAT-3 was expressed in approximately equal amounts in both the 
soluble and insoluble fractions.  Despite establishment of a suitable refolding protocol to 
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Figure 2.5:  1H15N- HSQC spectra of HPX-1.  The spectrum was recorded in 20 mM NaOAc pH 
4.8,  5 mM CaCl2, 50 μM ZnCl2, 0.02% (w/v) NaN3 and 10% D2O at 25°C and at a concentration of 
283 μM on an Agilent Inova 600 MHz spectrophotometer.   
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recover and reconstitute proCAT-3 by Dr Stephen Prior (detailed in Section 2.3.13), the 
assays in this study utilise only purified protein derived from the soluble fraction as 
shown in Figure 2.6.  Therefore, protein-expressing cells were grown overnight at 20 oC 
to maximise protein yields during large-scale H6-proCAT-3 preparations.  Subsequent 
IMAC was used to purify the H6-tagged target protein from the clarified crude cell 
extract ensuring significant reduction of  contaminating proteins.  
	 Activation of H6-proCAT-3 was initially achieved by incubation with 
chymotrypsin (1:60 molar concentration, respectively) for 10 minutes at 37 oC (data not 
shown).  However, this method was swiftly abandoned and replaced with the APMA 
activation protocol (Section 2.3.21), which removed the need to reintroduce an active 
protease, instead using autolysis to ensure PRO domain removal and convenient N-
terminal H6-tag removal.  Buffer-exchanged enzymatic digestion reactions were desalted 
and separation of post-digest products was achieved using size exclusion 
chromatography.  This purification strategy yielded ~ 2 mg of >99% homogeneous 
active CAT-3 per 500 mL of  LB media (Table 2.9).  
	 Activity of purified CAT-3 using a fluorogenic peptide substrate assay (Section 
2.3.24) was taken as suitable evidence for use in proMMP-1* activation (Figure 2.7).  
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Figure 2.6: proCAT-3 purification and activation. H6-proCAT-3 expressed in the soluble fraction 
(SF) was applied to an Ni Sepharose HisTrap HP column at a flow rate of 5 mL/min (A).  Bound protein 
was eluted with a 0-500 mM gradient of imidazole. Pooled fractions spanning the peak (*) were then 
incubated with 0.5 mM APMA, desalted and applied at 1 mL/min to a pre-equilibrated HiLoad 
Superdex 75 26/60 prep grade column (B). Fractions containing activated CAT-3 (*) were visualised 
alongside other stages of the purification strategy on a 16.5% (w/v) Tris-Tricine SDS-PAGE gel (C). 
Molecular weight was estimated using SeeBlue Plus2 prestained molecular weight marker (M). 
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 2.4.3 proMMP-1 protein
  2.4.3.1 Hydrolytically impaired proMMP-1*
The pET-3a/proMMP-1* construct, containing the sequence coding for the full-length 
human proMMP-1 protein was used for transformations in both E. coli DH5α and 
BL21-CodonPlus (DE3)-RIPL strains.  
	 High level protein expression was induced in the BL21-CodonPlus (DE3)-RIPL 
expression strain with 0.4 mM IPTG as visualised by SDS-PAGE analysis (Figure 2.8A). 
Despite the strong selectivity of the T7 promoter for its phage-encoded polymerase, 
residual basal level expression from this pET-3a construct was clearly present in the 
absence of IPTG treatment.  Furthermore, deposition of full-length protein in bacterial 
inclusion bodies (Figure 2.8B) appeared to protect the cells from any potentially toxic 
effects.  The inclusion body preparation protocol used during HPX-1 production 
(Section 2.3.12) was adopted, and again high concentrations of full-length protein was 
isolated in this manner, although it was clear that higher background protein levels were 
concomitant with overnight protein expression at 20 oC.  However, accumulation of 
precipitated bacterial proteins during the refolding procedure, which were removed by 
filtration, appeared to remove many of these contaminants as well as misfolded 
proMMP-1 aggregates.  Refolded protein samples were further purified by cation 
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Figure 2.7: CAT-3 activity against fluorogenic peptide substrate (Mca-Arg-Pro-Lys-Pro-
Val-Glu-Nva-Trp-Arg-Lys-(Dnp)-NH2).  Assays were performed at λex 325 nm and λem 393 nm. 
Detected changes in fluorescence is in arbitrary units (AU). Typical activity observed at a concentration of 
10 nM is shown in green.  Lack of  metalloproteinase activity was observed with EDTA treatment (black).
CAT-3
CAT-3 + 5 mM 
EDTA
exchange chromatography (Figure 2.9); this step also served to concentrate large dilute 
refolding volumes.
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Figure 2.9: Cation exchange purification of  proMMP-1*.
(A) Refolded protein solutions were applied to a pre-equilibrated 30 mL SP-Sepharose FF XK26 column 
at a flow rate of 10 mL/min. Bound protein was eluted with a 0-1 M NaCl gradient. (B) Pooled fractions 
spanning the peak (*) were visualised on a 16.5% (w/v) Tris-Tricine SDS-PAGE gel.  Molecular weight 
was estimated using SeeBlue Plus2 prestained molecular weight marker (M). 
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Figure 2.8: SDS-PAGE analysis of proMMP-1* expression and Inclusion Body 
preparation.  
(A) Expression of a protein of ~ 53 kDa (HPX-1) was induced upon treatment with 0.4 mM IPTG 
and visualised on a 16.5% (w/v) Tris-Tricine reducing gel, indicated by the dashed blue box. (B) 
Insoluble material was harvested by centrifugation (IF) and washed (W1 and W2). Pelleted inclusion 
bodies were then solubilised overnight  (SIB). All samples were ran alongside SeeBlue Plus2 
prestained molecular weight marker (M).
MW (kDa)
Final purification of proMMP-1* was achieved using gel filtration chromatography 
(Figure 2.10A) and resulted in samples of >99% homogeneity.  The final purification 
strategy yielded ~ 6 mg of  proMMP-1* (Table 2.9). 
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Figure 2.10: Gel filtration chromatography of proMMP-1* and activated MMP-1*. (A) CEX 
purified proMMP-1* was applied to a pre-equilibrated HiLoad Superdex 75 16/60 prep grade column 
column at a flow rate of 1 mL/min. Purified proMMP-1* is indicated with a blue asterisk (*). (B) Purified 
proMMP-1* was incubated with 0.1 mM APMA and CAT-3 (*) at a 10:1 molar concentration, desalted 
and purified by gel filtration chromatography. Purified MMP-1* is shown with a dashed red box. (C) 
proMMP-1* and MMP-1* samples purified by gel filtration chromatography were visualised on a 16.5% 
(w/v) Tris-Tricine SDS-PAGE reducing gel. Molecular weight was estimated using SeeBlue Plus2 
prestained molecular weight marker (M). 
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   2.4.3.1.1 Maturation of proMMP-1* 
	 Destabilisation and cleavage of the PRO-domain following enzymatic processing 
has been well-reported (Nagase, Enghild et al. 1990, Suzuki, Enghild et al. 1990). 
Initially, small-scale MMP-1 maturation was attempted using enzymatic digestion with 
trypsin, which led to molecular weight reduction and production of a 46 kDa 
intermediate (Figure 2.11A).  Impeded by inherent lack of autolytic activity in MMP-1*, 
and despite repeated attempts to optimize this activation method by altering both 
incubation length and trypsin concentration, the final yield of mature MMP-1* was 
insufficient for further studies. As an alternative, digestion with CAT-3 instead indicated 
specific cleavage of the final Gln80 and Phe81 bond yielding a ~42 kDa product, 
suggestive of PRO-domain loss and hence maturation of the enzyme (Figure 2.11B). 
However, incubation length studies of proMMP-1* in the presence of CAT-3 at 
equimolar concentrations, did indicate a requirement for extensive incubation times 
(>24 hours) and was further hampered during gel filtration chromatography, which was 
unable to separate post-digestion products.  Contrastly, it was observed that treatment 
with both APMA (Section 2.3.21) and CAT-3 allowed a reduction in both incubation 
length (4 hours) and in molar ratio of the activating protease (1:10).  The result of 
purification of mature MMP-1* by gel filtration chromatography is shown in Figure 
2.10B and 2.10C. 

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Figure 2.11: Protease activation of proMMP-1*. Cleavage by trypsin yields an intermediate 
46 kDa product. The final cleavage between Gln80 and Phe81 by CAT-3 yields mature MMP-1 (42 
kDa) (Murphy, Cockett et al. 1987).  (A) Enzymatic digestion of proMMP-1* using serially diluted 
trypsin visualised on a 12% (w/v) Tris-Tricine SDS-PAGE gel. Molecular weight was estimated using 
SeeBlue Plus2 prestained protein ladder (M). Pre-digested proMMP-1* control (Lane 1), proMMP-1* 
digested with trypsin-270 mg/mL (Lane 2), proMMP-1* digested with trypsin 27 mg/mL (Lane 3), 
proMMP-1* digested with trypsin-2.7 mg/mL (Lane 4),  proMMP-1* digested with trypsin-270 ng/
mL (Lane 5), proMMP-1* digested with trypsin-27 ng/mL (Lane 6).  (B) Enzymatic digestion 
timecourse (0-4 hours) of proMMP-1* using CAT-3 visualised on a 12% (w/v) Tris-Tricine SDS-
PAGE gel. An untreated proMMP-1* sample is shown for comparison (PI). 
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  2.4.3.2 Hydrolytically active MMP-1 proteins
   2.4.3.2.1 CAT-1
Fortuitously, it  was found that active CAT-1 could be generated by exploiting the 
autolytic activity of MMP-1 and purified simply with IMAC chromatography. 
Overnight incubation at 37oC was found sufficient to observe the presence of all major 
MMP-1 components due to autolysis.  The mass similarity between the CAT and HPX 
domain precluded subsequent purification by gel filtration chromatography.  However, 
application to a column prepacked with Ni Sepharose 6 Fast Flow resin separated the 
major domain components (Figure 2.12).  Unexpectedly, the CAT domain was found in 
the flowthrough while the HPX domain was retained on-column requiring an imidazole 
wash for removal.  This purification method was found to consistently separate the CAT 
and HPX domains, allowing CAT-1 isolation for hydrolytic and limited proteolysis 
studies.
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Figure 2.12: Nickel binding by HPX-1. Degraded proMMP-1 (DpM1) is separated by IMAC 
chromatography.  All HPX-1 containing fragments (blue dashed box) are retained on column.  The absence 
of HPX-1 prevents binding to a nickel-containing resin (FT).  Samples were visualised on a 12% (w/v) 
Tris-Tricine SDS-PAGE gel. Molecular weight was estimated using SeeBlue Plus2 prestained protein 
ladder (M). 
   2.4.3.2.2 proMMP-1
Generation of the proMMP-1 revertant by mutating E219A back to glutamate was 
completed using SDM of the proMMP-1* pET-3a plasmid using the Quikchange® II 
XL Site-Directed Mutagenesis Kit (Agilent Technologies).  The mutagenic efficiency 
level was 88%.  Clones potentially harbouring mutants plasmids were randomly selected 
and harvested using a QIAprep Spin Miniprep Kit prior to dilution to 100 ng/μL in 
preparation for sequencing.  DNA sequence analysis confirmed successful incorporation 
of mutagenic bases and hence substitution of the alanine residue with the glutamate 
residue required for catalytic activity in MMP-1 (See Appendix).
	 Hydrolytically active proMMP-1 was produced in an identical fashion to that of 
proMMP-1*, and subsequently yielded similar levels of purified protein.  The only 
notable observation was an increased level of proteolysis, with basal levels of enzyme 
maturation occurring when stored at concentrations exceeding 0.5 mg/mL.  Storage at 
4 oC reduced but did not prevent proteolysis.
	 Treatment with APMA (Section 2.3.21) was used to maximise the final yield of 
MMP-1 prior to purification by gel filtration chromatography (Section 2.3.22). Activity 
of mature MMP-1 against a chromogenic MMP substrate (Section 2.3.25) was 
compared with that of the MMP-1 catalytic domain to ensure the refolding protocol 
had not adversely impacted catalytic activity (Figure 2.13A).  Activity against the 
complex substrate Type I collagen was also assessed (Figure 2.13B).  
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 2.4.4 proCAT-1* protein
Two constructs containing C-terminally truncated inactive human proMMP-1 were 
initially tested for inducible protein expression.  In expression trials (Section 2.3.7), the 
untagged protein (pET-3a/proCAT-1* construct) was poorly expressed and showed no 
increase in expression levels upon induction with 0.4 mM IPTG.  In contrast, the 29.4 
kDa N-terminal hexahistidine tagged fusion protein (pET-28b/H6-proCAT-1* 
construct) showed inducible expression of soluble protein (Figure 2.14A). Therefore, the 
residual basal expression, observed previously for proMMP-1 (Figure 2.8A) using the 
pET-3a plasmid system, may well have detrimental toxic effects.
	 The N-terminal hexahistidine tag was successfully removed using thrombin 
(Section 2.3.16).  Clarified lysate was first applied to a HisTrap FF column, then 25 U 
thrombin was manually injected onto the column and incubated overnight at 37 oC. 
After the digest, 5.4 mL p-amidobenzamidine column was attached downstream of the 
HisTrap FF column and both columns were then washed with 5 column volumes of 
buffer to elute proCAT-1* whilst trapping the thrombin.  The uncut H6-proCAT-1* was 
eluted alongside other bacterial contaminants with a 0-500 mM imidazole gradient 
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Figure 2.13: MMP-1 activity. (A) MMP-1 (wild-type) activity against chromogenic peptide substrate 
(Ac-Pro-Leu-Gly-[2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OC2H5).  Assays were monitored at λ 412 
nm at 37 oC.  Lack of metalloproteinase activity was observed with 5 mM EDTA treatment. (B) Type I 
collagen hydrolysis.  Collagen samples were incubated overnight at 37 oC in the presence and absence 
of MMP-1 (1:30 molar ratio of MMP-1) and visualised on a 12% (w/v) Tris-Tricine SDS-PAGE 
alongside SeeBlue Plus2 prestained molecular weight marker (M) that had been run at 150 V for 150 
minutes.
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M - +
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¾ α2(I)
¼ α1(I)
¼ α2(I)
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(Figure 2.13B).  Despite significant removal of unbound material prior to proteolysis, 
bacterial contaminants continued to persist, most likely generated by non-specific 
thrombin cleavage.  Anion exchange chromatography was used to successfully remove 
virtually all contaminants (Figure 2.14C) and subsequent use of gel filtration 
chromatography resulted in samples of >99% homogeneity (Figure 2.15) with a yield of 
~ 5 mg of  protein per 500 mL of  LB media (Table 2.9).
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Figure 2.14: SDS-PAGE analysis of H6-proCAT-1* expression, tag-removal and 
purification. (A) Expression of a protein of ~ 30 kDa (H6-proCAT-1*) was induced upon treatment 
with 0.4 mM IPTG and visualised on a 16.5% (w/v) Tris-Tricine SDS-PAGE reducing gel. (B) Cell lysate 
(L) was incubated with thrombin overnight at 37 oC. Cleaved proCAT-1* (dashed blue box) was eluted with 5 
CV of buffer (WASH). Uncleaved bound material was eluted with a 0-500 mM imidazole gradient (IE). 
(C) Samples were then applied to a pre-equilibrated Q-Sepharose XK26 column at 1 mL/min.  Bound 
protein was eluted with a 0-1 M NaCl gradient (AEX peak). All samples were ran alongside SeeBlue 
Plus2 prestained molecular weight marker (M).
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The conformation of proCAT-1* was assessed by acquisition of a 2D 1H-15N HSQC 
spectrum (Section 2.3.29).  Like the HPX-1 1H-15N HSQC spectrum shown in Section 
2.4.1, proCAT-1* also exhibited chemical shift dispersion characteristic of a folded 
protein (Figure 2.16A).  
	 The exact role of APMA during the activation process remains unknown. 
Therefore, a 1H-15N HSQC spectrum was acquired to ensure that no detrimental 
structural effects occur after APMA treatment. The data showed that proCAT-1* 
remained folded with a number of changes in crosspeak position (Figure 2.16B), which 
suggests a mechanism of  interaction that involves perturbation of  the PRO domain. 
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Figure 2.15: Gel filtration chromatography of proCAT-1*. (A) AEX purified proCAT-1* was 
applied to a pre-equilibrated HiLoad Superdex 75 16/60 prep grade column column at a flow rate of 
1 mL/min.  The eluted peak was visualised on a 16.5% (w/v) SDS-PAGE gel (B) The eluted peak 
containing purified proCAT-1* (dashed red box) was visualised on a 16.5% (w/v) SDS-PAGE gel. 
Molecular weight was estimated using SeeBlue Plus2 prestained molecular weight marker (M). 
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Figure 2.16:  1H15N- HSQC spectra of proCAT-1*. (A) The spectrum of proCAT-1* (916 μM) prior to 
APMA treatment. (B) The spectrum of proCAT-1*  (786 μM) following a 4 hour treatment with 0.5 mM 
APMA. Residual APMA was removed using a HiPrep desalting column prior to spectral acquisition.  All 
spectra were recorded in 10 mM Tris-HCl pH 7.2, 5 mM CaCl2, 150 mM NaCl,  0.02% (w/v) NaN3 and10% 
D2O pH 7.4 at 25°C on a Agilent Inova 600 MHz spectrophotometer.
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2.5 Conclusions
The protocols developed and described herein were found to be both robust and 
reproducible, producing milligram quantities of HPX-1, proMMP-1, CAT-3 and 
catalytically-impaired proCAT-1* and proMMP-1*; suitable for all structural and 
functional assays described in later chapters. Production of full-length proMMP-1* 
proved most challenging.  Initially, an N-terminal hexahistidine tagged fusion protein 
(pET-3a/H6-proMMP-1* construct) was expressed but consistently precipitated during 
varying refolding protocols.  In contrast, the tag-free proMMP-1* protein was refolded 
and purified successfully.  
	 Activation of proMMP-1 by MMP-3 is well described (Murphy, Cockett et al. 
1987).  In this study, proCAT-3 was expressed, purified and activated for this purpose. 
APMA-initiated autolysis resulted in acquisition of full MMP enzymatic activity. 
Consequently, CAT-3 had catalytic activity against a fluorogenic peptide, and when 
incubated with proMMP-1* appeared to cleave at a specific bond, most likely the Q99-
F100 bond (Van Wart and Birkedal-Hansen 1990).  Limited proteolysis with increasing 
concentrations of trypsin indicated the presence of MMP-1* activation intermediates, 
which is consistent with previous studies (Nagase, Enghild et al. 1990, Suzuki, Enghild et 
al. 1990). Resistance to non-specific protease digestion by both CAT-3 and trypsin 
suggests that proMMP-1* possesses significant tertiary structure. 
	 The protein mass constraints of heteronuclear NMR spectroscopy unfortunately 
prohibited analysis of full-length proMMP-1 at the current University of Portsmouth 
NMR facility, however analysis of both proCAT-1* and HPX-1 domains in isolation 
indicated possession of folded tertiary structure in all three domains and concurs with 
the protease resistance data.  In the case of HPX-1, which requires refolding, the NMR 
data is particularly important when assessing the impact of mutated amino acid residues 
on substrate binding (Chapter 3).  Interestingly, NMR analysis indicated structural 
perturbation of proCAT-1* when treated with APMA. This observation supports an 
activation model that requires domain destabilisation rather than residue modification 
within the PRO domain alone.  Furthermore, the NMR data shown here supports 
previous studies of proMMP-2 and -3 activation (Chen, Noelken et al. 1993, Itoh, 
Binner et al. 1995, Galazka, Windsor et al. 1996), which appear to require zymogen 
perturbation.  
	 Restoration of full MMP-1 enzymatic activity was achieved using site-directed 
mutagenesis to replace the necessary glutamate residue.  In the presence of APMA, this 
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revertant was able to remove the inhibitory PRO domain by autolysis and displayed 
activity against a simple chromogenic peptide.  More importantly, refolded MMP-1 
exhibited activity against type I collagen, the complex natural substrate.  This suggests 
that all necessary determinants, both CAT-1 and HPX-1 (Chung, Yoshida et al. 2004), 
are present and functional. 
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CHAPTER 3: IDENTIFYING THE COLLAGEN-
BINDING SITE OF THE MMP-1 HEMOPEXIN 
DOMAIN BY MUTAGENESIS AND SURFACE 
PLASMON RESONANCE
3.1 Introduction
Fibrillar collagen degradation by the prototypic collagenase, MMP-1, results from the 
cooperative action of both the CAT and HPX domains (Chung, Yoshida et al. 2004). 
Previous studies have implicated the accessory HPX domain in binding the collagen 
substrate in preparation for hydrolysis of the Gly775-Ile776 or Gly775-Leu776 scissile 
bond by the CAT domain.  Despite the lack of obvious binding clefts or pockets on the 
HPX surface (Li, Brick et al. 1995, Jozic, Bourenkov et al. 2005, Iyer, Visse et al. 2006), 
the existence of ‘exosites’ necessary for substrate recognition and cleavage have been 
predicted (Overall 2002).  A recent study examining the interaction between an MMP-1 
active site mutant (E219A) and a synthetic triple helical peptide (THP) using hydrogen/
deuterium exchange mass spectrometry (HD/MS) implicated blades 1 and 4 of the 
HPX domain in collagen binding (Lauer-Fields, Chalmers et al. 2009).  Subsequent 
mutagenesis and assay identified residues Ile290 and Arg291 in the A-B loop of HPX-1 
blade 1 as an exosite for collagenolysis.  However, this ‘exosite’ appears to be much more 
extensive.  An NMR-monitored ligand titration of 15N-labeled HPX-1 with unlabeled 
α1(I)772-787 THP conducted in the laboratory of Dr Andrew Pickford, showed 
significant line-broadening indicative of substrate binding for residues Arg291-Glu293, 
Phe308-Glu311, Glu313-Phe316, Ser318-Val319 and Phe320-Gly328 of blade 1, and 
Gly353-Val356 of  blade 2 (Figure 3.1).
 This study uses a comprehensive programme of alanine-scanning site-directed 
mutagenesis and assay to study the complex formed between the HPX-1 domain and a 
synthetic THP that encompasses the MMP-1 cleavage site of the collagen α1(I) chain. 
Surface Plasmon Resonance (SPR) was used to examine the functional contribution of 
12 individual amino acid residues to the putative collagen binding site located in blades 
1 and 2 of HPX-1, while heteronuclear NMR spectroscopy was used to investigate 
selected HPX-1 point mutants to ensure that native structure was retained and 
unimpaired by mutagenesis. 
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 3.1.1 The Surface Plasmon Resonance phenomenon
An evanescent wave is generated when the total internal reflection of p-polarized light 
(polarization occurs parallel to the plane of incidence) occurs at the interface between a 
medium of high refractive index and a medium of low refractive index.  The amplitude 
of the evanescent wave decays exponentially away from the interface, but can be 
enhanced using a suitable-conducting thin film of inert metal at the interface, typically 
gold.  Optical excitation at a certain incident angle transfers energy to surface plasmons, 
collective electron oscillations; enhancing the evanescent electric field amplitude, 
penetrating the low refractive index medium, and thereby reducing the reflected light 
intensity.  Consequently, the incident angle (SPR angle) at which plasmon excitation 
(resonance) occurs is extremely sensitive to any change in the refractive index of the 
medium adjacent to the metal surface.  Mass bound to the surface alters the refractive 
index and therefore the SPR angle.  Thus, SPR is an optical phenomenon that can be 
exploited to observe interactions between immobilized biomolecules and their cognate 
binding partners.
 3.1.2 Biacore Technology
SPR-based biosensor assays offer rapid screening of molecular interactions in real time. 
Instruments have three primary components: an SPR optical detection system, a 
microfluidic flow cell system and a gold-dextran sensor surface, which together enable 
detection and quantitative measurements of binding interactions in real time 
(Components of Biacore systems are fully described in the Biacore Sensor Surface 
Handbook - GE Healthcare, 2008).  A prism coupling p-polarized light, the gold film 
and a light-detecting device in the Kretschmann configuration (Figure 3.2) is the most 
widely used optical system.  Biacore instruments utilise this arrangement to measure 
variations in the refractive index.  The subsequent shift of the SPR angle is proportional 
to the mass change at the sensor surface determined by the binding and dissociation of 
biomolecules.  This is monitored using the Biacore control software and is visualised as a 
sensorgram (Figure 3.2) with response units (RU), corresponding to the angle shift, 
plotted as a function of time.  Highly sensitive instruments like the Biacore T-200 can 
reliably detect changes of 1 RU, which corresponds to approximately 1 pg/mm2 of mass 
on the sensor surface area (GE Healthcare, 2008).
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 3.1.2.1  Sensor Chip
The Biacore CM sensor chip series is designed for efficient ligand immobilization to a 
surface suitable for SPR signal generation.  It is composed of a glass surface coated with 
a thin gold layer (~ 50 nm thick) and covered with a flexible carboxymethylated (CM) 
dextran matrix.  This matrix increases the immobilized ligand surface capacity, and is 
suitable for ligand attachment using various immobilization chemistries which exploit 
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Figure 3.2: Detection of  binding events using SPR technology.  
Schematic of a surface plasmon resonance biosensor in the Kretschmann configuration (top).  The 
p-polarized incident beam is directed at the sensor surface and the angle of incidence (SPR angle) 
is detected as a change in the detector position for the reflected intensity dip (*).  Binding of an 
analyte to the immobilized ligand (1:1) at the sensor chip causes a corresponding increase in 
refractive index altering the SPR angle (**) and is shown as an increase in response in the 
sensorgram (bottom).  Analyte dissociation results in a response drop as the SPR angle returns to 
the original position.
ligand functional groups.  Other derivitized matrices exist and the Biacore range also 
includes high affinity application sensor chips with streptavidin and nitrilotriacetic acid 
(NTA) for non-covalent capture of tagged ligands.  However, covalent immobilization is 
often a preferred approach for ligand attachment as it avoids ligand removal during chip 
regeneration, provided suitable regeneration conditions can be found.
	 The CM matrix is suitable for a range of surface immobilization chemistries 
including thiol and aldehyde coupling.  However, only amine coupling will be described 
here.  Amine coupling involves activating the sensor chip surface with a mixture of 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide (NHS) 
prior to ligand attachment via primary amine groups.  EDC activation of carboxylate 
molecules forms unstable O-acylisourea amine reactive intermediates, which are rapidly 
hydrolysed reforming the carboxyl group (Williams, Hill et al. 1981).  Increasing the 
efficiency of EDC mediated amine coupling can be achieved with the addition of NHS, 
which converts the intermediate to a stable, amine-reactive succinimide ester (Gilles, 
Hudson et al. 1990) (Figure 3.3).  Following the immobilization reaction, the sensor 
surface is treated with ethanolamine to deactivate excess reactive groups.
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(amide bond)
Figure 3.3: NHS/EDC cross-linking reaction scheme.
Carboxyl-to-amine cross-linking using the carbodiimide EDC and NHS. Molecules (1) and (2) can be 
peptides, proteins or any chemicals with carboxylate and primary amine groups. Addition of NHS to 
EDC reactions (bottom pathway) increases efficiency of EDC mediated amine coupling. (Image adapted 
from Carbodiimide Crosslinker Chemistry ThermoScientific 2009).
 3.1.3 Calculation of binding affinity constants by SPR
Major applications of label-free real-time SPR technology include measurement of 
thermodynamic properties and binding rate constants of biospecific macromolecular 
interactions.  Assuming a simple 1:1 interaction, the apparent rate and affinity constants 
are easy to calculate. The analyte (A) and immobilised ligand (B) associate at the sensor 
surface to form the complex (AB):
$ $ $
       
 
   (1)
and is defined by the association rate constant (ka) and dissociation rate constant (kd). 
The association phase is described by: 
(2)
The amount of complex (AB) formed is proportional to the observed shift in SPR angle 
and is expressed in RU.  At equilibrium,
(3)
Therefore, 
(4)
Rearrangement of equation 4 gives the equilibrium constant (Kd), which describes the 
affinity of this interaction determined from the ratio of the kinetic rate constants, kd/ka, 
or from the level of  binding at equilibrium as a function of  sample concentration: 
  
(5)
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Accurate interpretation of kinetic rate constants necessitates reduction of the mass 
transport effects, whereby the rate of ligand binding exceeds the rate of analyte 
transport to the sensor surface.  This phenomenon results in an apparent association 
rate slower than that of the true association rate.  Furthermore, rebinding artifacts 
during dissociation are exacerbated resulting in slower apparent dissociation rates.  Low 
immobilisation levels (<100 RU) and high flow rates (>30 μL min-1) are recommended 
to counteract mass transport effects (Myszka, Morton et al. 1997).
	 Preliminary experiments conducted by Dr Laurence Arnold indicated that the 
HPX-1:THP interaction was not amenable to analysis using kinetic rate constants due 
to rapid dissociation beyond the resolution limit of the instrumentation.  Therefore, the 
SPR experimental data described in this chapter were analysed using equilibrium 
analysis:
(6)
where Req is the response at equilibrium and Rmax is the maximum response.
 3.1.4 The synthetic α1(I)772-787 Triple Helical Peptide
Collagen possesses unique physiochemical properties, which make it difficult to study. 
Conversely, small triple helical peptides (THPs) that mimic the structure of collagen are 
more amenable to study. Consequently, they have been used extensively in structural 
stability studies, protein-collagen binding interactions and as substrates and inhibitors 
for MMPs (Reviewed in Koide 2007, Fields 2010).  
 The 10.7 kDa homotrimeric THP used in this study is based on the α1(I)  chain 
of  type I collagen and has the sequence:
NH2-C6-(GPO)4 GPQG~IAGQRGVVGLPGPO(GPO)3 -OH
in which ‘O’ denotes 4-hydroxyproline and the underlined ‘guest’ sequence is identical 
to residues Gly772-Gly787 of the collagen α1(I) chain.  The THP, which was kindly 
donated by Prof. Gregg Fields (Torrey Pines Institute, Florida), has an N-terminal 
hexanoic group (designated C6) followed by four GPO repeats, which together induce 
self-association and enhance thermal stability (Fields and Prockop 1996).  The tilde (~) 
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marks the MMP-1 cleavage site within the THP ‘guest’ sequence, a position analogous 
to that in type I collagen (Lauer-Fields and Fields 2002, Chung, Yoshida et al. 2004).  
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3.2 Materials and Methods
The mutagenesis necessary to investigate the role of HPX-1 amino acid residues 
contributing to the putative collagen binding has been previously described in Chapter 
2.  Oligonucleotide design and preparation was undertaken as described in Section 
2.3.4.  Site-directed mutagenesis of target residues was completed as described in 
Section 2.3.5.  Recombinant proteins were produced in accordance with protein 
expression and purification methods described in Table 2.5.

 3.2.1 Preparation of the α1(I)772-787 Triple Helical Peptide
Prior to each experiment, the THP monomers were annealed into a triple helix at a 
high concentration (>1 mM) by heating for 15 min at 65 °C followed by slow cooling 
from 65 to 4 °C over 2 h. Because of their lack of aromatic residues, these α1(I)772– 
787 THP solutions were quantitated spectrophotometrically according to the formula: 
[THP] (mg/ml) = ((A215 - A225) X 0.144)/e; where e is the path length in cm (Sober 
1968).
 3.2.2 Surface Plasmon Resonance
All SPR experiments were performed using a Biacore T-100 instrument (GE 
Healthcare) at 25 °C.  
 3.2.2.1 THP immobilisation to the CM4 sensorchip by amine-
coupling
Ligand immobilisation was performed by Dr Andrew Pickford.  In brief, the N-
terminally aminated α1(I)772-787 THP was immobilized to the dextran surface of a 
CM4 sensorchip (GE Healthcare) flow cell using amine coupling in 10 mM HEPES pH 
7.4.  The more commonly used CM5 sensorchip (which has a higher degree of dextran 
carboxylation) was found to exhibit unacceptably high levels of non-specific electrostatic 
binding to WT HPX-1 (which has a pI of 9.45).  The chip surface was activated prior to 
ligand immobilization using EDC and NHS solutions applied at the recommended flow 
rate and contact time specified in the GE Healthcare Biacore Sensor Surface Handbook 
(2008). Free succinimide esters were blocked with ethanolamine.  All proprietary 
solutions were provided in the Amine-coupling Kit (GE Healthcare).
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 3.2.2.2 THP:HPX-1 Binding Assay 
The running buffer for all SPR binding assays was HBSCP+ (10 mM HEPES, 150 mM 
NaCl, 10 mM CaCl2, 0.05% (v/v) poly-sorbate-20), pH 7.4.  Due to the extremely rapid 
dissociation rates of WT HPX-1 from immobilized α1(I)772-787 THP seen in 
preliminary experiments (which were beyond the T100 capability), the equilibrium 
dissociation constants (Kds) for the wild-type and each mutant were determined from the 
SPR response at equilibrium.  Thus, long-duration (10-min contact time) triplicate 
injections were performed with a suitable range of analyte concentrations (e.g. ~40 nM 
to ~40μM for WT HPX-1) at a flow rate of 1 μL/min.  In each case, the equilibrium 
point was taken to be 5 s from the end of  the analyte injection.  
 3.2.2.3 THP:HPX-1 Binding Data Analysis
Data analysis was performed using BIAevaluation™ software (GE Healthcare) by 
nonlinear least squares fitting using: 
	
(7)
where Req is the equilibrium response at a given concentration (c) of the WT or mutant 
protein, Rmax is the maximum response possible if the immobilized THP ligand were 
saturated with analyte, and Kd is the dissociation constant.	
 3.2.3 Nuclear Magnetic Resonance of HPX-1 Mutants
1D 1H, and 2D 1H-15N heteronuclear single quantum coherence (HSQC) spectra of the 
purified isotopically 15N-labelled target proteins were acquired as described in Section 
2.3.28 and 2.3.29.  

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3.3 Results
 3.3.1 Production of HPX-1 mutants
Mutated pET-3a:HPX-1 constructs were successfully produced by Dr Laurence Arnold 
using site-directed mutagenesis and confirmed by DNA sequencing.  These constructs 
were then transformed into E. coli expression strain BL21-CodonPlus (DE3)-RIPL and 
screened for IPTG-induced recombinant protein expression.  A protein of ~24 kDa was 
expressed in all cases at levels equivalent to or even exceeding that of  the WT HPX-1.  
 All target proteins were found to deposit into bacterial inclusion bodies and were 
therefore solubilised, refolded and purified in accordance with the standard procedures 
described in Chapter 2.  However, during the refolding stage, three of the mutant 
HPX-1 domains (D299A, F316A and Q352A) precipitated leaving insufficient material 
for functional analysis.  The remaining HPX-1 mutants that remained soluble during 
the refolding stage were found to elute from the cation exchange column at identical 
NaCl concentration to that of the WT HPX-1, suggesting that each protein possessed a 
native-like structure.  In contrast, aggregation or an altered structural state unable to 
bind the structural Ca2+ at the centre of the HPX β-propeller would change the charge 
properties of  the recombinant proteins and therefore the subsequent elution profile. 
	 Completion of the standard expression and purification procedure produced 
sufficient milligram quantities of target recombinant proteins sufficient for the assays 
described in this chapter.
 3.3.2 Functional Analysis by SPR
Equilibrium analysis was used to characterise the binding affinity of WT HPX-1 and 
mutants thereof (R300A, F301A, S318A, V319A, P325A, R337A, D338A, Q354A, 
H358A, P361A) for immobilised α1(I)772-787 THP.
  3.3.2.1 Binding of WT HPX-1 to immobilised THP
Triplicate injections were performed using a suitable range of analyte concentrations 
(0.2 μM-45 μM) and affinities were determined by fitting to a 1:1 Langmuir isotherm 
binding model using the maximum response at equilibrium, taken to be 5 s from the end 
of the analyte injection.  WT HPX-1 bound to α1(I)772-787 THP with an apparent 
equilibrium dissociation constant (Kd) value of 10.9 ± 0.9 μM (Figure 3.4).  This finding 
opposes that of a previous study, which reported undetectable HPX-1 binding levels to 
collagenous heterotrimeric peptides (Ottl, Gabriel et al. 2000).
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  3.3.2.2 Screening mutant HPX-1 proteins
A minimum of duplicate injections were performed using a suitable range of analyte 
concentrations (~0.2 μM-~100 μM) and affinities were determined as described in 
Section 3.3.2.1.
 HPX-1 mutants bound to α1(I)772-787 THP with apparent Kd values between 
9.8-27.4 μM (Figure 3.5).  The binding activity of HPX-1 mutants R300A, S318A, 
P325A, Q354A and H358A were very similar to that of the WT HPX-1, suggesting that 
they play no direct role in contacting the collagen substrate.  Conservative increases in 
Kd were observed for mutants R337A and P361A.  However, mutants F301A, V319A 
and D338A exhibited an approximate 3-fold reduction in binding relative to WT 
HPX-1 implying that these residues are important contributors to collagen recognition. 
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HPX-1
200 nM
45 μM
Figure 3.4: Equilibrium binding of HPX-1 to α1(I)772-787 THP. (A) Overlaid SPR sensorgrams 
showing the dose-dependent binding of the analyte, HPX-1, to an immobilised ligand, THP. (B) Hyperbolic 
binding curves for HPX-1 from the equilibrium SPR data.  The fitted curve is of the form R/Rmax = (c/c + 
Kd), where c is the analyte protein concentration.  Error bars indicate the S.D. from triplicate measurements.
Kd = 10.9 ± 0.9 μM
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Kd = 10.0 ± 0.4 μM Kd = 27.4 ± 0.9 μM
Kd = 14.7 ± 0.8 μM Kd = 26.4 ± 1.5 μM
Kd = 16.5 ± 2.6 μM
Kd = 24.5 ± 
0.9 μM
Kd = 9.8 ± 0 μM
Kd = 12.8 ± 0.2 μM
The binding affinities for all HPX-1 mutants tested are shown compared with WT 
HPX-1 in Figure 3.6.
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Figure 3.5: Binding to the α1(I)772-787 THP by HPX-1 mutants.  Hyperbolic binding curves 
generated from the equilibrium SPR data.   The fitted curve is of the form R/Rmax = (c/c + Kd),  where c is the 
analyte protein concentration.  Error bars indicate the S.D. from replicate measurements.  The dashed line 
shows concentration-dependent binding of  wild-type HPX-1 for the THP substrate.
Figure 3.6: Equilibrium dissociation constants (Kd) for the binding of WT HPX-1 and 
mutant proteins to immobilised THP. Error bars indicate the S.D. from replicate measurements. The 
horizontal dashed line emphasises the Kd of the WT HPX-1 protein for comparative purposes.  P values were 
determined by comparing binding affinities of mutant proteins with WT HPX-1. Statistical analysis was 
performed using an unpaired two-tailed Student’s t-test (df=4) and statistically significant P values (p<0.05) 
are shown.  The asterisk indicates statistical significance with P-values of p<0.05 (*),  p<0.01 (**), p<0.001 
(***) and p<0.0001 (****).  P values greater than or equal to 0.05 are not considered statistically significant 
(ns).
Kd = 9.8 ± 0.2 μM Kd = 20.8 ± 1.0 μM
*
**** ***
**
****
*
***
ns ns ns
 3.3.3 Structural integrity of HPX-1 F301A and V319A
Heteronuclear NMR spectroscopy was used to confirm that the reduced THP binding 
observed for HPX point mutants F301A and V319A was the result of selective removal 
of a critically important side-chain rather than perturbation of the native tertiary 
structure (Figure 3.7).  In each case, the 1H, 15N-HSQC of the 15N-labeled HPX-1 
mutant was very similar to that of the WT protein with excellent chemical shift 
dispersion in each dimension. In neither case were any extensive changes in 1H or 15N 
chemical shifts observed that would indicate a substantial change in the HPX-1 
structure. Furthermore, no significant line broadening was observed in the HPX-1 
mutants that could indicate a conformational exchange and thus destabilization of the 
domain.
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3.4 Conclusions
Mutated pET-3a:HPX-1 constructs were successfully transformed into E. coli BL21-
CodonPlus (DE3)-RIPL cells, prior to inducing protein expression.  With the exception 
of D299A, F316A and Q352A HPX mutants, all proteins were successfully, refolded 
and purified at equivalent levels to WT HPX-1.  
 Despite a number of reports describing collagen binding by MMP HPX 
domains (Allan, Hembry et al. 1991, Murphy, Allan et al. 1992, Tam, Wu et al. 2002), a 
previous study observed no interaction between HPX-1 and a heterotrimeric THP using 
kinetic SPR analysis (Ottl, Gabriel et al. 2000).  However, each chain of the α1(I)2 α2(I) 
THP used in the previous study lacked L785, part of the hydrophobic collagen region 
believed to contribute to MMP-1 recognition (Fields 1991, Leikina, Mertts et al. 2002). 
The synthetic THP utilised in this SPR-based assay incorporates both the MMP-1 
cleavage site and L785, which may account for detectable HPX-1 binding thereby 
allowing elucidation of  binding affinities (Kd values).
 All residues selected for testing were located within β-propellor blades 1 and 2 
(Figure 3.8), implicated in collagen recognition during an NMR-monitored ligand 
titration.  Of those residues tested using SPR, mutants that exhibited significantly 
decreased affinity (≥ 2 fold) for immobilised THP were F301A, V319A and D338A. 
Interestingly, D338 contributes to a salt-bridge with R291, a residue highlighted during 
analysis of MMP-1:THP interactions using HD/MS (Lauer-Fields, Chalmers et al. 
2009), therefore alanine substitution at position 338 will disrupt the salt-bridge 
restricting ligand recognition.  However, F301A and V319A HPX-1 mutations had the 
most pronounced effect on functional binding.  1H15N- HSQC spectra of HPX-1 
mutants F310A and V319A indicated that both proteins possessed folded tertiary 
structure, therefore the reduction in THP-binding for these mutants was taken as an 
indication of direct involvement in collagen recognition rather than deleterious 
structural effects from site-directed mutagenesis.  
	 Intriguingly, F301 is concealed within the CAT-HPX domain interface as shown 
by examination of the mature MMP-1* crystal structure.  Consequently, the role of this 
residue within the blade 1 exosite of the full-length enzyme remains to be elucidated. 
Further study is required and is the subject of  Chapter 4.
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CHAPTER 4: MMP-1 IS IN EQUILIBRIUM BETWEEN 
COMPACT AND DOMAIN-DISLOCATED STATES
4.1 Introduction
The lack of collagenolytic activity in HPX-deletion mutants of MMP-1, -8, -13 and -14 
demonstrates the presence of collagenolytic determinants within the HPX domain 
(Hurst, Schwartz et al. 2004).  These ‘exosites’ may, in part, explain how collagenase 
activity is achieved despite conflicting size dimensions of enzyme and substrate, which 
typically prevent peptide bond hydrolysis.  It has been postulated that these exosites may 
impart collagenases with helicase activity, the ability to bind and partially unwind the 
triple helical collagen substrate (Tam, Moore et al. 2004), thereby allowing a single α-
chain to enter the active site cleft of the CAT domain (Chung, Yoshida et al. 2004) and 
exposing the scissile bond necessary for sequential polypeptide cleavage.  However, the 
molecular basis for this mechanism remains to be elucidated. 
 The NMR and SPR data obtained and presented in the previous chapter 
suggest that for MMP-1 an exosite exists in blade 1 of HPX-1.  The highest impact 
mutation, F301A, reduced binding activity (2.5-fold) highlighting its role as an important 
contributor to collagen recognition.  However, close inspection of the crystal structure 
reveals F301 lies at the end of β-strand D in blade 1 with its aromatic ring oriented 
away from the the core of HPX-1 and is buried at the CAT-HPX domain interface, a 
position likely to prohibit involvement in collagen binding in the full-length enzyme. 
Intriguingly, together with residues R300 and F316, residue F301 forms part of a ball 
and socket joint at the CAT-HPX domain interface (Figure 4.1). Rotation around this 
joint, may allow global structure reconfiguration of the compact arrangement, opening 
a groove between CAT-1 and HPX-1 that has been proposed to form the collagen 
binding site (Jozic, Bourenkov et al. 2005), a hypothesis that would explain the apparent 
lack of binding by proMMP-1 to collagen (Welgus, Jeffrey et al. 1981).  Furthermore, 
differences in the reciprocal orientation of the CAT and HPX domains upon activation 
(discussed further in Chapter 6) and interdomain flexibility observed during solution 
studies of MMP-9 and -12 (Rosenblum, Cohen et al. 2007, Bertini, Calderone et al. 
2008) support the notion that domain mobility may be a general feature of MMPs, and 
a significant property for the recognition and unwinding of  triple helical collagen.  
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Ball
R300
F316F301
Socket
Figure 4.1: The ball and socket joint in the CAT-HPX interface of MMP-1. A space-filling 
model of the crystal structure of MMP-1 is shown looking into the active site cleft with the Zn2+ ion 
colored yellow. Dislocation of the ball and socket joint and rotation by 90o of the CAT (green) and HPX 
(blue) domains reveals the interacting surfaces. The three residues comprising the ball are highlighted.
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F316
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! The study described in this chapter used alanine-scanning site-directed 
mutagenesis and assay to investigate the role of residues R300, F301 and F316.  SPR 
was utilised to confirm the contribution of these residues towards binding a synthetic 
THP substrate, and a chromogenic assay was used to quantitate and characterise the 
catalytic activity of full-length mutant proteins.  Finally, small angle x-ray scattering 
(SAXS) was used to investigate whether the compact arrangement of domains observed 
in the crystal structure is representative of  the conformation in solution. 
	 4.1.1 Small Angle X-Ray Scattering
Small angle x-ray scattering (SAXS) is a powerful technique that can be used for low-
resolution structural characterization of biological macromolecules in solution and can 
provide information concerning the size, molecular weight, volume, shape and 
conformation of single molecules under a variety of conditions.  The availability of 
high-brilliance synchrotron radiation sources, improving levels of automation during 
data acquisition and processing, and the ease of sample preparation have led to 
increasing popularity of this low-resolution structural technique (Reviewed in Svergun 
and Koch 2002, Lipfert and Doniach 2007).  SAXS requires only micro-milligram 
quantities of the purified monodisperse target protein that can be monitored in varying 
conditions.  In contrast, x-ray crystallography necessitates specialist crystallization 
conditions, while NMR demands isotopic-labelling of  target proteins.  
! 4.1.1.1 SAXS Data Acquisition and Analysis
During a SAXS experiment monochromatic x-rays (λ = 0.5-2Å) are used to irradiate a 
dilute solution of macromolecules (Figure 4.2).  Attenuation of the incident radiation 
occurs as it interacts with the electron cloud of atoms within the macromolecule.  At low 
angles of incidence, the beam (ki) is elastically scattered, without energy transfer 
(Thomson scattering) and the synchronised plane waves produce interference patterns at 
the detector’s position, the intensity of which depends on the orientation and distance of 
the scattering atoms in relation to the observation angle, 2θ.
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For elastic scattering both wave vectors have the magnitude 2π/λ and the scattered 
intensity (I), is measured as a function of the reciprocal space momentum transfer, q, 
which is defined as:
 (1)
where λ is the wavelength and 2θ is the scattering angle as shown in Figure 4.2.  As such, 
the units of q are inverse length units (Å-1 or nm-1). For randomly oriented scattering 
molecules, the two-dimensional intensity pattern is azimuthally averaged and resulting 
intensity I(q) can be plotted as a function of the momentum transfer q (Glatter and 
Kratky 1982, Feigin and Svergun 1987).  
! The amplitude of the scattered wave (ks) depends on the electron density 
distribution ρ(r) of the sample and therefore electron density contributions from both the 
scattering particle and the solvent must be considered (~0.33 e-/Å3 and ~0.44 e-/Å3, for 
pure water and protein respectively).  The normalised scattered intensity after accurate 
solvent background subtraction is given by:
                                                      (2)
where N is the number density of scattering particles, V is the average particle volume, 
Δρ is the scattering contrast between the particle of interest and the surrounding 
medium, P(q) is the form factor describing the size and shape of the particles and S(q) is 
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I(q) = NV 2Δρ2P(q)S(q)
ki
ki
ks
2θ
detector
sample
Figure 4.2: Scattering geometry in small angle scattering. Schematic showing the path of  
incidence (ki) and scattered beams (ks), respectively.
q = 4π sinθ
λ
the structure factor describing particle interactions.  For monodisperse dilute 
suspensions S(q)≈1, thus I(q) is governed by the shape of the scattering molecules.  In the 
case of non-interacting particles, I(q) at small angles follows the Guinier approximation, 
which describes the moment of inertia for a particle using the electron density as a 
weighting factor:
     (3)
where I(0) is the intensity extrapolated to q=0 and Rg is the radius of gyration.  This is 
valid over a q range limited by qRg<1.3 for globular proteins (Putnam, Hammel et al. 
2007).  When (ln(I(q)) versus q2) is plotted the y-axis intercept provides ln(I(0)) and the 
slope gives -Rg2/3, from which the Rg can be derived.  Deviations from linearity in this 
region are indicative of sample aggregation, polydispersity or interparticle effects (Figure 
4.3).
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Figure 4.3: Guinier Analysis. Standard SAXS curves (A) and Guinier plots (B) for BSA samples 
measured at X33 (DORIS, Hamburg) in different buffers showing (1) aggregation, (2) good data and 
(3) inter-particle repulsion. The Guinier fits for estimation of Rg and I(0) are displayed, with the linear 
regions used for parameter estimation indicated by the thick lines (Adapted from Mertens and 
Svergun 2010).
log I ln I
q (nm-1) q2 (nm-1)
I(q) = I(0) exp −Rg
2q2
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Inversion of reciprocal space using a Fourier transform of the scattered intensity, I(q) is 
known as the pair distance distribution function, P(r):
  (4) 
which describes the paired intramolecular atomic distances of a particle and is useful for 
detecting overall shape, conformational changes (Figure 4.4), real space approximation 
of Rg and maximal dimensions (Dmax), which have the smallest frequency and can 
therefore be determined by the x-axis intercept (Feigin and Svergun 1987). The function 
requires measurement over the entire q range, which is prevented as scattering rapidly 
decreases at high q angles.  Typically, the P(r) function is therefore calculated by indirect 
Fourier transformation to avoid the inherent problems of sampling over a finite q range 
(Glatter 1977). 
  
 
!
! 4.1.1.2 SAXS Data Processing and Analysis Software
The quantity of data generated by small angle scattering experiments continues to 
increase as a result of hardware developments.  Large area hybrid pixel detectors 
developed for high-energy experiments feature high dynamic ranges, millisecond read-
out times and single pixel photon counting (Broennimann, Eikenberry et al. 2006) with 
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Figure 4.4: Theoretical P(r) functions for monomeric and dimeric bodies with 
simple shapes.  The bead models used for the calculation are shown.  Conformational 
variation is easily detectable by observing changes in peak height, shape and maximal 
dimension  (Reproduced from Chandrasekaran 2011).
count rates of 3.108 photons per mm2 per sec recorded (Dectris® 2012).  Therefore, 
users can easily expect to generate several gigabytes of  data during a single SAXS visit.  
	 To manage SAXS experimental data evaluation several program packages 
are freely available. Developed at EMBL, Hamburg, ATSAS (Konarev, Petoukhov et al. 
2006) is one popular program suite dedicated to biological macromolecule analysis and 
allows users to accomplish most data analysis tasks.  The workflow begins with raw data 
processing and finishes with a low-resolution three-dimensional (3D) structural model. 
PRIMUS (Konarev, Volkov et al. 2003) is a graphical package for preliminary analysis of 
1D data.  Using this programme, it is possible to complete a variety of data 
manipulations including buffer subtraction, merging data from different angular ranges, 
extrapolation to infinite dilution, and evaluation of key SAXS parameters including the 
Rg and I(0) .  Good quality data can be further analysed using GNOM (Svergun 1992), 
an indirect Fourier Transform programme, that uses the 1D scattering data to calculate 
the distance distribution function for the target macromolecule.  Successive iterations are 
required to specify an appropriate distribution range and optimum Dmax value; this 
parameter is user-defined and so care must be taken to ensure a good solution is found.
	 Three dimensional ab initio reconstructions can be derived from 1D scattering 
intensity data and several shape restoration programmes are available for determining 
macromolecular shapes.  DAMMIN and DAMMIF use the GNOM output file to 
produce low-resolution structures. (Volkov and Svergun 2003, Franke and Svergun 
2009)  Using simulated annealing of dummy atoms in a spherical search volume, the 
programs are able to calculate optimal protein configurations that fit the experimental 
SAXS data.
	 Known high-resolution atomic structures can be compared to experimental 
intensity data using CRYSOL (Svergun, Barberato et al. 1995), which generates a 
theoretical SAXS scattering profile for the known structure and uses the chi2 agreement 
to evaluate the fit.  The ab initio envelopes can be superimposed using SUPCOMB 
(Kozin and Svergun 2001), a program that minimises the normalised spatial discrepancy 
(NSD) to find the best alignment between models.  Model alignment discrepancy may 
be apparent for proteins with disordered regions or proteins experiencing 
conformational freedom.  
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4.2. Materials and Method
The mutagenesis and SPR methods necessary to investigate the role of residues Arg300, 
Phe301 and Phe316 have previously been described in Chapters 2-3.  Oligonucleotide 
design and preparation was undertaken as described in Section 2.3.4.  Site-directed 
mutagenesis of target residues was completed as described in Section 2.3.5. 
Recombinant proteins were produced in accordance with protein expression and 
purification methods described in Section 2.3.  Substrate-binding by proMMP-1* and 
MMP-1* recombinant proteins was assayed using SPR as described in Section 3.2.2. 
Substrate cleavage by active MMP-1 recombinant proteins was conducted as described 
in Section 2.3.23.  

 4.2.1 Analytical Gel Filtration
Purified samples were concentrated, using centrifugal filter units with 10 kDa MWCO 
(Millipore), to a volume of 1 mL using a Beckman Coulter Allegra 25R refrigerated 
centrifuge (rotor AT-14-10) pre-chilled to 4 oC.  Samples were resuspended after each 
spin (3000 rpm for 1-10 minutes).  Following concentration, the samples were applied at 
1 mL/min to a HiLoad Superdex 75 16/60 prep grade column pre-equilibrated with 
TNC buffer.  1 mL fractions were collected and were analysed by SDS-PAGE (Section 
2.3.19.
 4.2.2 Small Angle X-Ray Scattering Data Acquisition
Recombinant proMMP-1* and MMP-1* proteins purified by gel filtration (Section 
2.3.22) were dialysed overnight (Spectrum Standard Regenerated Cellulose Spectra/Por 
dialysis membrane MWCO 3.5 kDa) against 1000 volumes of TNC buffer at 4 oC prior 
to transportation on ice to the Diamond Light Source (DLS), Harwell Science and 
Innovation Campus, Didcot.  Protein solutions were concentrated as described in 
Section 2.3.22 and the protein concentration was assessed. SAXS data was collected on 
the high-brilliance I22 beamline using a wavelength (λ) of 1.0 Å and an energy of 12.4 
keV, and equipped with a photon counting detector at a distance of 3.25 m from the 
sample cell.  The scattering patterns were measured for several protein concentrations in 
the range from 0.84 to 8.25 mg/ml, each with multiple successive 1s exposures over a 
60s period (to check for radiation-induced damage and aggregation).  Bovine serum 
albumin (BSA) was used for calibration purposes.  Measurements of the dialysis buffer 
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at equilibrium with the sample were used for buffer subtraction and to assess beam 
intensity fluctuations.
	 4.2.3 Small Angle X-Ray Scattering Data Processing and 
 Analysis
The data were normalised to the intensity of the beam, radially averaged and buffer 
scattering was subtracted using the Non-crystalline Diffraction data reduction 
programme provided by DLS.  Successive frames displaying changes in scattering 
intensity, indicative of radiation damage, were removed before further processing.  A q 
range of between 0.016 and 0.609 Å-1 was used in the analysis to exclude the parasitic 
scattering near the beam stop. Data were analysed and processed using the ATSAS 
software package (Konarev, Petoukhov et al. 2006).  The data were extrapolated to 
infinite dilution using the program PRIMUS (Konarev, Volkov et al. 2003) and the 
forward scattering, I(0), and the radius of gyration, Rg, were evaluated using the Guinier 
approximation, assuming that at very small angles (s < 1.3/Rg). 
	 The molecular mass of proMMP-1* was estimated using the following 
equation:
(5)
where I(0)p and I(0)st are the scattering intensities at zero angle of the target protein and 
the standard protein, respectively.  MMp and MMst are the corresponding molecular 
masses and cp and cst are the relevant concentrations (Mylonas and Svergun 2007).  The 
P(r) function was used to ensure a suitable number of data points was included for 
extrapolation of accurate I(0) values for both the target protein and the BSA standard 
(Putnam, Hammel et al. 2007).  
	 The values of I(0), the real space Rg, the maximum dimension (Dmax), and the 
interatomic distance distribution function, P(r), were calculated using the program 
GNOM (Svergun 1992). Simulated SAXS curves were generated from the atomic 
resolution crystal structures of proMMP-1* and MMP-1* (PDB accession codes 1SU3 
and 2CLT, respectively) using the program CRYSOL (Svergun, Barberato et al. 1995). 
Where appropriate, ten independent ab initio low resolution atomic reconstructions were 
generated from the P(r) data by simulated annealing using the DAMMIF program 
(Franke and Svergun 2009), which was run using default parameters and no enforced 
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MMp = I(0)p / cp MMstI(0)st / cst
particle symmetry.  DAMMIF ab initio models were individually checked for outliers and 
then aligned, averaged, and filtered using DAMAVER (Volkov and Svergun 2003). 
Overlay of the SAXS models with those from x-ray crystallography was performed with 
the program SUPCOMB (Kozin and Svergun 2001), in which a low NSD value 
indicated an acceptable fit.
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4.3. Results
  4.3.1 Mutagenesis
Site-directed mutagenesis of proMMP-1* and proMMP-1 plasmids was completed 
using the Quikchange® II XL Site-Directed Mutagenesis Kit (Agilent Technologies). 
Mutagenic efficiency was monitored by blue/white colour selection of transformed 
pWhitescript control mutagenesis reactions.  Mutagenic efficiency was calculated as the 
percentage of colonies displaying a blue phenotype indicative of incorporation of the 
functional (lacZ+) mutation.  Typical mutagenic efficiency levels were in excess of 94%. 
Transformations of mutated proMMP-1* and proMMP-1 plasmids yielded 10-150 cfu/
250 μL of transformation reaction.  Clones potentially harbouring mutants plasmids 
were randomly selected and harvested using a QIAprep Spin Miniprep Kit prior to 
dilution to 100 ng/μL in preparation for sequencing.  DNA sequencing was undertaken 
by the QuickLane Express Sequencing service provided by Beckman Coulter Genomics. 
DNA sequence analysis confirmed successful incorporation of mutagenic bases and 
hence single alanine amino acid substitutions in either proMMP-1* or proMMP-1 (See 
Appendix).
  4.3.2 Protein Production of Zymogens
Successfully mutated proMMP-1* and proMMP-1 plasmids were transformed into E. 
coli expression strain BL21-CodonPlus® (DE3)-RIPL and screened for IPTG-induced 
recombinant protein expression.  A protein of approximately 52 kDa was expressed in 
all cases, this is consistent with the expected mass predicted for proMMP-1 using the 
ExPASy ProtParam tool (Gasteiger, Gattiker et al. 2003) (See Appendix).  
 All target proteins were found to deposit into bacterial inclusion bodies and 
were therefore solubilised, refolded and purified in accordance with standard procedure 
(See Chapter 2).  Soluble target proteins were found to elute from the cation exchange 
column at an identical NaCl concentration to that of proMMP-1*, suggesting that each 
protein possessed a native-like structure.  In contrast, aggregation or an altered 
structural state unable to bind the structural Ca2+ at the centre of the HPX β-propeller 
would change the charge properties of the recombinant proteins and therefore the 
subsequent elution profile.  
	 Completion of the standard expression and purification procedure produced 
sufficient milligram quantities of monodisperse target recombinant proteins for the 
assays described in this chapter (Table 4.1). 
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	 	 4.3.2.1 Protein Production of Mature Enzymes
Recombinant proMMP-1* and proMMP-1 proteins were treated with APMA and 
CAT-3, and all showed complete enzyme maturation within a four hour incubation 
period concomitant with an appropriate reduction in molecular weight of ~10 kDa as 
shown by SDS-PAGE analysis (data not shown). During the final purification by gel 
filtration chromatography, it was noted that ‘ball’ mutant proteins appeared to elute 
earlier than expected suggestive of  a less compact structure in solution.
 4.3.3 Analytical Gel Filtration
Analytical gel filtration chromatography was used to maximise the resolution of the 
elution profile of activated proteins.  All three mutants exhibited a decrease in elution 
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Table 4.1: Purification of  proMMP-1* proteinsab
Protein Fraction Total 
Volume 
(mL)
Protein 
Concentration 
(mg/mL)
Total 
Protein 
(mg)
Recovered 
Protein 
(%)
proMMP-1*
Solubilised 
Inclusion Bodies
20 4.46 89.2 100
Post-CEX 30 0.97 29.1 32.62
Post-GF 25 0.60 15.0 16.82
proMMP-1* 
R300A
Solubilised 
Inclusion Bodies 20 7.87 157.4 100
Post-CEX 30 0.44 13.2 8.38
Post-GF 25 0.24 5.99 3.81
proMMP-1* 
F301A
Solubilised 
Inclusion Bodies 20 5.88 117.6 100
Post-CEX 30 0.48 14.4 12.24
Post-GF 25 0.23 5.75 4.89
proMMP-1* 
F316A
Solubilised 
Inclusion Bodies 20 5.45 109.0 100
Post-CEX 30 0.41 12.3 11.28
Post-GF 25 0.23 5.63 5.16
a from 500 mL of  culture 
b protein concentration was determined spectrophotometrically (A280) using the molar extinction  
coefficient values obtained from ProtParam analysis (Gasteiger, Gattiker et al. 2003).
volume, which correlated with an increase in hydrodynamic radius relative to MMP-1* 
(Figure 4.5) and is suggestive of  a less compact structure. 
	

  4.3.4 Functional Analysis by SPR
Equilibrium SPR analysis was used to characterise the binding affinity of the 
proMMP-1* zymogen, mature MMP-1* and the MMP-1* ‘ball and socket’ mutants 
(R300A, F301A and F316A)  for immobilised α1(I)772-787 THP.
 Triplicate injections were performed using a suitable range of analyte 
concentrations (~0.1 nM-40 μM) and affinities were determined by fitting to a 1:1 
Langmuir isotherm binding model using the maximum response at equilibrium, taken 
to be 5 s from the end of  the analyte injection.
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Figure 4.5: Gel filtration of MMP-1* and MMP-1* F301A.  Mutation of ‘ball’ residues 
induces conversion to a less compact form as shown by the reduced elution volume. Elution of 
CAT-3 is shown by an asterisk (*).  Elution profiles for R300A and F316A were superimposable upon 
that for F301A but have been omitted for clarity. 
*
  4.3.4.1 Binding of proMMP-1* to Immobilised THP
The zymogen, proMMP-1* bound to α1(I)772-787 THP with an apparent equilibrium 
dissociation constant (Kd) value of 7.37 ± 1.34 μM (Figure 4.6).  Interestingly, this is in 
contrast to previous reports, which claim that proMMP-1 lacks the capacity to bind 
collagen (Welgus, Jeffrey et al. 1985, Murphy, Allan et al. 1992).  
 The experimentally-derived Kd value is similar to that observed for HPX-1 
alone (Kd  = 10.9 ± 1.0 μM) suggesting that binding is most likely solely mediated by 
contributions from the HPX domain.  Occlusion of the CAT domain active site by the 
inhibitory propeptide would support this observation.  
  4.3.4.2 Binding of MMP-1* to Immobilised THP
MMP-1* bound to α1(I)772-787 THP with an apparent Kd value of 0.92 ± 0.09 μM 
(Figure 4.7), an order of magnitude lower than HPX-1 alone (Kd  = 10.9 ± 1.0 μM). 
Therefore, it is clear that the observed increase in affinity by the full-length enzyme is a 
consequence of  contributions made by the CAT domain and/or the CAT-HPX linker.  
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Figure 4.6: Equilibrium binding of proMMP-1* to α1(I)772-787 THP. (A) Overlaid SPR 
sensorgrams showing the dose-dependent binding of the analyte, proMMP-1*, to an immobilised 
ligand, THP. (B) Hyperbolic binding curve for proMMP-1* from the equilibrium SPR data.  The fitted 
curve is of the form R/Rmax = c/(c + Kd), where c is the analyte protein concentration. Error bars 
indicate the S.D. from triplicate measurements.   
proMMP-1*
160 nM
30 μM
Kd = 7.37 ± 1.34 μM
A B
  
  
 4.3.4.3 Binding of Mutant proMMP-1* Proteins (R300A 
  and F316A) to Immobilised THP
Zymogen proteins, proMMP-1* R300A and F316A, bound to α1(I)772-787 THP with 
apparent Kd values of 10.68 ± 0.40 μM and 7.29 ± 0.11, respectively (Figure 4.8). 
Interestingly, the F316A mutation appeared not to affect THP binding; in contrast the 
R300A mutation had an adverse effect, reducing binding by 45%.  However, statistical 
analysis revealed no significant difference between the mutants and proMMP-1*. 
	 It is anticipated that the impact of the F301A  mutation in the weak-binding 
zymogen form would require high protein concentrations likely to impede elucidation of 
Kd values, therefore this particular mutation remains untested.   
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Figure 4.7: Equilibrium binding of MMP-1* to α1(I)772-787 THP. (A) Overlaid SPR 
sensorgrams showing the dose-dependent binding of the analyte, MMP-1*,  to an immobilised ligand, 
THP. (B) Hyperbolic binding curve for MMP-1* from the equilibrium SPR data.   The fitted curve is of 
the form R/Rmax = c/(c + Kd), where c is the analyte protein concentration. Error bars indicate the S.D. 
from triplicate measurements.   
MMP-1*
70 nM
 Kd = 0.92 ± 0.09 μM
10 μM
A B
  
 4.3.4.4 Binding of Mutant MMP-1* Proteins (R300A, 
  F301A and F316A) to Immobilised THP
MMP-1* R300A, F301A and F316A bound to α1(I)772-787 THP with apparent Kd 
values of 2.78 ± 1.26 μM, 27.02 ± 2.98 μM and 2.69 ± 0.71 μM, respectively (Figure 
4.9).  Surprisingly the introduction of the highest impact HPX-1 mutation, F301A, into 
the full length MMP-1* form resulted in a drastic (30-fold) decrease in binding activity. 
Comparatively, the R300A and F316A mutations conferred conservative effects on 
binding (3-fold). 
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Kd = 10.68 ± 0.40 μM Kd = 7.29 ± 0.11 μM
Figure 4.8: Hyperbolic binding curves for proMMP-1* R300A and F316A from the 
equilibrium SPR data (A and B).   The fitted curve is of the form R/Rmax = c/(c + Kd), where c is the 
analyte protein concentration. The non-linear fit for proMMP-1* is shown for comparison (dashed line). 
Error bars indicate the S.D. from triplicate measurements. (C) Plot of equilibrium dissociation constants 
(Kd) for the binding of wild-type* and mutant proteins to immobilised THP.  P values were determined 
by comparing binding affinities of mutant proteins with proMMP-1*. Statistical analysis was performed 
using an unpaired two-tailed Student’s t-test (df=4) and P values were found to be greater than or equal 
to 0.05 were not considered statistically significant. 
A B
C

 4.3.5 Assay of Hydrolytic Activity using a Chromogenic 
  Peptide
Hydrolytic activities of activated MMP-1 proteins (WT, R300A, F301A and F316A) 
were determined spectrophotometrically at 412 nm following the generation of 2-
nitro-5-thiobenzoic acid product from the thiopeptolide substrate Ac-Pro-Leu-Gly-[2-
mercapto-4-methyl-pentanoyl]-Leu-Gly-OC2H5 (Enzo® Life Sciences) (See Section 
2.3.23).  Active CAT-1 was used as the positive control in this study and deemed 
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Figure 4.9: Hyperbolic binding curves for MMP-1* R300A, F301A F316A from the 
equilibrium SPR data (A-C).  The fitted curve is of the form R/Rmax = c/(c + Kd),  where c is the 
analyte protein concentration. The non-linear fit for MMP-1* is shown for comparison (dashed line). Error 
bars indicate the S.D. from triplicate measurements. (D) Plot of equilibrium dissociation constants (Kd) 
for the binding of wild-type* and mutant proteins to immobilised THP.  P-values were determined by 
comparing binding affinities of mutant proteins with MMP-1*. Statistical analysis was performed using 
an unpaired two-tailed Student’s t-test (df=4) and statistically significant P-values (p<0.05) are shown. 
The asterisk indicates statistical significance with P-values of p<0.05 (*), p<0.01 (**), p<0.001 (***) and 
p<0.0001 (****).  P-values greater than or equal to 0.05 are not considered statistically significant.
Kd = 2.78 ± 1.26 μM Kd = 27.02 ± 2.98 μM
A B
C D
*
****
**
representative of full activity (i.e. 100% relative activity).  In contrast, treatment of 
MMP-1 recombinant proteins with 5 mM EDTA abolished hydrolytic activity, as 
expected,  in all cases.
 All ‘ball’ mutant MMP-1 proteins cleaved the thiopeptide substrate at a 
similar rate (Figure 4.10) as WT MMP-1.  Specific activity values are reported in Table 
4.2. 
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Figure 4.10: Hydrolytic activity of MMP-1 mutants.  (A) Plot depicting the proportional increase of 
the initial reaction rates of MMP-1-catalysed thiopeptolide substrate hydrolysis by mutants. Data are mean 
values of three independent experiments and error bars indicate the SD. (B) Plot of relative activity (%) 
compared to CAT-1 (horizontal dashed line).   P values were determined by comparing the hydrolytic activity 
of mutant proteins with CAT-1. Statistical analysis was performed using an unpaired two-tailed Student’s t-
test (df=4) and P values were found to be greater than or equal to 0.05, which were not considered 
statistically significant.
B
Table 4.2: Hydrolytic activity of  catalytically active MMP-1 
mutants determined at 37 oC
Protein Specific Activity (U/min/μmol)a
CAT-1 2650 ± 104
WT MMP-1 2353 ± 190
MMP-1 (R300A) 2791 ± 140
MMP-1 (F301A) 2468 ± 99
MMP-1 (F316A) 2500 ± 81
a data from triplicate experiments is given as mean values ± SD
A
Interestingly, MMP-1 (R300A) showed a slight enhancement of activity when compared 
to both CAT-1 and MMP-1.  However, it appears that specific mutations of the ‘ball’ 
joint have largely unaffected the CAT domain structure and consequently catalytic 
activity as would be expected since all the mutations are located in the HPX domain.
 4.3.6 Low Resolution Structural Analysis using SAXS
The structural basis for the dramatic reduction in α1(I)772-787 THP binding by 
MMP-1* mutants, particularly MMP-1* (F301A), was investigated using SAXS.  In 
addition, proMMP-1* was examined to determine whether the compact arrangement of 
domains in the crystal structure is representative of  the conformation in solution.   
 4.3.6.1 proMMP-1*
The apparent molecular mass of proMMP-1* was estimated as 43.8 kDa, an 
underestimation of 17% from the theoretical MW.  This is not surprising as I(0) values 
can not be directly determined experimentally and deviations of expected molecular 
mass can exceed 10% (Mylonas and Svergun 2007)  The Rg, from Guinier analysis, was 
calculated at 32.8 ± 0.2 Å (Figure 4.11B).  The pair distance distribution, P(r), plot 
shown in Figure 4.11C indicates an asymmetric shape, characteristic of an elongated 
globular protein with a maximal particle dimension (Dmax) of 90 Å.  The back 
transformation of the P(r) overlaid well with the experimental data, indicating that it 
was a good solution for the average size and shape of proMMP-1* in solution. 
CRYSOL (Svergun, Barberato et al. 1995) was used to compare theoretical scattering of 
proMMP-1* in the crystal structure conformation with the experimental scattering data 
of the proMMP-1* solution conformation (Figure 4.11D).  At low angles the curves 
overlay and show a good agreement between both structures, however the curves within 
the medium q range (> 0.2 Å-1) show variation and may indicate changes in relative 
domain orientation between the two structures. 
	 A representative low resolution ab initio DAMMIF (Franke and Svergun 2009) 
model of the proMMP-1* conformation is shown in Figure 4.14.  SUPCOMB (Kozin 
and Svergun 2001) was used to dock the high resolution crystal structures within the 
molecular envelope. This shows that the model largely agrees with the compact 
arrangement of the domains in the crystal structure, as shown by the reasonably low 
normalised spatial discrepancy (NSD) value of 1.65.  The discrepancies that do exist 
between the two may be due to the fact that a significant proportion of the electron 
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density map for proMMP-1* is missing from the crystal structure, namely that for the N-
terminal residues (F20-V31), the bait region (N46-S57), and the PRO-CAT linker (Q99-
N106) (Jozic, Bourenkov et al. 2005).  
 
	 	 4.3.6.2 MMP-1*
The molecular mass of MMP-1* was estimated as described in Section 4.3.5.1 at 34.8 
kDa.  This is an underestimation of 18% but clearly indicates a reduction in mass of 8.9 
kDa, which is accounted for by the loss of the ~ 9-kDa PRO domain upon activation. 
Furthermore, zymogen activation is concomitant with a significant reduction in Rg  of 
12% to 28.7 ± 0.2 Å when compared with proMMP-1* (Figure 4.12A), which agrees 
with the previous report of 29 ± 1 Å for MMP-1* (Bertini, Fragai et al. 2009).  The 
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Rg = 32.8 ± 0.2 Å 
Dmax = 90 Å
Figure 4.11: SAXS analysis of proMMP-1*. (A) Experimental SAXS scattering profile of zymogen 
proMMP-1* after solvent subtraction. (B) Guinier plot of the low-angle region limited by qRg<1.3. (C) P(r) 
function generated by GNOM (Svergun 1992). (D) Theoretical scattering curve (red) calculated from the 
crystal structure (PDB accession code: 1SU3) overlaid on the experimental scattering data (black).
푥2 = 4.278
BA
C D
absence of the PRO domain also results in a small decrease in the Dmax from 90 to 88 Å 
(Figure 4.12C). 
 The asymmetric P(r) plot indicates significant variation when compared to 
that of proMMP-1*.  The distinctive shoulder at ~55 Å is indicative of a discrete 
domain structure and implies a slight separation of CAT and HPX domains as observed 
by Bertini and co-workers (Bertini, Fragai et al. 2009).  Variations in the CRYSOL 
(Svergun, Barberato et al. 1995) output throughout the sampled q range are also 
apparent with significant differences in the low q range (< 0.2 Å-1).  This is consistent 
with an increased experimental Rg value of 28.6 Å when compared with the theoretical 
Rg value of 25.95 Å for the crystal structure (Bertini, Fragai et al. 2009), and is further 
highlighted by the DAMMIF (Franke and Svergun 2009) generated molecular envelope, 
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Figure 4.12: SAXS analysis of MMP-1*. (A) Experimental SAXS scattering profile of mature 
MMP-1* after solvent subtraction. (B) Guinier plot of the low-angle region limited by qRg<1.3.  (C) P(r) 
function generated by GNOM (Svergun 1992). The proMMP-1* P(r) distribution plot is shown for 
comparison (dashed line).  (D) Theoretical scattering curve (red) calculated from the crystal structure (PDB 
accession code: 2CLT) overlaid on the experimental scattering data (black).
Rg = 28.7 ± 0.2 Å
Dmax = 88 Å 푥2 = 8.033
BA
DC
which is considerably larger than expected from its compact crystal structure (Figure 
4.14).  Superimposition of these low and high resolution structures results in a 
considerably higher NSD value of 2.07 compared to proMMP-1*, and leaves an entire 
lobe of  the solution-state model unaccounted for.  
	 Control models were generated (Figure 4.14) using artificial scattering data 
synthesised from the crystal structure coordinates of proMMP-1* (PDB accession code: 
1SU3) and MMP-1* (PDB accession code: 2CLT) to ensure that the molecular envelope 
discrepancy observed for MMP-1* was not an artefact of the modelling process.  These 
control models were in close agreement with the crystal structure coordinates with NSD 
values of  1.24 and 1.19, respectively.  
 4.3.6.3 MMP-1* Mutants R300A, F301A and F316A
SAXS analysis of MMP-1* mutants R300A, F301A and F316A indicated Rg values of 
34.7 ± 0.03 Å, 33.6 ± 0.04 Å and 30.9 ± 0.01 Å, respectively (Figure 4.13).  The 
greatest increases observed were 21% for MMP-1* (R300A), and 17% for MMP-1* 
(F301A) with comparable Rg values to proMMP-1 despite the absence of the PRO 
domain in these mutants.  Similarly, increases over the WT value of 88 Å were observed 
with Dmax values of 104 Å, 90 Å and 93 Å for the R300A, F301A and F316A mutants, 
respectively.  Furthermore, the P(r) plots of these mutants indicate that the distinct 
shoulder observed for MMP-1* becomes much more exaggerated as shown by the 
increasing distribution of larger distances.  This implicates a significant separation of 
the CAT and HPX domains.  In light of the adversely impacted THP binding seen by 
MMP-1* F301A,  ab initio modelling was conducted for this mutant.  The low resolution 
envelope exhibits two discrete lobes (Figure 4.14), which may be attributed to 
permanent dislocation of the CAT and HPX domains brought about by mutation of 
residues at the CAT:HPX interface.
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4.4 Conclusions
Mutant pET3a:proMMP-1* and proMMP-1 constructs were successfully produced by 
site-directed mutagenesis and transformed into E. coli BL21-CodonPlus® (DE3)-RIPL 
cells, where the recombinant proteins were expressed at comparable levels to that of the 
WT enzyme.  The standard refolding and purification strategy for proMMP-1 
production, devised previously (Chapter 2), resulted in sufficient material for the assays 
described herein.  Successful activation of proMMP-1 with acquisition of full hydrolytic 
activity against a peptolide substrate, when compared to CAT-1, was taken as suitable 
evidence that each protein was folded correctly and suitable for further study.
 Characterisation of homotrimeric collagen THP binding by full length 
proMMP-1* and MMP-1* enzymes was completed using an SPR-based assay. 
Interestingly, binding activity was detected for the proMMP-1* zymogen. Previous 
studies, using gel filtration chromatography and ELISA, have concluded that 
proMMP-1 is unable to bind collagen substrates, an activity acquired upon PRO 
domain removal (Welgus, Jeffrey et al. 1985, Murphy, Allan et al. 1992).  However, our 
experimental observations result from a particularly sensitive technique likely to detect 
this interaction, which we report as significantly weaker (~10-fold) than that observed 
for mature MMP-1*.  Furthermore, dissociation constants previously determined for 
MMP-1* bound to both homo- and heterotrimeric mouse tail tendon type I collagen 
display similar values to those observed here, 1.3 ± 0.2 and 1.3 ± 0.3 μM, respectively 
(Han, Makareeva et al. 2010). Increases in Kd  for MMP-1* were observed for both 
mutants R300A and F316A.  However, the highest impact HPX-1 mutation, F301A, 
had significant adverse effects on THP binding (See Chapter 3), decreasing MMP-1* 
affinity 30-fold.  This suggests that this F301A is an important contributor to collagen 
recognition despite being located within the CAT:HPX interface, a position that would 
appear to prevent involvement in collagen binding.  The seemingly moderate 
detrimental effects seen for R300A and F316A may therefore result from distortions of 
the peptide backbone affecting positioning of the F301A sidechain, rather than direct 
interactions between these residues and the substrate, or more likely via disruption of 
the cooperative domain binding mechanism.
 These mutations also appear to have affected the structure of MMP-1*, with 
increases in hydrodynamic radii detectable by analytical gel filtration.  Therefore, the 
structural basis for the reduction in binding activity compared with MMP-1* was 
investigated using SAXS.  Initial analysis indicated that both proMMP-1* and MMP-1* 
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are elongated proteins with solution structures differing from that of the compact crystal 
structure conformations, this is particularly evident for MMP-1* (Figure 4.14).  Most 
interestingly, ab initio modelling produced a considerably larger molecular envelope than 
expected from the crystal structure with additional regions of density unaccounted for 
when superimposed with the high resolution structure.  Thus, the elongated low-
resolution solution structure of MMP-1* is indicative of an equilibrium between the 
compact state seen in crystallographic analyses and a more extended state.  This is in 
agreement with the previous study by that used NMR and SAXS to demonstrate that 
the compact arrangement of domains for MMP-1* is not fully representative of the 
conformation in solution (Bertini, Fragai et al. 2009).  Instead, for approximately one 
third of the time, the enzyme exists in an elongated state with an extended CAT and 
HPX domain arrangement. This investigation shows the apparent dislocation of the 
CAT and HPX domains in mature MMP-1* is further exacerbated by mutation of 
residues that constitute the ‘ball’ joint at the CAT:HPX interface.  The P(r) distance 
distribution function and Rg values for R300A, F301A and F316A MMP-1* mutants are 
indicative of an extended structural state, which may have disrupted the dynamic 
interdomain interaction, that is a feature of the WT enzyme.  This is more evident in 
the low resolution model of MMP-1* (F301A), which exhibited a dislocated state with 
two discrete lobes and a loss of density that correlates with a compact state. 
Furthermore, it has been demonstrated that the compact conformation of MMP-1* is 
biologically relevant, as complete disruption of the CAT:HPX interface reduces collagen 
binding activity.  Thus, MMP-1 collagenase activity most probably depends on a subtle 
equilibrium between these compact and dislocated states, the second of which exposes a 
collagen binding exosite involving F301A. 
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CHAPTER 5: ROLE OF THE DOMAIN-DISLOCATED 
STATE IN PROTEOLYTIC SUSCEPTIBILITY AND 
COLLAGEN BINDING
5.1 Introduction
	 In the previous chapter the data suggests that MMP-1* undergoes apparent 
transient separation of domains. This observation is supported by previous reports of 
MMP interdomain flexibility, where domain reorientation may be mediated by the 
variable-length flexible linker (Tsukada & Pourmotabbed, 2002).  The findings in 
Chapter 4 also implicate contributions from residues at the CAT-HPX interface in 
domain separation impacting substrate recognition.  Restriction of domain mobility, by 
tethering the CAT and HPX domains, could be achieved by introduction of an 
interdomain disulfide bond.  If successful, any disruption to the conformational 
equilibrium could be assessed.
 Disulfide bond formation generally occurs in the ER by oxidation, 
consequently disulfide bonds are mostly found in extracellular, secreted and periplasmic 
proteins where they contribute to protein mechanical stability and function.  This 
stabilising property makes non-native disulfide-bonding a powerful strategy for 
engineering additional conformational stability using site-directed mutagenesis. 
Disulfide-bond engineering has successfully been used to investigate functional aspects of 
structural heterogeneity, this includes receptor activation by the chemokine 
Lymphotactin (Tuinstra, Peterson, Elgin, Pelzek, & Volkman, 2007), σ factor binding by 
the β’ subunit of E. coli RNA polymerase (Anthony, Dombkowski, & Burgess, 2002) and 
ligand binding by the I domain of  integrin αLβ2 (Shimaoka et al., 2001). 
 Examination of the MMP-1* structure indicates a position at the CAT-HPX 
interface, which is of a suitable distance (Figure 5.1A inset) to allow engineering of such 
a novel disulfide bond (Figure 5.1B).  The Cα atoms of S243 of the CAT domain and 
S318 of the HPX domain are separated by 5.2 Å, with correct side chain orientation 
this is an optimal distance for disulfide bond formation as assessed by the Disulfide by 
Design 2 program (Dombkowski, 2003).  Furthermore, this program predicts the 
geometry of cysteine pairs in a favourable orientation for disulfide bond formation 
(Figure 5.1C), this is consistent with the proximity and geometry constraints for disulfide 
formation, defined by Petersen (1999).  
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	 The study described in this chapter uses site-directed mutagenesis and assay 
to investigate the role of the dislocated state by tethering the CAT and HPX domains at 
the interface.  Limited proteolysis was used to probe domain structure and assess 
successful enzyme maturation. SPR was used to assess the impact of domain tethering 
on substrate recognition using a synthetic THP substrate, and a chromogenic assay was 
used to characterise and quantitate the hydrolytic activity of the domain-stapled mutant, 
S243C, S318C.  SAXS was used to investigate domain arrangement and define global 
structural parameters for comparison to both solution and solid-state structures.  Finally, 
preliminary crystallisation attempts are described.
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MMP-1* MMP-1* S243C, S318C
Site-directed 
mutagenesis
A B
Figure 5.1: Domain stapling of MMP-1* using site-directed mutagenesis. The crystal 
structure of MMP-1* (PDB accession code 2CLT) is shown as a ribbon diagram. Zinc atoms are depicted 
as yellow spheres and calcium ions are coloured black.  (A) Serine residues targeted for mutation are shown as 
spheres and are coloured according to atom.  Internuclear distance between S243 and S318 ɣ-oxygen 
atoms is shown inset. (B) Modelled cysteine substitution at positions 243 and 318, shown as spheres and 
coloured according to atom. (C) Schematic ball and stick representation of the non-native disulfide bond 
designed using the Disulfide by Design 2 program v 2.06 (Dombkowski,  2003). The Χ3 torsion angle is 
defined by the Cβ-Sɣ-Sɣ-Cβ bonds, and is consistent with the Χ3 bond angles of disulfides, which show 
peaks in distribution at +100 and -80 (Petersen et al., 1999). Atoms of the CAT domain and HPX domain 
are denoted (1) and (2), respectively. Rendered using the Pymol Molecular Graphics System (version 
1.5.0.4.), Schrödinger, LLC.
N1
Cα1
Cβ1
N2
Cα2Cβ2
Sɣ2
Χ3
Sɣ1
Predicted Χ3 torsion angle -79.28
C
S243
S3184.8 Å
5.2. Materials and Methods
The majority of methods necessary to investigate domain-stapling effects on MMP-1 
structure and function have previously been described in Chapters 2-4.  Oligonucleotide 
design and preparation was undertaken as described in Section 2.3.4.  Site-directed 
mutagenesis of target residues was completed as described in Section 2.3.5. THP 
substrate-binding was assayed and analysed using SPR as described in Section 3.2.2.2 
and 3.2.2.3. MMP-1* S243C, S318C global shape parameter analysis was completed 
using SAXS as described in Section 4.2.3.
 5.2.1 Limited proteolysis using CAT-1
Purified mature WT MMP-1 samples (40 nM) were incubated for 24 hours in a 37oC 
waterbath, prior to application at 1 mL/min to a pre-equilibrated 5 mL HisTrap FF 
column pre-packed with Ni Sepharose 6 Fast Flow resin using the ÄKTAprime system. 
Unbound CAT-1 was collected in the flowthrough and concentrated, using centrifugal 
filter units with an  appropriate MWCO (Millipore) using a Beckman Coulter Allegra 
25R refrigerated centrifuge (rotor AT-14-10) pre-chilled to 4 oC.  Samples were 
resuspended after each spin (3000 rpm for 1-10 minutes).  Bound proteinaceous material 
was eluted with a 0-100% gradient of TNC buffer supplemented with 500 mM 
imidazole and collected in 1 mL fractions for further SDS-PAGE analysis (Section 
2.3.19).  
	 A three-fold molar excess of CAT-1 was added to proMMP-1* proteins in 
TNC Buffer.  Samples were then incubated at 37 oC for 0-20 hours.  Reactions were 
stopped with 2X SDS-PAGE reducing loading buffer as described in Section 2.3.20.2.
	 5.2.2 Crystallisation of MMP-1* (S243C, S318C)
Crystallisation of MMP-1* (S243C, S318C) at a concentration of 120 μM in TNC 
buffer was performed in an attempt to obtain atomic resolution of the domain-stapled 
species.  The following sparse matrix crystallisation screens (Molecular Dimensions) 
were used: Morpheus, JCSG-plus and PACT-premier. Sitting drops were set up in a 96 
condition MRC-style two well plate using the Cartesian dispensing system (Genomic 
Solutions) run with Honey Bee software (Digilabs). The robot dispensed 200 nL of 
sample and 200 nL of the well solution. The trays were stored at 16°C and checked at 
regular intervals using polarizing light microscopy.
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  5.3.1 Mutagenesis
Site-directed mutagenesis of the pET-3a proMMP-1* plasmid construct was completed 
using the Quikchange II XL Site-directed Mutagenesis kit (Agilent Technologies). 
Mutagenic efficiency levels were determined as previously described and were consistent 
with previous observations (Section 4.3.1). DNA sequence analysis confirmed successful 
incorporation of mutagenic bases and hence single cysteine amino acid substitutions at 
positions 243 and 318 in proMMP-1* (See Appendix 12). Once the proMMP-1* 
S243C, S318C mutations were confirmed, a A219E revertant was then generated in the 
same manner to restore hydrolytic activity.
	 5.3.2 Protein Production
Catalytically impaired proMMP-1* S243C, S318C and the equivalent revertant 
constructs were transformed into E. coli expression strain BL21-CodonPlus (DE3)-RIPL 
and screened for IPTG-induced recombinant protein expression.  Proteins of ~52 kDa 
were expressed, which is consistent with the expected mass.
	 As shown previously (Chapters 2, 3 and 4) all target proteins were found to 
deposit into bacterial inclusion bodies and were therefore solubilised, refolded and 
purified in accordance with standard procedures (See Chapter 2).  Despite refolding 
under the same conditions as the wild-type zymogen, precipitated protein levels were 
found to increase impacting negatively on the yield of purified protein obtained from 
500 mL of culture.  This was anticipated due to the increased potential of incorrect 
inter- and intramolecular disulphide bond formation.  However, sufficient milligram 
quantities were obtained by pooling purified protein grown from multiple cultures, and 
analytical gel filtration chromatography and non-reducing SDS-PAGE was used to 
confirm that no soluble disulphide-bonded multimers were present (Figure 5.2).    
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Figure 5.2: Determining the presence of disulphide-bonded multimers.  (A) Lack of 
disulphide-bonded multimers in the S243C, S318C proMMP-1* mutant as shown by oxidized and 
reduced SDS-PAGE and visualised on a 16.5% (w/v) Tris-Tricine SDS-PAGE gel. Molecular weight 
was estimated using SeeBlue Plus2 pre-stained protein ladder (M). (B) Elution profile of MMP-1* 
S243C, S318C by analytical gel filtration using a HiLoad Superdex 75 16/60 prep grade column. 
Purified mature protein is shown with a dashed red box.  The elution profile of MMP-1* is shown for 
comparison purposes (dashed line). Elution position of PRO-1 and CAT-3 is indicated with a blue (*) and 
green asterisk (*), respectively.
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 5.3.3 Low resolution structural analysis using SAXS
SAXS was used to determine whether the solution state of the proposed domain-stapled 
mutant possessed a compact arrangement of domains similar to that of the crystal 
structure. The Rg, from Guinier analysis, was calculated at 27.8 ± 0.2 Å (Figure 5.3A), 
which is 3% lower than that observed for the experimentally-derived MMP-1* solution 
structure but 7% greater than that estimated by Bertini and co-workers from the crystal 
structure (Bertini et al., 2009).  Analysis of the P(r) plot (Figure 5.3B) shows the 
asymmetric shape that appears to be characteristic of MMP-1 (Chapter 4) with a 
shoulder at ~55 Å indicative of bilobal protein structure.  However, a reduction in Dmax 
of 6 Å is observable, which with the Rg value, indicates a general reduction in overall 
dimensions.  Furthermore, the ab initio molecular envelope generated using DAMMIF 
(Franke & Svergun, 2009) and superimposed with the crystal structure gave a reasonably 
low NSD value of 1.73.  This is a better fit than that observed for the MMP-1* solution 
data (NSD 2.07) and is suggestive of  a more compact two lobe state.
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Rg = 27.8 ± 0.2 Å Dmax = 82 Å
Figure 5.3: SAXS analysis of MMP-1* S243C, S318C. (A) Experimental SAXS scattering profile 
of the domain-stapled mature MMP-1* mutant after solvent subtraction. Guinier plot of the low-angle 
region limited by qRg<1.3 (Inset). (B) P(r) function generated by GNOM (Svergun, 1992). The domain-
stapled mutant is shown in red and MMP-1* (dashed black line) is shown for comparison (Chapter 4). (C) Ab 
initio modelling from experimental scattering data with orthogonal views of the MMP-1* crystal 
structure (PDB accession code: 2CLT) overlaid using the program SUPCOMB (Kozin & Svergun, 2001). 
In the crystal structure, the CAT domain is coloured in green and the HPX domain in blue.  The cysteine 
mutations (S243C, S318C) at the CAT-HPX interface are shown as spheres and coloured according to 
atom.
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	 5.3.4 Limited proteolysis of proMMP-1* S243C, S318C by 
 CAT-3 and CAT-1
The domain-stapled mutant was incubated with an equimolar concentration of CAT-3 
to determine accessibility and cleavage of the Gln80-Phe81 bond in the PRO-CAT 
linker, concomitant with PRO-domain loss.  Comparison with both the catalytically-
impaired zymogen and domain-dislocated proMMP-1* ‘ball’ mutant F301A (See 
Chapter 4), indicated that proMMP-1* S243C, S318C was resistant to specific 
proteolysis and could be activated in the same way (Figure 5.4A).
	 The linker of active MMP-1 is susceptible to autolysis producing two discreet 
products, CAT-1 and HPX-1 (Li et al., 1995).  The fortuitous observation that HPX-1 
bound immobilised nickel (Chapter 2) provided a method enabling CAT-1 isolation, 
which was then used to probe CAT-HPX linker accessibility of zymogen forms (Figure 
5.4B).  After 20 hours incubation both proMMP-1* and the F301A mutant showed 
degradation characteristic of linker cleavage.  In contrast, there was a distinct absence of 
both proCAT-1* and HPX-1 products when proMMP-1* S243C, S318C was incubated 
with catalytically active CAT-1.  This suggests that the domain-stapled mutant is 
significantly more resistant to hydrolysis of  the CAT-HPX interdomain linker.  
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Figure 5.4: Limited proteolysis of recombinant proMMP-1* proteins by CAT-3 and 
CAT-1. (A) Purified proMMP-1* (WT) and mutant proteins were incubated with CAT-3 in TNC 
buffer at an equimolar concentration for 0 and 20 hours at 37oC. (B) Purified proMMP-1* (WT) 
and mutant proteins were incubated with CAT-1 in TNC buffer at a 3:1 molar concentration for 0 
and 20 hours at 37oC.  The products indicative of linker cleavage are indicated by boxed titles.  All 
reactions were visualised on 16.5% (w/v) Tris-Tricine SDS-PAGE gels. Molecular weight was 
estimated using SeeBlue Plus2 pre-stained protein ladder (M). 
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	 5.3.5 Functional analysis by SPR
Equilibrium SPR analysis was used to characterise the binding affinity of both the 
proMMP-1* zymogen and mature MMP-1* domain-stapled proteins for immobilised 
α1(I)772-787 THP.  Triplicate injections were performed using a suitable range of 
analyte concentrations (0.2 μM-20 μM) and affinities were determined as described in 
Section 3.2.2.2 and 3.2.2.3. 
 The binding of the S243C, S318C zymogen form was significantly impaired 
prohibiting the calculation of a Kd value.  Upon PRO-domain removal, the domain-
stapled mutant bound to α1(I)772-787 THP with an apparent Kd value of 8.9 ± 0.6 μM 
(Figure 5.5A).  Cysteine substitution at positions 243 and 318 clearly diminished THP 
binding, with a ~10-fold reduction in Kd when compared to MMP-1*.  However, the 
impact on collagen recognition was not as severe as that observed for the F301A 
domain-dislocation mutant but more so than for R300A and F316A (Figure 5.5B).
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Kd = 8.9 ± 0.6 μM
A B
Figure 5.5: Equilibrium binding of MMP-1* S243C, S318C to α1(I)772-787 THP. (A) Hyperbolic 
binding curves for MMP-1* from the equilibrium SPR data.  The fitted curve is of the form R/Rmax = c/(c + 
Kd), where c is the analyte protein concentration.  The non-linear fit for MMP-1* is shown for comparison 
(dashed line). Error bars indicate the S.D. from triplicate measurements. (B) Plot of equilibrium dissociation 
constants (Kd) for the binding of MMP-1* and mutant proteins to immobilised THP.  P-values were 
determined by comparing binding affinities of mutant proteins with MMP-1*.  Statistical analysis was 
performed using an unpaired two-tailed Student t-test (df = 4) and statistically significant P-values (p<0.05) 
are shown.  The asterisk indicates statistical significance with P-values of p<0.05 (*), p<0.01 (**), p<0.001 
(***) and p<0.0001 (****).  P-values greater than or equal to 0.05 are not considered statistically significant.
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	 5.3.6 Assay of hydrolytic activity using a chromogenic 
 peptide substrate
Hydrolytic activity of the catalytically-active, domain-stapled mutant was determined as 
described in Section 2.3.25.  The S243C, S318C mutant showed significantly 
diminished hydrolytic activity (Figure 5.6) with a specific activity value of 847 ± 68 U/
min/μM (enzyme), which is a reduction of  64% when compared to wild-type MMP-1.  
 5.3.7 Preliminary crystallisation of MMP-1* S243C, S318C
Crystallisation trials were set up in an attempt to produce an atomic resolution model of 
the domain-stapled mutant.  Small crystals formed after 3 months in a buffer containing 
0.1 M succinic acid, pH 7.0 with 15% (w/v) PEG 3350 as a precipitant (Figure 5.7). 
Current attempts to optimise these conditions have, as yet, been unsuccessful.
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Figure 5.6: Hydrolytic activity of MMP-1 S243C, S318C. (A) Plot depicting the dose-dependence of 
reaction rates with MMP-1 S243C, S318C using an MMP-1 catalysed thiopeptolide substrate.  Data are 
mean values of three independent experiments and error bars indicate the SD. (B) Plot of relative activity 
(%) compared to CAT-1 (horizontal dashed line).  P-values were determined by comparing hydrolytic activity of 
mutant proteins with CAT-1.  Statistical analysis was performed using an unpaired two-tailed Student t-test 
(df = 4) and statistically significant P-values (p<0.05) are shown.  The asterisk indicates statistical 
significance with a P-value of p<0.001 (***).   P-values greater than or equal to 0.05 are not considered 
statistically significant (ns).
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Figure 5.7: Preliminary crystallographic trial of MMP-1* S243C, S318C. Conditions: 0.1 M 
succinic acid, pH 7.0, 15% (w/v) PEG 3350 (200 nl protein at 5 mg/ml with 2 μl precipitant).
5.4 Conclusions
Site-directed mutagenesis was successfully used to introduce two serine to cysteine 
substitution mutations at position 243 in the CAT domain and position 318 in the HPX 
domain of the pET-3a: proMMP-1* construct.  This construct was then transformed 
into E.coli BL21-CodonPlus (DE3)-RIPL cells.  Despite comparable WT expression 
levels after treatment with IPTG, the double mutant appeared to be susceptible to 
increased aggregation when using the standard proMMP-1* refolding protocol. 
However, sufficient purified material was obtained and appeared free from soluble 
disulphide-bonded multimers.  Furthermore, global mature enzyme structure appeared 
unaffected by the double mutation, with no notable increases in hydrodynamic radii as 
shown by  analytical gel filtration.
	 Reduction in the Rg and Dmax, derived from Guinier and P(r) analysis, 
indicated that in solution MMP-1* S243C, S318C possessed a structure more compact 
than that of the equivalent wild-type protein.  Furthermore, ab initio modelling produced 
a molecular envelope that appeared to lack the regions of density, which are congruent 
with a dynamic extended state (See Chapter 4).  Instead, the data is more consistent with 
the structural parameters expected for the crystal structure so the mutations have indeed 
stapled the domains together and prevented domain dislocation.
	 Limited proteolysis with CAT-3 and CAT-1 was used to determine zymogen 
activation potential and linker susceptibility, respectively.  Equal proteolytic susceptibility 
was seen when CAT-3 was applied, resulting in enzyme maturation and almost identical 
digestion profiles for both zymogen mutants, F301A and S243C, S318C.  However, the 
S243C, S318C mutant exhibited significant resistance to hydrolysis of the CAT-HPX 
interdomain linker when treated with CAT-1.  Shielding of the linker region from 
proteolysis suggests existence of a compact global structure conferred by formation of 
the interdomain disulphide bond.  In addition, it also suggests that, in the WT enzyme, 
interdomain autolysis only occurs when the enzyme is in its dislocated state.  Therefore, 
the structural basis for linker hydrolytic resistance was investigated using SAXS. 
	 Characterisation of THP-binding by the domain-stapled MMP enzyme was 
completed using an SPR-based assay.  Interestingly, binding by the zymogen was 
abolished.  Enzyme maturation restored some binding activity, but a significant decrease 
in affinity was still observed (~10-fold).  Importantly, neither of the mutated residues 
appear to be directly involved in substrate recognition since neither residue was detected 
during a HD/MS study using MMP-1* incubated with a THP substrate (Lauer-Fields et 
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al., 2009), and alanine substitution of serine 318 had only subtle effects on THP-binding 
by HPX-1 (See Chapter 3).  Therefore, the deleterious effects observed here would again 
suggest that domain mobility is necessary for exosite exposure and collagen recognition.   
 Whilst the presence of the HPX domain is an absolute requirement for MMP 
collagenolysis, cleavage of simple peptides requires only the CAT domain.  This was 
evident when testing the domain-dislocated mutants, all of which showed unimpaired 
hydrolytic activity compared to the WT enzyme and the CAT domain alone (See 
Chapter 4). Surprisingly, the mature, domain-stapled revertant displayed compromised 
hydrolytic activity (~30%) against a peptolide substrate.  Previously, inhibitor-induced 
conformational changes in the catalytic domains of MMP-2, -3, -8 and -13 have been 
observed (Chen et al., 1999; Feng et al., 2002; Zhang et al., 2000) thereby suggesting 
that active-site plasticity plays a key role in recognition and hydrolysis of diverse 
substrates.  Therefore, it is possible that introduction of the interdomain disulfide bond 
has conferred increased rigidity to the CAT domain impacting on the S1’ pocket and/or 
the flexibility of the S1’ loop.  This observation may have implications for future 
inhibitor design, whereby MMP hydrolytic activity could be attenuated by targeting 
long-range interactions that impact active-site plasticity.
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CHAPTER 6: ROLE OF PRO-HPX INTERFACE 
C O N TA C T S I N D O M A I N M O B I L I T Y A N D 
COLLAGEN RECOGNITION
6.1 Introduction
The crystal structure of human latent and mature MMP-1 reveal substantial global 
conformational rearrangements occur upon removal of the inactivating PRO-1 domain 
(Figure 6.1) during enzyme maturation (Jozic, Bourenkov et al. 2005, Iyer, Visse et al. 
2006). 
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Figure 6.1: Interdomain interactions of proMMP-1. PRO-1, CAT-1 and HPX-1 domains are shown in 
red, green and blue respectively. (A) HPX-1 domain rearrangement upon activation.  Molecules have been 
superimposed using their catalytic domains (backbone atomic RMSD 0.815 Å). The curved arrow indicates the 
relative movement between pro- and active MMP-1. An asterisk marks the position of residues RWTNNFREY 
(B) Residues involved in the PRO-HPX interaction are shown as sticks.   Hydrogen bonds are shown as green 
dotted lines. and the residues are shown as stick models in atom type.  Secondary structure elements are indicated by 
bold type.  Coordinates taken from PDB depositions (1SU3 and 2CLT).
(B)
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HPX-1
(A)
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The zymogen structure is restrained by predominantly hydrophobic PRO-HPX contacts 
that may keep the pro-enzyme in a ‘closed’ configuration, a state considered unable to 
bind its collagen substrate (Iyer, Visse et al. 2006).  These interdomain contacts occur 
between PRO-1 residues in loop 2 and helix 3, and residues in the loop between β sheets 
C and D on blade 1 of the HPX domain.  Propeptide removal disrupts these 
interdomain contacts, unmasking residues Phe308, Tyr309 and Pro310, which undergo 
large shifts in Cα position (by 16, 12 and 9 Å, respectively) when compared with mature 
MMP-1 (Iyer, Visse et al. 2006).  Correspondingly, a shift is also observed for porcine 
MMP-1 (Figure 6.2), although much larger at 38, 27 and 24 Å, respectively (Li, Brick et 
al. 1995, Jozic, Bourenkov et al. 2005).   
	 The physiological relevance of the PRO-HPX domain interactions is 
currently unknown. One might speculate that the location of the PRO domain in the 
catalytic cleft is itself sufficient to prevent hydrolysis. However, these interactions may 
confer other properties.  These could include stabilisation of the PRO domain thus 
blocking substrate binding and preventing low-level collagen proteolysis, or perhaps 
restrained domain mobility reducing linker susceptibility to proteolysis and/or exposure 
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Figure 6.2: Conformational shift of the blade 1 CD loop region of HPX-1 upon activation. 
The HPX-1 of proMMP-1 (PDB accession code 1SU3) and mature MMP-1 (PDB accession code 2CLT) 
is shown in light blue and dark blue, respectively. Inset: residues 307-310 are displayed as sticks; orange P307; 
magenta F308; green Y309 and yellow P310.  Zymogen residues are denoted by an asterisk (*).  
of the collagen binding site, thought to include CAT-1 residues RWTNNFREY (Chung, 
Shimokawa et al. 2000), which are necessary for collagenolysis (Figure 6.1A). 
	 The role of these PRO-HPX interdomain contacts will be investigated using 
site-directed mutagenesis of residues in the CD loop to disrupt these interactions, in 
both the full-length enzyme and HPX-1 protein.  The global shape and relative domain 
orientation of recombinant zymogen proteins will be characterised by SAXS.  Substrate 
binding activity of proMMP-1*, MMP-1* and HPX-1 mutants  will be quantified with 
SPR.
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6.2 Materials and Methods
The methods necessary to investigate the role of PRO-HPX interdomain contacts have 
previously been described in Chapters 2-4.  Oligonucleotide design and preparation was 
undertaken as described in Section 2.3.4.  Site-directed mutagenesis of target residues 
was completed as described in Section 2.3.5.  Substrate-binding was assayed using SPR 
as described in Section 3.2.2.2.  Low resolution solution structural analysis of 
recombinant proteins was completed using SAXS as described in Section 4.2.2 and 
4.2.3.
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6.3 Results
 6.3.1 Mutagenesis
Site-directed mutagenesis of the pET-3a proMMP-1* and HPX-1 plasmid constructs 
was successfully completed with mutagenic efficiency levels consistent with previous 
observations (Section 4.3.1).  
	 6.3.2 Protein Production
Mutant constructs were transformed into E. coli expression strain BL21-CodonPlus 
(DE3)-RIPL and screened for IPTG-induced recombinant protein expression.  Proteins 
of ~52 kDa and ~24 kDa were expressed, which is consistent with the expected mass 
predicted for proMMP-1* and HPX-1, respectively.
	 All target proteins were found to deposit into bacterial inclusion bodies, and 
were therefore solubilised, refolded and purified in accordance with standard procedures 
(See Chapter 2).  During the refolding procedure, the HPX-1 F308A mutant and all 
P310A protein forms precipitated leaving insufficient material for further analysis.  For 
all other proteins produced using the standard expression and purification procedure, 
sufficient milligram quantities were obtained (Table 6.1).
 Recombinant proMMP-1* proteins were treated with APMA and CAT-3 as 
described in Section 2.3.21, and all showed complete enzyme maturation within a four 
hour incubation period concomitant with an appropriate reduction in molecular weight 
of ~10 kDa as shown by SDS-PAGE analysis (data not shown).  Activated mutant 
MMP-1* proteins were purified by gel filtration chromatography and eluted at a 
position consistent with that of  WT MMP-1*.

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 6.3.3 Functional analysis by SPR
Equilibrium analysis was used to characterise the binding affinity of HPX-1 mutants 
(P307A and Y309A), proMMP-1* mutants (P307A, F308A and Y309A) and MMP-1* 
mutants (P307A, F308A and Y309A) for immobilised α1(I)772-787 THP.  Triplicate 
injections were performed using a suitable range of analyte concentrations (0.2 μM-85 
μM) and affinities were determined as described in Section 3.2.2.3. 
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Table 6.1: Purification of  recombinant HPX-1 and proMMP* proteinsab
Protein Fraction Total 
Volume 
(mL)
Protein 
Concentration 
(mg/mL)
Total 
Protein 
(mg)
Recovered 
Protein 
(%)
HPX-1 
P307A
Solubilised 
Inclusion Bodies
20 5.43 108.6 100
Post-CEX 30 0.42 12.6 11.6
HPX-1 
Y309A
Solubilised 
Inclusion Bodies
20 5.39 107.8 100
Post-CEX 30 0.33 9.9 9.18
proMMP-1*
P307A
Solubilised 
Inclusion Bodies 20 11.82 236.4 100
Post-CEX 30 0.78 23.4 9.89
Post-GF 25 0.58 14.51 6.14
proMMP-1*
F308A
Solubilised 
Inclusion Bodies 20 6.393 127.86 100
Post-CEX 30 0.582 17.46 13.66
Post-GF 25 0.25 6.26 4.89
proMMP-1*
Y309A
Solubilised 
Inclusion Bodies
20 7.87 157.4 100
Post-CEX 30 0.44 13.2 8.39
Post-GF 25 0.32 8.0 5.08
a from 500 mL of  culture 
b protein concentration was determined spectrophotometrically (A280) using the molar extinction  
coefficient values obtained from ProtParam analysis (Gasteiger, Gattiker et al. 2003).
	 6.3.3.1 Binding of HPX-1 proteins to immobilised THP 
  
HPX-1 mutants P307A and Y309A bound to α1(I)772-787 THP with apparent Kd 
values of 27.4 ± 0.7 μM and 18.1 ± 0.3 μM, respectively (Figure 6.3).  Alanine 
substitution of both these residues clearly diminished the THP substrate binding 
potential of HPX-1.  Interestingly, P307A bound with a 3-fold reduction in Kd value, 
which approximates that of F301A (Chapter 3).  The observed reduction in binding 
implies that both CD-loop mutants Y309A and P307A may play a role in collagen 
recognition.

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Kd = 27.4 ± 0.7 μM Kd = 18.1 ± 0.3 μM
A
C
B
Figure 6.3: Equilibrium binding of HPX-1 mutants to α1(I)772-787 THP. Hyperbolic binding 
curves from equilibrium SPR data (A) and (B).  Binding of wild-type HPX-1 is shown for comparison 
(dashed line). (C) Plot of Kd values for binding to immobilised THP. Error bars indicate the S.D. from 
triplicate measurements.  P-values were determined by comparing binding affinities of mutant proteins with 
WT HPX-1.  Statistical analysis was performed using an unpaired two-tailed Student’s t-test (df = 4) and 
statistically significant P-values (p<0.05) are shown.  The asterisk indicates statistical significance with P-
values of p<0.05 (*), p<0.01 (**), p<0.001 (***) and p<0.0001 (****). P-values greater than or equal to 0.05 
are not considered statistically significant (ns).
****
**
 6.3.3.2 Binding of proMMP-1* proteins to immobilised THP
In contrast, mutations within the HPX CD-loop of proMMP-1* had moderate effects 
on THP binding when compared with the WT enzyme.  The P307A, F308A and 
Y309A zymogens bound α1(I)772-787 THP with apparent Kd values of 8.1 ± 0.6 μM, 
10.4 ± 2.4 μM and 12.9 ± 0.2 μM, respectively. (Figure 6.4).  Alanine substitution 
appeared to impact THP binding affinity for both F308A and Y309A but the greatest 
effect was observed for the Y309A mutation, which reduced binding by 75%.  However, 
the reduction in binding observed for HPX-1 P307A was masked in the equivalent 
proMMP-1* mutant, which most closely exhibited proMMP-1* THP binding activity.
  
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Kd = 8.1 ± 0.6 μM Kd = 10.4 ± 2.4 μM
Kd = 12.9 ± 0.2 μM
A B
C D
Figure 6.4: Equilibrium binding of proMMP-1* mutants to α1(I)772-787 THP. Hyperbolic 
binding curves from equilibrium SPR data (A), (B) and (C).   Binding of proMMP-1* is shown for 
comparison (dashed line). (D) Plot of Kd values for binding to immobilised THP. Error bars indicate the S.D. 
from triplicate measurements.  P-values were determined by comparing binding affinities of mutant 
proteins with proMMP-1*.  Statistical analysis was performed using an unpaired two-tailed Student’s t-
test (df = 4) to define statistically significant P-values (p<0.05). P-values greater than or equal to 0.05 were 
not considered statistically significant (ns).
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 6.3.3.3 Binding of MMP-1* proteins to immobilised THP
As anticipated, PRO domain removal appeared to increase affinity for the immobilised 
THP when compared to proMMP-1* mutant forms.  The P307A, F308A and Y309A 
MMP-1* proteins bound α1(I)772-787 THP with apparent Kd values of 0.9 ± 0.4 μM, 
2.3 ± 0.05 μM and 1.2 ± 0.02 μM, respectively (Figure 6.5).  Again, THP binding by the 
P307A mutant was not significantly impacted by alanine substitution, suggesting that the 
presence of the CAT domain is sufficient to restore function for this mutant.  Binding 
activity for Y309A was reduced by 34% , while F308A exhibited the largest reduction in 
Kd (~1.5 fold). 
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Kd = 1.2 ± 0.02 μM
A
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Kd = 0.9 ± 0.4 μM Kd = 2.3 ± 0.05 μM
Figure 6.5: Equilibrium binding of MMP-1* mutants to α1(I)772-787 THP. Hyperbolic binding 
curves from equilibrium SPR data (A),  (B) and (C). Binding of MMP-1* is shown for comparison (dashed 
line).  (D) Plot of Kd values for binding to immobilised THP. Error bars indicate the S.D. from triplicate 
measurements.  P-values were determined by comparing binding affinities of mutant proteins with 
MMP-1*.  Statistical analysis was performed using an unpaired two-tailed Student’s t-test (df = 4) and 
statistically significant P-values (p<0.05) are shown.  The asterisk indicates statistical significance with P-
values of p<0.05 (*), p<0.01 (**), p<0.001 (***) and p<0.0001 (****). P-values greater than or equal to 0.05 
are not considered statistically significant (ns).
ns
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SAXS was used to determine the structural impact of mutating on residues involved in 
the PRO-HPX interdomain interaction.  SAXS experiments were carried out as 
described in Section 4.1.1.1 and 4.1.1.2.
 The Rg, from Guinier analysis, was calculated at 35.8 ± 0.7 Å, 33.2 ± 1.0  Å 
and 32.0 ± 1.7 Å for proMMP-1* P307A, F308A and Y309A, respectively (Figure 6.6). 
Only P307A showed significant divergence from proMMP-1* with an increase in Rg by 
8%.  The asymmetric pair distribution, P(r), plots shown in Figure 6.6 indicate that all 
mutants possess a similar structure to that of the hydrolytically-impaired WT enzyme. 
The notable observation is a reduction of 4-5 Å in the maximal dimension (Dmax) value 
in all cases when compared to proMMP-1*.  However, despite being a user-defined 
parameter, each Dmax value was considered an excellent solution using GNOM (Svergun 
1992) and remained consistent for the three mutated proteins.
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6.4 Conclusions
Mutant pET3a:HPX-1 and proMMP-1* constructs were successfully produced by site-
directed mutagenesis and transformed into E. coli BL21-CodonPlus (DE3)-RIPL cells. 
Comparable expression levels with WT proteins were observed in all cases.  The 
standard refolding and purification protocols, devised previously (Chapter 2), resulted in 
sufficient homologous monodisperse samples of all mutant proteins with the exception 
of HPX-1 F308A and P310A proteins, which like HPX-1 mutants D299A, F316A and 
Q352A (Chapter 3), precipitated during refolding.  
 Proline residues possess unique structural properties as a result of restricted 
rotation around the N-Cα bond, which precludes adoption of many protein main-chain 
conformations.  Therefore, substitution of proline residues may have deleterious effects 
on protein folding and/or stability.   Consequently, alanine substitution at position 307 
may have reduced rigidity in the CD loop between β strands C and D, while disrupting 
the local hydrogen bond network (Figure 6.1B), and appears to be a critical residue for 
HPX stability.      
	 The significant reduction in THP-binding observed for HPX-1 P307A may 
also suggest deleterious structural effects.  However, this effect is neutralised in the full-
length enzyme.  SAXS studies indicate that P307A is similar in shape while exhibiting a 
larger Rg when compared to proMMP-1*.  Yet any structural diversity has virtually no 
impact on THP-binding in the full-length mutant, which displays equivalent functional 
WT binding activity.  This suggests that P307A has no role in collagen recognition.
 In the proMMP-1* crystal structure F308 and Y309 residues are involved in 
hydrogen-bonding interactions with PRO domain residues K74 and E82, interactions 
resulting in the ‘closed’ zymogen configuration (Jozic, Bourenkov et al. 2005).  In 
contrast, the Rg values for F308A and Y309A proMMP-1* mutants obtained using 
SAXS indicate no significant structural alterations. This seems incongruous with a 
model involving PRO domain stabilisation via the HPX CD loop.  The role of the CD 
loop appears better attributed to a role in collagen recognition with THP-binding 
potential reduced in both Y309A and F308A full-length mutants.  This observation is 
supported by a previous study that reported reduced deuterium incorporation in HPX-1 
residues 302-316 when incubated with a triple helical peptide substrate (Lauer-Fields, 
Chalmers et al. 2009).    Furthermore, a recent published structure of MMP-1* bound 
to a collagen peptide showed F308 and Y309 made van der Waals contacts with two α 
chains.  However, in that study a triple CD loop MMP-1 mutant retained 76% of WT 
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collagenolytic activity  suggesting these residues are not critical for collagen breakdown 
(Manka, Carafoli et al. 2012).
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CHAPTER 7: DISCUSSION AND FUTURE 
PERSPECTIVES
7.1 Background
The work described herein aimed to explore MMP-1 collagen recognition and the 
postulated flexible state of MMP-1, with the intention to facilitate understanding of the 
collagenolytic mechanism.  Initially, this required development and optimisation of 
growth and purification strategies resulting in protein yields sufficient for structural and 
functional characterisation (Chapter 2).  
	 Using an extensive program of mutagenesis combined with SPR and SAXS, 
this study has confirmed the presence of a, previously uncharacterised, collagen-binding 
exosite within the HPX domain (Chapter 3).  SAXS experiments have highlighted the 
discrepancy between MMP-1 solid and solution states and demonstrate, for the first 
time, solution-state structural alterations upon zymogen activation (Chapter 4). 
Furthermore, this study has explored the relevance of these interdomain interactions in 
both proteolytic susceptibility and collagenolytic activity (Chapter 4, 5 and 6).
 
7.2 Potential roles for MMP-1 interdomain flexibility 
Originally, comparison of the mature MMP-1 crystal structure with that of proMMP-1 
revealed extensive global structural rearrangements, which were posited as a 
contributory factor in collagen recognition and degradation.  In the case of MMP-1, 
this study confirms that enzyme maturation is accompanied by domain separation.  This 
observation is supported by the recent results from Bertini and co-workers, who 
demonstrated that mature MMP-1 undergoes transient domain separation concomitant 
with exposure of domain-domain interface residues using a paramagnetic probe 
(Bertini, Fragai et al. 2009). Other MMP family members have been shown to adopt an 
array of conformations as observed in SAXS, AFM, NMR and modelling studies 
(Rosenblum, Cohen et al. 2007, Bertini, Calderone et al. 2008, Diaz and Suarez 2012) 
suggesting flexibility is not limited to collagenases, but is a general property of MMPs. 
However, it is unknown what role these extended interdomain arrangements play in 
MMP function.  	
 Perhaps, domain mobility is necessary for locating and accessing sites of 
action.  Intramolecular flexibility might facilitate enzyme migration along fibrils and 
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ECM components. Mobility of MMP-1 and MMP-14 has been investigated during 
fluorescence correlation spectroscopy experiments, which showed that MMPs appear to 
move processively along collagen fibrils (Saffarian, Collier et al. 2004, Collier, Legant et 
al. 2011). Furthermore, in AFM experiments MMP-9 has been shown to undergo 
conformational contraction upon binding collagen (Rosenblum, Van den Steen et al. 
2010) and is able to move processively along the substrate (Collier, Legant et al. 2011). 
More recently, single-molecule tracking experiments have shown MMP-1 undergoes 
lateral diffusion along collagen fibrils without noticeable dissociation at a velocity of 
11.8 ± 0.6 µm s−1 (Sarkar, Marmer et al. 2012).  However, the molecular mechanism of 
such mobility remains to be elucidated.  It is also unknown whether proMMP-1 
possesses the ability to traverse the triple helical substrate, particularly as the zymogen 
form has reduced affinity for collagen (~ 10-fold). The proMMP-1 solution structure 
determined here largely agrees with that of the compact crystal structure.  Should this 
compact state restrict mobility it would likely effect the spatial load distribution of 
enzyme along the fibril and consequently may add another level of  regulation.
 Arguably, the primary focus of MMP-1 studies remains focused on interstitial 
collagen breakdown.  It is equally possible that extended conformations play a role in 
other molecular interactions.  There is evidence that the HPX domain is required for 
maximal TIMP inhibition.  In TIMP-1 and -4 inhibition studies, full-length MMP-1 
displayed higher association rate (kon) and lower Ki  values when compared with CAT-1 
(Murphy, Allan et al. 1992, Troeberg, Tanaka et al. 2002).  The same trend was 
observed for MMP-3.  While structural rearrangements have not been directly shown to 
impact TIMP binding it is difficult to reconcile an interaction with two multi-domain 
proteins not involving domain mobility, especially when the CAT-3/TIMP-1 crystal 
complex (PDB accession code 1UEA) shows the C-terminal end of the CAT-3 
polypeptide chain oriented well away from full-length TIMP-1.  Equally, adoption of a 
range of variable structural conformations would likely allow the ability to bind and/or 
process a diverse substrate repertoire. PAR-1, CD44, integrins, MCPs (monocyte 
chemoattractant protein) and TGF-β are just a few of the known MMP substrates 
(McQuibban, Gong et al. 2002, Boire, Covic et al. 2005, Chetty, Vanamala et al. 2012, 
Kryczka, Stasiak et al. 2012).  Many of these molecules are associated with the cell 
surface and may be assembled in large multi-component complexes.  As such, variable 
inter-conformations would maintain MMP versatility.
	 It has been postulated that active-site plasticity is necessary for such diverse 
substrate recognition and processing (Lovejoy, Welch et al. 1999, Moy, Chanda et al. 
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1999).  An unexpected finding from this study was the compromised hydrolytic activity 
resulting from introduction of an interdomain disulfide bond (MMP-1 S243C, S318C) 
to confine the enzyme to a compact state.  In contrast, the activity of domain-dislocated 
mutants (MMP-1 R300A, F301A and F316A) was unimpaired. Therefore, promotion of 
compact states in vivo may confer rigidity to the CAT-1 subsite pockets, thereby spatially 
and temporally modulating activity against preferred substrates.  Furthermore, the 
compact state appears to confer resistance to proteolysis of the inter-domain linker. 
This too may have significant consequences, by either promoting retention of the HPX 
domain for specific localisation within the ECM, regulating functions that are 
independent of catalytic activity and are mediated solely by the HPX domain (i.e. cell 
signalling pathways (Mantuano, Inoue et al. 2008)) or reducing clearance of MMPs 
from the ECM.  What is certain, the compact state has biological relevance in collagen 
processing, as complete disruption of the CAT-HPX interface, confirmed by SAXS 
experiments, drastically reduces (~ 30-fold) collagen binding activity in mature MMP-1.  
7.3 Collagen recognition and degradation
During the latter stages of this project, two studies were published that provide 
considerable insight into collagen catabolism by MMP-1. The work conducted by 
Bertini and co-workers describes a mechanism of collagenolysis that is derived from 
NMR experimental data of enzyme-substrate complexes, and docking experiments 
using docking programme HADDOCK (Bertini, Fragai et al. 2012).  
 Initially, the triple helical peptide structure was confirmed and assigned using 
13C,15N-enriched α1(I)772–786 THP.  Full-length enzyme and isolated domains in 
complex with the THP were subsequently monitored by 1H,15N TROSY-HSQC 
spectroscopy for changes in signal intensity.  This determined a notably strong localised 
interaction between HPX-1 (residues 291-292 and 311-326) with two chains of the THP 
(analogous to type I collagen residues 782-785), with further points of peptide 
interaction with active site residues in CAT-1 (residues 160-199 and 216-224).  In part, 
this agrees with some of the data described in this thesis (Chapter 3 and 4).  SPR THP 
binding data confirms reduced affinity for alanine mutated residue V319 (26.4 ± 1.5 
μM) in the isolated HPX-1 domain.  Furthermore, mutation of F316 in full-length 
MMP-1 reduces THP affinity 2-fold.  However, despite their selection as restraints in the 
iterative HADDOCK docking process, residues R300 and F301 failed to be identified in 
the NMR study.  Instead Bertini and co-workers used these residues as pseudo-restraints, 
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along with 233, 241, 243, 247, 250, 271, 272, 300, 301, 316, 318 and 326, which 
constitute CAT-HPX interface residues and part of the linker, to induce structural 
reorientation during the docking procedure. The SAXS data presented herein for 
MMP-1 R300A, F301A and F316A, which highlights elongated solution structural 
states, would support this rationale.  In addition, the linker proteolysis study (Section 
5.3.4) supports a model of an enzyme with domains that transiently separate (Figure 
7.1A) leading to linker exposure. The collagenolytic mechanism proposed by Bertini et 
al. (2012) describes a process whereby an extended MMP-1 molecule forms an 
‘encounter complex’ with the THP (Figure 7.1B) as defined by NMR data.  
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Figure 7.1: The Bertini Model of collagenolysis. (A) Compact (left) and extended (right) forms 
of mature MMP-1 in equilibrium. (B) Initially extended MMP-1 binds the triple helix.  The HPX 
domain binds via four amino acids (analogous to type I collagen residues 782-785) and the triple 
helix is presented to the catalytic domain. (C) In the compact conformation, MMP-1 releases one 
chain (magenta),  which is positioned in the CAT domain active site for hydrolysis. (D) After hydrolysis, 
both peptide fragments (C- and N-terminal) are initially bound to the active site. (E) The C-terminal 
region of  the N-terminal peptide fragment is released. (Reproduced from Bertini, Fragai et al. 2012).
	 Nuclear overhauser effects (NOEs), which are a useful probe of spatial 
proximity, indicate distortion of the THP helical state in the presence of MMP-1. 
Therefore, the authors speculate that domain back-rotation to form the compact 
crystallographic MMP-1 state is required to induce substrate distortion and unwinding 
in preparation for hydrolysis (Figure 7.1C).  It must be stressed that there is no 
experimental evidence that domain mobility is retained upon enzyme-substrate complex 
formation, although our data show that permanently separated domain states have 
negative effects on THP-binding.  
	 The proposed final substrate cleavage steps (Figure 7.1D and E) are the most 
tenuous, using previously published MMP-12 data (PDB accession code: 2OXZ) as a 
model for hydrolysis (Bertini, Calderone et al. 2006).  This study involved crystallisation 
of the catalytic domain of MMP-12 in the presence of a simple peptide in order to 
study the steps of the MMP reaction mechanism.  The relevance of this data is 
questionable; MMP-12 is not a collagenase and therefore is unable to process complex 
triple helical collagen-like peptides.  Furthermore, the study focused on CAT domain 
interactions only. As such, there is no evidence that involvement of the HPX domain 
remains in the subsequent chain processing stages of  collagenolysis.
	 The second study performed by Manka and co-workers culminated in the 
first crystallographic structure of MMP-1 in complex with a THP (PDB accession code: 
4AUO), showing that collagenolysis relies on multiple exosite interactions (Manka, 
Carafoli et al. 2012).      
 Analysis of a Collagen Toolkit library of triple-helical peptides encompassing 
the entire collagen II sequence confirmed the importance of leucine residues at 
positions P1‘ and P10’, thereby validating the choice of THP used in this study (Section 
3.1.4), which contains the necessary binding motif (residues 772-787) for MMP-1 
recognition.  
 Using an ELISA assay, the authors confirm MMP-1* binds native type I 
collagen with an apparent Kd of 0.4 μM.  In contrast, CAT-1* showed no detectable 
binding and HPX-1 bound weakly, thereby illustrating the necessity of cooperative 
domain interactions for effective collagen recognition. This substantiates the 
experimental SPR data presented here, which saw an order of magnitude reduction in 
Kd value for MMP-1* (0.92 ± 0.1 μM) when compared to HPX-1 (10.9 ± 1.0 μM). 
Moreover, HD/MS experiments highlight regions involved in type I collagen binding 
(Figure 7.2A) and clearly identify multiple sites that span both domains. Delayed 
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deuterium exchange was observed across the following sites: residues 164-180 (site 1), 
224-234 (site 3), 285-296 (site 4), 302-316 (site 5), 349-365 (site 6)).  Enhanced H/D 
exchange was observed for residues 198-212 (site 2).  Sites 4 and 5 have been previously 
identified in similar experiments (Lauer-Fields, Chalmers et al. 2009) and constitute 
surface regions of HPX-1 blade 1.  The residues selected for investigation in this thesis 
are primarily located in blade 1 but focus on individual contributions to collagen 
recognition.  Reassuringly, most of these residues are found in sites 5 and 6 (Figure 
7.2B).  However, of the ‘ball’ residues selected in this study, only F316 (site 5) displayed 
deuterium exchange.  This is not surprising as most residues comprising the ‘ball and 
socket’ would be protected from the solvent in the compact state thereby reducing the 
potential for detection.
	 Interestingly, site 2 is composed of the sequence RWTNFFREY, previously 
identified as a critical component of collagenolytic activity (Chung, Yoshida et al. 2004). 
Deuterium exchange amplification in this region is suggestive of increased exposure and 
mobility within in the CAT domain.  Therefore, site 2 may be another long-range 
region affected by domain-stapling as introduction of mutation S243C, S318C reduced 
both hydrolytic activity and THP binding (~10 fold).  It may also be suggestive of a 
mobility mechanism that requires domain separation, either for initial recognition or in 
later binding events.
 Further mutational analysis of candidate residues identified by docking was 
performed, and collagenolytic activity was tested.  The double mutant L357A, H358A 
showed a marginal increase in relative collagen hydrolysis.  This fits with the SPR data 
presented in Section 3.2.2.2, which also showed a slight decrease in Kd for single mutant 
H358A.  Double mutant I290A/R291A (Lauer-Fields, Chalmers et al. 2009) exhibited 
the largest reduction, retaining only 4% of activity.  A review of this position (Figure 7.2) 
shows the close proximity of D338.  Further analysis of the crystal structure (PDB 
accession code: 2CLT) indicates the presence of a salt bridge between this residue and 
R291.  Therefore, disruption of this interaction may account for the significant 
reduction in both affinity (Kd = 24.5 ± 0.9 μM) and subsequent hydrolysis.  Hydrolytic 
activity of mutant F320Y also showed reduced activity (10%).  The crystal structure 
complex (Figure 7.3) indicates a role in forming the S10’ binding pocket of HPX-1. 
However, there is no attempt to assess the structural impact of this mutation, it is 
therefore possible that mutation has affected positioning of adjacent residue V319, 
which when mutated is negatively impacted with an increase in Kd (26.4 ± 1.5 μM). 
 Perhaps most intriguing is the role of CD loop residues.  Triple alanine 
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substitution of F308,Y309 and P310 only reduces hydrolytic activity by ~25%, yet both 
F308 and Y309 make hydrophobic contacts with the P10’ residue of the trailing strand 
that is considered a critical binding motif (Figure 7.3B).  Furthermore, the largest 
reduction in Kd for the CD loop residues was observed during SPR experiments of single 
mutant MMP-1* F308A (~1.5 fold).  However, this reduction in affinity was moderate 
when placed in context of other full-length mutants tested; MMP-1* R300A, F301A 
and F316A showed reductions in Kd  of 3-fold, 30-fold and 3-fold, respectively.  Then 
consider the reduction in type I collagenolysis (13%) displayed by linker residue G272A 
(Tsukada and Pourmotabbed 2002). This would imply that domain mobility and 
cooperation, with stabilisation from catalytic domain residues is more important than 
the hydrophobic interactions provided by the CD loop.  
 Notably, the wall-forming segment of the CAT-1 S1’ pocket (G233-A-L-M-Y-
P-S-Y240) is proximal to the ‘socket’ residues, and a hydrogen bond exists between the 
G233 main chain carbonyl group and ‘ball’ residue R300.  Potential disruption of this 
bond may account for the reduced THP affinity observed.  Another factor may reside in 
the impact on Y237, P238, S239 and Y240, which are directly involved in binding the 
leading chain (Figure 7.4), by MMP-1 domain separation.
 The MMP-1*-collagen peptide complex is undoubtedly important, providing 
for the first time clear structural insights into collagenolysis.  However, like the Bertini 
model described previously, it too poses some controversy.  The structure is of a type II 
collagen homotrimeric peptide bound to MMP-1*.  Despite differences in MMP-1 
kinetic parameters for different collagen substrates (Table 1.1), presumably the 
mechanism of binding is similar to type I collagen.  The crytallised complex is deemed 
“non-productive” by the authors as the S1’ pocket remains empty with the leucine at P1’ 
9 Å away.  They recognise that a productive mode could be achieved by separation of 
the CAT-HPX interface, which is consistent with experimental reports of MMP 
flexibility in solution and the data presented herein.  Yet, this was discounted in favour of 
a proposed mechanism that involves a compact MMP-1* state and axial rotation of the 
substrate, despite no experimental evidence to support this proposal.  
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Figure 7.4: Schematic representation of MMP-1 collagen interactions. MMP-1 residues are 
shown as ovals (CAT-1) or rectangles (HPX-1). Collagen subsites P1' and P10' are shown in cyan and purple, 
respectively. (A) Hydrogen bonds (dashed lines) between MMP-1 and THP. (B) Contacts of 4 Å distance or 
less (solid lines) between MMP-1 and THP. Hydrophobic contacts are emphasized by red lines. Residues 
involved in forming the S1’ pocket are shown in green. HPX-1 residues with significantly reduced THP 
affinity upon alanine substitution are shown in blue (Adapted from Manka, Carafoli et al. 2012). 
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The crystallised complex is in a compact structural form, not dissimilar to that shown 
for MMP-1* S243C, S318C (Chapter 5).  Mutagenic modelling of the MMP-1:THP 
complex reveals a structure also amenable to cysteine substitution at position 243 and 
318 (Figure 7.5).  However, the data presented here demonstrates, that when trapped in 
a compact form, MMP-1* S243C, S318C shows a reduction in THP affinity (~10-fold 
reduction in Kd).  Arguably, while the compact state plays a role in THP binding due to 
the negative effects of domain dislocation, the compact form is also detrimental to 
effective collagen-processing.
	 It is clear that both studies offer valuable insight into collagen breakdown. 
Yet, both present conflicting models of collagen recognition and processing.  The data 
presented here would suggest a structurally dynamic enzymatic form exists that requires 
both an elongated and compact form for effective collagen binding.  Therefore, with 
further study, the mutants used in this thesis could assist elucidation of the correct role of 
elongated and compact states in collagenolysis.
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Figure 7.5: A model of MMP-1* S243C, S318C complexed to a collagen peptide.  The 
crystallised complex (PDB accession code: 4AUO) is depicted as a cartoon. Note the distance of the 
trailing chain from the active site zinc atom (yellow sphere) with the histidine triad shown as sticks.  Cysteine 
substitution at serine positions 243 and 318 has been modelled using the Pymol Molecular Graphics 
System (version 1.5.0.4.), Schrödinger,  LLC.  The mutations are shown as spheres are coloured according to 
atom. The upper rim of the catalytic site cleft anchors the middle chain (green), and the HPX-1 anchors the 
leading chain (cyan).  
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7.4 Proposed future work
Clearly the mechanism of collagenolysis by MMP-1 remains to be fully elucidated. 
While the structural and functional characterisation of MMP-1, the subject of this 
thesis, has provided valuable insights into cooperative domain interactions, there 
remains many outstanding questions that require answers.  The following discussion 
covers many potential avenues of  investigation but is by no means an exhaustive list.
	 Firstly, the structure of the domain stapled mutant requires further validation. 
The SAXS, proteolysis and SPR data presented here suggest MMP-1* S243C, S318C is 
a more compact molecule than the wild-type enzyme, with subsequent negative effects 
on substrate interactions.  Ideally, an atomic resolution model of the domain stapled 
mutant would corroborate the low resolution structural data.  At present, preliminary 
crystallisation has taken place, small crystals have formed but attempts to optimise the 
crystallisation conditions have, as yet, been unsuccessful.  Therefore, an NMR study to 
study structure and dynamics, like that performed by Bertini et al. (2012), may be more 
appropriate.  The impaired hydrolytic activity may result from CAT domain rigidity. 
Therefore, differential scanning calorimetry should be used to assess the thermostability 
of this mutant.  Furthermore, cysteine bond reduction using oxidative agents could be 
used to assess restoration of  THP binding and hydrolytic activity.  
	 The work contained herein, looked primarily at the effect of structural 
flexibility on THP recognition and binding.  The actual effect of elongated and compact 
states on collagen hydrolysis remains to be identified.  Utilising mutants that are 
effectively trapped in either permanently dislocated or compact stapled forms should 
allow full elucidation of kinetic parameters (on/off rates) and definition of kcat/KM 
values for collagen breakdown thereby solving the nature of the initial encounter 
complex that remains a contentious point in the previously described Bertini and Manka 
models.  This could be complemented with HD/MS experiments in order to explore 
potential changes in the collagen footprint of these mutants for comparison to the sites 
identified by Manka and co-workers. 
	 Long-term prospects might include targeting transient domain separation 
and/or HPX exosites involved in collagen recognition as a potential therapeutic avenue. 
One of the fundamental issues with MMP inhibitors is the broad spectrum effects as a 
consequence of high homology in the CAT domain (Reveiwed in Nuti, Tuccinardi et al. 
2007).  By targeting exosites and/or mobility mechanisms it may be possible to attenuate 
specific collagenase activity by MMP-1.  Small molecule inhibitors have already been 
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developed against the HPX domain of MMP-14 with significant reductive effects on 
protumorigenic activity in vivo (Remacle, Golubkov et al. 2012).  Such an approach 
would need to include compound generation, selection and screening, determination of 
inhibiton Ki values and assessments of  in vivo effects. 
	 Finally, as a variety of studies exist that suggest interdomain flexibility is a 
general property of MMPs (MMP-2, -9, -12), the methods of experimentation utilised 
in this study could be applied to other MMP family members like the gelatinases and 
stromelysins.  Alignment of seven MMP sequences (Figure 7.6) show that the arginine 
residue at position 300 is strictly conserved with a general preference for an aromatic 
residue at position 301.  In MMP-1 R300 interacts with G233 of the wall-forming 
socket and therefore this may play a role in substrate hydrolysis.  
In conclusion, the data presented here identifies HPX-1 residues forming a collagen 
binding exosite, this has since been validated by crystallisation of an MMP-1*-THP 
complex (Manka, Carafoli et al. 2012).  Moreover, the data confirms, the previously 
postulated, flexible state of MMP-1 and has shown that interfering with this subtle 
dynamic equilibrium has significant effects on collagen recognition.
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300 310
Figure 7.6: MMP alignment of proposed interface residues.  Residues comprising the MMP-1 
‘ball’ joint are indicated by black triangles. Amino acid sequence alignment is coloured with increasing 
percentage identity (75-100%).  Members of the collagenase family are highlighted in lilac.  Protein 
sequences were obtained from the Uniprot/Swiss-Prot database (Apweiler,  Bairoch et al. 2004), aligned 
using CLUSTAL Omega (Sievers, Wilm et al. 2011) and rendered using Jalview (Waterhouse,  Procter et 
al. 2009). 
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APPENDIX 3
H6-proCAT-3
ProtParam
User-provided sequence:
        10         20         30         40         50         60 
MGSSHHHHHH SSGLVPAGSH MFRTFPGIPK WRKTHLTYRI VNYTPDLPKD AVDSAVEKAL 
        70         80         90        100        110        120 
KVWEEVTPLT FSRLYEGEAD IMISFAVREH GDFYPFDGPG NVLAHAYAPG PGINGDAHFD 
       130        140        150        160        170        180 
DDEQWTKDTT GTNLFLVAAH EIGHSLGLFH SANTEALMYP LYHSLTDLTR FRLSQDDING 
       190 
IQSLYGPPPD SPET 
Number of amino acids: 194
Molecular weight: 21605.0
Theoretical pI: 5.56
Amino acid composition: 
Ala (A)  14"   7.2%
Arg (R)   7"   3.6%
Asn (N)   6"   3.1%
Asp (D)  15"   7.7%
Cys (C)   0"   0.0%
Gln (Q)   3"   1.5%
Glu (E)  10"   5.2%
Gly (G)  16"   8.2%
His (H)  15"   7.7%
Ile (I)   8"   4.1%
Leu (L)  17"   8.8%
Lys (K)   6"   3.1%
Met (M)   4"   2.1%
Phe (F)  10"   5.2%
Pro (P)  15"   7.7%
Ser (S)  14"   7.2%
Thr (T)  14"   7.2%
Trp (W)   3"   1.5%
Tyr (Y)   8"   4.1%
Val (V)   9"   4.6%
Pyl (O)   0"   0.0%
Sec (U)   0"   0.0%
 (B)   0"  0.0%
 (Z)   0"  0.0%
 (X)   0"  0.0%
220
Total number of negatively charged residues (Asp + Glu): 25
Total number of positively charged residues (Arg + Lys): 13
Atomic composition:
Carbon      C"        974
Hydrogen    H"       1443
Nitrogen    N"        263
Oxygen      O"        290
Sulfur      S"          4
Formula: C974H1443N263O290S4
Total number of atoms: 2974
Extinction coefficients:
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water.
Ext. coefficient    28420
Abs 0.1% (=1 g/l)   1.315
Estimated half-life:
The N-terminal of the sequence considered is M (Met).
The estimated half-life is: 30 hours (mammalian reticulocytes, in 
vitro).
                            >20 hours (yeast, in vivo).
                            >10 hours (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 26.99
This classifies the protein as stable.
Aliphatic index: 70.93
Grand average of hydropathicity (GRAVY): -0.449
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APPENDIX 4
CAT-3
ProtParam
User-provided sequence:
        10         20         30         40         50         60 
FRTFPGIPKW RKTHLTYRIV NYTPDLPKDA VDSAVEKALK VWEEVTPLTF SRLYEGEADI 
        70         80         90        100        110        120 
MISFAVREHG DFYPFDGPGN VLAHAYAPGP GINGDAHFDD DEQWTKDTTG TNLFLVAAHE 
       130        140        150        160        170 
IGHSLGLFHS ANTEALMYPL YHSLTDLTRF RLSQDDINGI QSLYGPPPDS PET 
Number of amino acids: 173
Molecular weight: 19395.5
Theoretical pI: 4.89
Amino acid composition: 
Ala (A)  13"   7.5%
Arg (R)   7"   4.0%
Asn (N)   6"   3.5%
Asp (D)  15"   8.7%
Cys (C)   0"   0.0%
Gln (Q)   3"   1.7%
Glu (E)  10"   5.8%
Gly (G)  13"   7.5%
His (H)   8"   4.6%
Ile (I)   8"   4.6%
Leu (L)  16"   9.2%
Lys (K)   6"   3.5%
Met (M)   2"   1.2%
Phe (F)  10"   5.8%
Pro (P)  14"   8.1%
Ser (S)   9"   5.2%
Thr (T)  14"   8.1%
Trp (W)   3"   1.7%
Tyr (Y)   8"   4.6%
Val (V)   8"   4.6%
Pyl (O)   0"   0.0%
Sec (U)   0"   0.0%
 (B)   0"  0.0%
 (Z)   0"  0.0%
 (X)   0"  0.0%
Total number of negatively charged residues (Asp + Glu): 25
Total number of positively charged residues (Arg + Lys): 13
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Atomic composition:
Carbon      C"        882
Hydrogen    H"       1310
Nitrogen    N"        228
Oxygen      O"        264
Sulfur      S"          2
Formula: C882H1310N228O264S2
Total number of atoms: 2686
Extinction coefficients:
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water.
Ext. coefficient    28420
Abs 0.1% (=1 g/l)   1.465
Estimated half-life:
The N-terminal of the sequence considered is F (Phe).
The estimated half-life is: 1.1 hours (mammalian reticulocytes, in 
vitro).
                            3 min (yeast, in vivo).
                            2 min (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 24.60
This classifies the protein as stable.
Aliphatic index: 75.03
Grand average of hydropathicity (GRAVY): -0.414
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APPENDIX 5
HPX-1
ProtParam
User-provided sequence:
        10         20         30         40         50         60 
PIGPQTPKAC DSKLTFDAIT TIRGEVMFFK DRFYMRTNPF YPEVELNFIS VFWPQLPNGL 
        70         80         90        100        110        120 
EAAYEFADRD EVRFFKGNKY WAVQGQNVLH GYPKDIYSSF GFPRTVKHID AALSEENTGK 
       130        140        150        160        170        180 
TYFFVANKYW RYDEYKRSMD PGYPKMIAHD FPGIGHKVDA VFMKDGFFYF FHGTRQYKFD 
       190        200 
PKTKRILTLQ KANSWFNCRK N 
Number of amino acids: 201
Molecular weight: 23757.0
Theoretical pI: 9.26
Amino acid composition: 
Ala (A)  12"   6.0%
Arg (R)  11"   5.5%
Asn (N)  10"   5.0%
Asp (D)  13"   6.5%
Cys (C)   2"   1.0%
Gln (Q)   6"   3.0%
Glu (E)   9"   4.5%
Gly (G)  13"   6.5%
His (H)   5"   2.5%
Ile (I)   9"   4.5%
Leu (L)   8"   4.0%
Lys (K)  18"   9.0%
Met (M)   5"   2.5%
Phe (F)  22"  10.9%
Pro (P)  13"   6.5%
Ser (S)   7"   3.5%
Thr (T)  11"   5.5%
Trp (W)   4"   2.0%
Tyr (Y)  13"   6.5%
Val (V)  10"   5.0%
Pyl (O)   0"   0.0%
Sec (U)   0"   0.0%
 (B)   0"  0.0%
 (Z)   0"  0.0%
 (X)   0"  0.0%
Total number of negatively charged residues (Asp + Glu): 22
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Total number of positively charged residues (Arg + Lys): 29
Atomic composition:
Carbon      C"       1105
Hydrogen    H"       1610
Nitrogen    N"        282
Oxygen      O"        293
Sulfur      S"          7
Formula: C1105H1610N282O293S7
Total number of atoms: 3297
Extinction coefficients:
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water.
Ext. coefficient    41495
Abs 0.1% (=1 g/l)   1.747, assuming all pairs of Cys residues form 
cystines
Ext. coefficient    41370
Abs 0.1% (=1 g/l)   1.741, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is P (Pro).
The estimated half-life is: >20 hours (mammalian reticulocytes, in 
vitro).
                            >20 hours (yeast, in vivo).
                            ? (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 35.41
This classifies the protein as stable.
Aliphatic index: 53.38
Grand average of hydropathicity (GRAVY): -0.587
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APPENDIX 6
proMMP-1
        10         20         30         40         50         60 
MFPATLETQE QDVDLVQKYL EKYYNLKNDG RQVEKRRNSG PVVEKLKQMQ EFFGLKVTGK 
        70         80         90        100        110        120 
PDAETLKVMK QPRCGVPDVA QFVLTEGNPR WEQTHLTYRI ENYTPDLPRA DVDHAIEKAF 
       130        140        150        160        170        180 
QLWSNVTPLT FTKVSEGQAD IMISFVRGDH RDNSPFDGPG GNLAHAFQPG PGIGGDAHFD 
       190        200        210        220        230        240 
EDERWTNNFR EYNLHRVAAH ELGHSLGLSH STDIGALMYP SYTFSGDVQL AQDDIDGIQA 
       250        260        270        280        290        300 
IYGRSQNPVQ PIGPQTPKAC DSKLTFDAIT TIRGEVMFFK DRFYMRTNPF YPEVELNFIS 
       310        320        330        340        350        360 
VFWPQLPNGL EAAYEFADRD EVRFFKGNKY WAVQGQNVLH GYPKDIYSSF GFPRTVKHID 
       370        380        390        400        410        420 
AALSEENTGK TYFFVANKYW RYDEYKRSMD PGYPKMIAHD FPGIGHKVDA VFMKDGFFYF 
       430        440        450 
FHGTRQYKFD PKTKRILTLQ KANSWFNCRK N 
Number of amino acids: 451
Molecular weight: 51975.4
Theoretical pI: 6.41
Amino acid composition: 
Ala (A)  27"   6.0%
Arg (R)  24"   5.3%
Asn (N)  22"   4.9%
Asp (D)  33"   7.3%
Cys (C)   3"   0.7%
Gln (Q)  23"   5.1%
Glu (E)  25"   5.5%
Gly (G)  34"   7.5%
His (H)  14"   3.1%
Ile (I)  18"   4.0%
Leu (L)  27"   6.0%
Lys (K)  30"   6.7%
Met (M)  10"   2.2%
Phe (F)  34"   7.5%
Pro (P)  28"   6.2%
Ser (S)  18"   4.0%
Thr (T)  25"   5.5%
Trp (W)   7"   1.6%
Tyr (Y)  22"   4.9%
Val (V)  27"   6.0%
Pyl (O)   0"   0.0%
Sec (U)   0"   0.0%
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 (B)   0"  0.0%
 (Z)   0"  0.0%
 (X)   0"  0.0%
Total number of negatively charged residues (Asp + Glu): 58
Total number of positively charged residues (Arg + Lys): 54
Atomic composition:
Carbon      C"       2356
Hydrogen    H"       3519
Nitrogen    N"        633
Oxygen      O"        678
Sulfur      S"         13
Formula: C2356H3519N633O678S13
Total number of atoms: 7199
Extinction coefficients:
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water.
Ext. coefficient    71405
Abs 0.1% (=1 g/l)   1.374, assuming all pairs of Cys residues form 
cystines
Ext. coefficient    71280
Abs 0.1% (=1 g/l)   1.371, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is M (Met).
The estimated half-life is: 30 hours (mammalian reticulocytes, in 
vitro).
                            >20 hours (yeast, in vivo).
                            >10 hours (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 34.58
This classifies the protein as stable.
Aliphatic index: 62.26
Grand average of hydropathicity (GRAVY): -0.639
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APPENDIX 7
MMP-1
ProtParam
User-provided sequence:
        10         20         30         40         50         60 
FVLTEGNPRW EQTHLTYRIE NYTPDLPRAD VDHAIEKAFQ LWSNVTPLTF TKVSEGQADI 
        70         80         90        100        110        120 
MISFVRGDHR DNSPFDGPGG NLAHAFQPGP GIGGDAHFDE DERWTNNFRE YNLHRVAAHE 
       130        140        150        160        170        180 
LGHSLGLSHS TDIGALMYPS YTFSGDVQLA QDDIDGIQAI YGRSQNPVQP IGPQTPKACD 
       190        200        210        220        230        240 
SKLTFDAITT IRGEVMFFKD RFYMRTNPFY PEVELNFISV FWPQLPNGLE AAYEFADRDE 
       250        260        270        280        290        300 
VRFFKGNKYW AVQGQNVLHG YPKDIYSSFG FPRTVKHIDA ALSEENTGKT YFFVANKYWR 
       310        320        330        340        350        360 
YDEYKRSMDP GYPKMIAHDF PGIGHKVDAV FMKDGFFYFF HGTRQYKFDP KTKRILTLQK 
       370 
ANSWFNCRKN 
Number of amino acids: 370
Molecular weight: 42634.7
Theoretical pI: 6.17
Amino acid composition: 
Ala (A)  24"   6.5%
Arg (R)  20"   5.4%
Asn (N)  19"   5.1%
Asp (D)  28"   7.6%
Cys (C)   2"   0.5%
Gln (Q)  15"   4.1%
Glu (E)  18"   4.9%
Gly (G)  29"   7.8%
His (H)  14"   3.8%
Ile (I)  18"   4.9%
Leu (L)  20"   5.4%
Lys (K)  20"   5.4%
Met (M)   7"   1.9%
Phe (F)  31"   8.4%
Pro (P)  23"   6.2%
Ser (S)  17"   4.6%
Thr (T)  21"   5.7%
Trp (W)   7"   1.9%
Tyr (Y)  19"   5.1%
Val (V)  18"   4.9%
Pyl (O)   0"   0.0%
Sec (U)   0"   0.0%
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 (B)   0"  0.0%
 (Z)   0"  0.0%
 (X)   0"  0.0%
Total number of negatively charged residues (Asp + Glu): 46
Total number of positively charged residues (Arg + Lys): 40
Atomic composition:
Carbon      C"       1943
Hydrogen    H"       2853
Nitrogen    N"        519
Oxygen      O"        554
Sulfur      S"          9
Formula: C1943H2853N519O554S9
Total number of atoms: 5878
Extinction coefficients:
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water.
Ext. coefficient    66935
Abs 0.1% (=1 g/l)   1.570, assuming all pairs of Cys residues form 
cystines
Ext. coefficient    66810
Abs 0.1% (=1 g/l)   1.567, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is F (Phe).
The estimated half-life is: 1.1 hours (mammalian reticulocytes, in 
vitro).
                            3 min (yeast, in vivo).
                            2 min (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 34.71
This classifies the protein as stable.
Aliphatic index: 60.65
Grand average of hydropathicity (GRAVY): -0.594
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APPENDIX 8
H6-proCAT-1
ProtParam
User-provided sequence:
        10         20         30         40         50         60 
MGSSHHHHHH SSGLVPAGSH MFPATLETQE QDVDLVQKYL EKYYNLKNDG RQVEKRRNSG 
        70         80         90        100        110        120 
PVVEKLKQMQ EFFGLKVTGK PDAETLKVMK QPRCGVPDVA QFVLTEGNPR WEQTHLTYRI 
       130        140        150        160        170        180 
ENYTPDLPRA DVDHAIEKAF QLWSNVTPLT FTKVSEGQAD IMISFVRGDH RDNSPFDGPG 
       190        200        210        220        230        240 
GNLAHAFQPG PGIGGDAHFD EDERWTNNFR EYNLHRVAAH ELGHSLGLSH STDIGALMYP 
       250        260 
SYTFSGDVQL AQDDIDGIQA IYG 
Number of amino acids: 263
Molecular weight: 29504.7
Theoretical pI: 5.68
Amino acid composition: 
Ala (A)  16"   6.1%
Arg (R)  12"   4.6%
Asn (N)  11"   4.2%
Asp (D)  20"   7.6%
Cys (C)   1"   0.4%
Gln (Q)  15"   5.7%
Glu (E)  16"   6.1%
Gly (G)  24"   9.1%
His (H)  16"   6.1%
Ile (I)   9"   3.4%
Leu (L)  20"   7.6%
Lys (K)  12"   4.6%
Met (M)   6"   2.3%
Phe (F)  12"   4.6%
Pro (P)  15"   5.7%
Ser (S)  15"   5.7%
Thr (T)  14"   5.3%
Trp (W)   3"   1.1%
Tyr (Y)   9"   3.4%
Val (V)  17"   6.5%
Pyl (O)   0"   0.0%
Sec (U)   0"   0.0%
 (B)   0"  0.0%
 (Z)   0"  0.0%
 (X)   0"  0.0%
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Total number of negatively charged residues (Asp + Glu): 36
Total number of positively charged residues (Arg + Lys): 24
Atomic composition:
Carbon      C"      1305
Hydrogen    H"      1980
Nitrogen    N"       372
Oxygen      O"       400
Sulfur      S"         7
Formula: C1305H1980N372O400S7
Total number of atoms: 4064
Extinction coefficients:
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water.
Ext. coefficient    29910
Abs 0.1% (=1 g/l)   1.014, assuming all pairs of Cys residues form 
cystines
Ext. coefficient    29910
Abs 0.1% (=1 g/l)   1.014, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is M (Met).
The estimated half-life is: 30 hours (mammalian reticulocytes, in 
vitro).
                            >20 hours (yeast, in vivo).
                            >10 hours (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 31.86
This classifies the protein as stable.
Aliphatic index: 67.83
Grand average of hydropathicity (GRAVY): -0.664
Back to the Top
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APPENDIX 9
Thrombin-cleaved proCAT-1
ProtParam
User-provided sequence:
        10         20         30         40         50         60 
GSHMFPATLE TQEQDVDLVQ KYLEKYYNLK NDGRQVEKRR NSGPVVEKLK QMQEFFGLKV 
        70         80         90        100        110        120 
TGKPDAETLK VMKQPRCGVP DVAQFVLTEG NPRWEQTHLT YRIENYTPDL PRADVDHAIE 
       130        140        150        160        170        180 
KAFQLWSNVT PLTFTKVSEG QADIMISFVR GDHRDNSPFD GPGGNLAHAF QPGPGIGGDA 
       190        200        210        220        230        240 
HFDEDERWTN NFREYNLHRV AAHELGHSLG LSHSTDIGAL MYPSYTFSGD VQLAQDDIDG 
IQAIYG 
Number of amino acids: 246
Molecular weight: 27707.8
Theoretical pI: 5.23
Amino acid composition: 
Ala (A)  15"   6.1%
Arg (R)  12"   4.9%
Asn (N)  11"   4.5%
Asp (D)  20"   8.1%
Cys (C)   1"   0.4%
Gln (Q)  15"   6.1%
Glu (E)  16"   6.5%
Gly (G)  22"   8.9%
His (H)  10"   4.1%
Ile (I)   9"   3.7%
Leu (L)  19"   7.7%
Lys (K)  12"   4.9%
Met (M)   5"   2.0%
Phe (F)  12"   4.9%
Pro (P)  14"   5.7%
Ser (S)  11"   4.5%
Thr (T)  14"   5.7%
Trp (W)   3"   1.2%
Tyr (Y)   9"   3.7%
Val (V)  16"   6.5%
Pyl (O)   0"   0.0%
Sec (U)   0"   0.0%
 (B)   0"  0.0%
 (Z)   0"  0.0%
 (X)   0"  0.0%
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Total number of negatively charged residues (Asp + Glu): 36
Total number of positively charged residues (Arg + Lys): 24
Atomic composition:
Carbon      C"      1229
Hydrogen    H"      1871
Nitrogen    N"       343
Oxygen      O"       379
Sulfur      S"         6
Formula: C1229H1871N343O379S6
Total number of atoms: 3828
Extinction coefficients:
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water.
Ext. coefficient    29910
Abs 0.1% (=1 g/l)   1.079, assuming all pairs of Cys residues form 
cystines
Ext. coefficient    29910
Abs 0.1% (=1 g/l)   1.079, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is G (Gly).
The estimated half-life is: 30 hours (mammalian reticulocytes, in 
vitro).
                            >20 hours (yeast, in vivo).
                            >10 hours (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 30.24
This classifies the protein as stable.
Aliphatic index: 69.35
Grand average of hydropathicity (GRAVY): -0.657
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APPENDIX 10
CAT-1
ProtParam
User-provided sequence:
        10         20         30         40         50         60 
FPATLETQEQ DVDLVQKYLE KYYNLKNDGR QVEKRRNSGP VVEKLKQMQE FFGLKVTGKP 
        70         80         90        100        110        120 
DAETLKVMKQ PRCGVPDVAQ FVLTEGNPRW EQTHLTYRIE NYTPDLPRAD VDHAIEKAFQ 
       130        140        150        160        170        180 
LWSNVTPLTF TKVSEGQADI MISFVRGDHR DNSPFDGPGG NLAHAFQPGP GIGGDAHFDE 
       190        200        210        220        230        240 
DERWTNNFRE YNLHRVAAHE LGHSLGLSHS TDIGALMYPS YTFSGDVQLA QDDIDGIQAI 
YG 
Number of amino acids: 242
Molecular weight: 27295.3
Theoretical pI: 5.15
Amino acid composition: 
Ala (A)  15"   6.2%
Arg (R)  12"   5.0%
Asn (N)  11"   4.5%
Asp (D)  20"   8.3%
Cys (C)   1"   0.4%
Gln (Q)  15"   6.2%
Glu (E)  16"   6.6%
Gly (G)  21"   8.7%
His (H)   9"   3.7%
Ile (I)   9"   3.7%
Leu (L)  19"   7.9%
Lys (K)  12"   5.0%
Met (M)   4"   1.7%
Phe (F)  12"   5.0%
Pro (P)  14"   5.8%
Ser (S)  10"   4.1%
Thr (T)  14"   5.8%
Trp (W)   3"   1.2%
Tyr (Y)   9"   3.7%
Val (V)  16"   6.6%
Pyl (O)   0"   0.0%
Sec (U)   0"   0.0%
 (B)   0"  0.0%
 (Z)   0"  0.0%
 (X)   0"  0.0%
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Total number of negatively charged residues (Asp + Glu): 36
Total number of positively charged residues (Arg + Lys): 24
Atomic composition:
Carbon      C"       1213
Hydrogen    H"       1847
Nitrogen    N"        337
Oxygen      O"        374
Sulfur      S"          5
Formula: C1213H1847N337O374S5
Total number of atoms: 3776
Extinction coefficients:
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in 
water.
Ext. coefficient    29910
Abs 0.1% (=1 g/l)   1.096, assuming all pairs of Cys residues form 
cystines
Ext. coefficient    29910
Abs 0.1% (=1 g/l)   1.096, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is F (Phe).
The estimated half-life is: 1.1 hours (mammalian reticulocytes, in 
vitro).
                            3 min (yeast, in vivo).
                            2 min (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 30.58
This classifies the protein as stable.
Aliphatic index: 70.50
Grand average of hydropathicity (GRAVY): -0.657
Back to the Top
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APPENDIX 11
PRIMER SEQUENCES
A219E revertant
forward:  5’- GTTGCGGCTCATGAACTCGGCCATTCT -3’
reverse: 5’- AGAATGGCCGAGTTCATGAGCCGCAAC -3’
R300A
forward:  5’- GAAGTGATGTTCTTTAAAGACGCGTTCTACATGCGCACAAATCC -3’
reverse: 5’- GGATTTGTGCGCATGTAGAACGCGTCTTTAAAGAACATCACTTC -3’
F301A
forward: 5’- GATGTTCTTTAAAGACAGAGCGTACATGCGCACAAATCCC -3’
reverse: 5’- GGGATTTGTGCGCATGTACGCTCTGTCTTTAAAGAACATC -3’
P307A
forward: 5’- CTACATGCGCACAAATGCCTTCTACCCGGAAG -3’
reverse: 5’- CTTCCGGGTAGAAGGCATTTGTGCGCATGTAG -3’
F308A
forward:  5’- CATGCGCACAAATCCCGCCTACCCGGAAGTTGAG -3’
reverse:  5’- CTCAACTTCCGGGTAGGCGGGATTTGTGCGCATG -3’
Y309A
forward:  5’- GCACAAATCCCTTCGCCCCGGAAGTTGAGCTC -3’
reverse:  5’- GAGCTCAACTTCCGGGGCGAAGGGATTTGTGC -3’
F316A
forward:  5’- CGGAAGTTGAGCTCAATGCGATTTCTGTTTTCTGGCC -3’
reverse:  5’- GGCCAGAAAACAGAAATCGCATTGAGCTCAACTTCCG -3’
S243C
forward:  5’- CCTAGCTACACCTTCTGTGGTGATGTTCAGCTA -3’
reverse:  5’- TAGCTGAACATCACCACAGAAGGTGTAGCTAGG -3’
S318C
forward:  5’- GAGCTCAATTTCATTTGTGTTTTCTGGCCACAACTG -3’
reverse:  5’- CAGTTGTGGCCAGAAAACACAAATGAAATTGAGCTC -3’
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APPENDIX 12
EXAMPLE SEQUENCE DATA
proMMP-1* S243C, S318C237
237
10 20 30 40 50 60 70 80 90 100 110 120
C A GG G G T T T CC T C TA G AA T AA T T T T G T T T A C T T T A A G A A G G A G AT A T A C A T A T G T T C C C A G C G A C T C T A G A A A C A C A A G A G C A A G A T G T G G A C T T A G T C C A G A A A T A C C T G G A A A A A T A C
130 140 150 160 170 180 190 200 210 220 230 240
T A C A A C C T G A A G A A T G A T G G G A G G C A A G T T G A A A A G C G G A G A A A T A G T G G C C C A G T G G T T G A A A A A T T G A A G C A A A T G C A G G A A T T C T T T G G G C T G A A A G T G A C T G G G A A A C C A G A T G C T
250 260 270 280 290 300 310 320 330 340 350 360
G A A A C C C T G A A G G T G A T G A A G C A G C C C A G A T G T G G A G T G C C T G A T G T G G C T C A G T T T G T C C T C A C T G A G G G G A A C C C T C G C T G G G A G C A A A C A C A T C T G A C C T A C A G G A T T G A A A A T T A C
370 380 390 400 410 420 430 440 450 460 470 480
A C G C C A G A T T T G C C A A G A G C A G A T G T G G A C C A T G C C A T T G A G A A A G C C T T C C A A C T C T G G A G T A A T G T C A C A C C T C T G A C A T T C A C C A A G G T C T C T G A G G G T C A A G C A G A C A T C A T G A T A
490 500 510 520 530 540 550 560 570 580 590 600
T C T T T T G T C A G G G G A G A T C A T C G G T T T T T C A A A G G G A A T A A G T A C T G G G C T G T T C A G G G A C A G A A T G T G C T A C A C G G A T A C C C C A A G G A C A T C T A C A G C T C C T T T G G C T T C C C T A G A A C T
610 620 630 640 650 660 670 680 690 700 710 720
G T G A A G C A T A T C G A T G C T G C T C T T T C T G A G G A A A A C A C T G G A A A A A C C T A C T T C T T T G T T G C T A A C A A A T A C T G G A G G T A T G A T G A A T A T A A A C G A T C T A T G G A T C C A G G T T A T C C C A A A
730 740 750 760 770 780 790 800 810 820 830 840
A T G A T A G C A C A T G A C T T T C C T G G A A T T G G C C A C A A A G T T G A T G C A G T T T T C A T G A A A G A T G G A T T T T T C T A T T T C T T T C A T G G A A C A A G A C A A T A C A A A T T T G A T C C T A A A A C G A A G A G A
850 860 870 880 890 900 910 920 930 940 950 960
A T T T T G A C T C T C C A G A A A G C T A A T A G C T G G T T C A A C T G C A G G A A A A A T T G A A C A T T A C T A A T T T G A A T G G A A A A C A C A T G G T G T G A G T C C A A A G G A G G T G T T T T C C T G A A G A A C T G T C T A
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
T T T T C T C A G T C A T T T T T A A C C T C T A G A G G A T C C G G C T G C T A A C A A A G C C C G A A A G G A A G C T G A G T T G G C T G C T G C C A C C G C T G A G C A A T A A C T A G C A T A A C C C C T T G G G G C C T C T A A A C G
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
G G T C T T G A G G G G T T T T T T G C T G A A A G G A G G A A C T A T A T C C G G A T A T C C C C A G G A C G G G T G T GG T C C C C A T G A T C G C G TAA T CC A T A G T G G C T C C A A T A A C G A A A C G A G C A A G A C T G G G C G
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300
G C G G C C A A A C CC G T C G G A C A T T GC T CC GA A A A C G G G T G C G C A AA G A A T T GG A TC C A C G C A T AT A G C G C T A GC A GC C CG C C A A A T G GAC T GG C G A TG CT TG
Sequence: API534255_01_T7P
Order: COL11-0W0K
Machine: ZB-1402-008
Signal: A (152), C (115), G (177), T (114)
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